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Abstract 
There has been an astonishing variety of sesqui- and diterpene metabolites isolated—mainly 
from Laurencia species, or their predators—which possess the enantiopure α,α-dimethylcyclohexyl 
bromide moiety. The key step in their biogenesis is generally considered to be an enzyme-mediated 
formation of an asymmetric bromonium ion which initiates a cation-π cyclisation. This diverse 
array of terpene natural products is explored in the introduction to this thesis and their biogenesis 
via cation-π cyclisations analysed. Synthetic sources of electrophilic bromine such as NBS, TBCO 
and BDSB have been shown to initiate brominative polyene cyclisations with excellent control of 
relative stereochemistry albeit as necessarily racemic products. At the start of this work no 
asymmetric bromonium ion-induced polyene cyclisations had been demonstrated. 
Studies on a model system for the key in situ enantiopure bromonium ion generation and 
intramolecular trapping are described. Sharpless asymmetric dihydroxylation provides access to 
enantiopure diols of a trisubstituted alkene which can be manipulated to enantiopure 
bromohydrins. These are activated as 2,3,4,5-tetrafluorobenzoate esters which cyclise cleanly 
under the action of catalytic triflic acid to give enantiopure bromo-bicycles without racemisation 
from bromonium ion to alkene transfer. The mechanism of this reaction is investigated, it is 
practically demonstrated and shorter routes are explored. 
The synthesis of high purity linear terpene: homogeranyl 4-methoxybenzene is discussed, from 
which the synthesis of enantiopure bromo-tetrafluorobenzoate esters is carried out. The use of 
Lewis acid, in this case dimethylaluminium triflate, was found to successfully enact the cyclisation 
of these alkene containing substrates. Full conversion to cyclic products was achieved and the 
desired tricyclic product was isolated as a mixture of enantiopure diastereomers. Absolute and 
relative configuration of both diastereomers were determined by radical dehalogenation and 
comparison of the sign of the optical rotation of the product to literature values. 
Finally, the synthesis of homofarnesyl 4-methoxybenzene derived substrates is detailed. The 
cyclisation of which has the potential to generate tetracyclic compounds. This forms the basis of 
future work to be carried out. 
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1 Introduction 
In modern pharmaceutical science, chemical compounds produced by living organisms i.e. 
metabolites, found in nature from marine1 and terrestrial environments are the source, or the 
inspiration, for drug discovery and design.2 For example, since the 1940’s, the area of small-
molecule anti-cancer therapeutics has seen the introduction of 175 different compounds, half of 
which are directly derived from known natural products.3 This is still the case in 2010 where the 
natural products field is responsible for 50% of all new small molecule therapeutics.4 The process 
of isolating and characterising natural products often only provides a small quantity of the 
compound, insufficient for complete biological evaluation. Consequently the synthetic chemist’s 
ability to prepare natural products and their structural analogues is essential to the investigation 
and development of more effective drug molecules and to enable production of pharmaceuticals 
on an industrial scale. 
1.1 Terpenes and cyclic terpenoids 
Resins and essential oils have been used since ancient times as medicines, fragrances, 
flavourings and rubber.5 Turpentine; the distillate of resin obtained from live trees, usually pines 
and historically named after the terebinth tree from which it was obtained,6 and other essential oils 
compose mainly of terpenes and their derivatives: terpenoids. Terpenes can be found in all classes 
of living organisms7 and they represent the largest group of natural products with over 55,000 
having been isolated up to 2007.5a Terpenes consist of five-carbon isoprene units that are often 
joined in a head-to-tail fashion first described by the isoprene rule in the late 19th century.8 
Depending on the number of isoprene subunits they are described as hemi- (C5),
9 mono- (C10),
10 
sesqui- (C15),
11 di- (C20),
12 sester- (C25),
13 tri- (C30),
14 sesquar- (C35),
15 tetra- (C40)
16 and polyterpenes (C5)n 
where n > 8.17 In mono-, sesqui-, di- and sesterterpenes the isoprene units are linked to each other 
from head-to-tail, tri- and tetraterpenes contain one tail-to-tail connection in the centre (e.g. squalene 
(C30) see Figure 1).
5b 
 
Figure 1 - Linear terpenes and their relation to isoprene  
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Many terpenoids differ not only in their functional group substituents but also in their basic 
carbon skeletons. In nature these compounds are arranged from units of isopentyl pyrophosphate 
(IPP) and its regioisomer: dimethylallyl pyrophosphate (DMAPP) (Figure 2).18 DMAPP represents 
a good SN2 electrophile and alkylating agent and IPP reacts as a nucleophile to form geranyl 
pyrophosphate (GPP).19 The reaction of a further IPP unit generates farnesyl pyrophosphate, and 
its coupling by squalene synthase produces squalene.20 Oxidation by squalene monooxygenase to 
2,3-oxidosqualene21 and then terpene cyclase enzymes such as lanosterol synthase initiate a cation-
π cascade to form polycyclic cholesterols such as lanosterol.22 
 
Figure 2 - Overview of lanosterol biosynthesis from dimethylallyl pyrophosphate and isopentyl pyrophosphate 
Terpene cyclase enzymes assemble simple linear terpenes such as geranyl pyrophosphate and 
squalene into an exotic array of chiral, carbocyclic skeletons23 via a cation-π cyclisation cascade, 
where further modification by oxidation and rearrangement can lead to an almost endless array of 
conceivable structures, Figure 3.5a 
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Figure 3 - Examples of terpenoid natural products demonstrating the diversity of structure.20 
The enormous structural diversity of terpenoid compounds23-24 provides a broad range of 
properties25 and functions demonstrated by Figure 3.26 The biosynthesis of these compounds via 
cation-π cyclisations, and the rapid access to complex enantiopure structures that are the basis for 
so many biologically active compounds, therefore makes this reaction very appealing to the 
synthetic organic chemist. 
1.2 Cation-π cyclisations  
In nature cation-π cyclisations provide the simultaneous formation of several carbon-carbon 
bonds in one step, creating a number of quaternary carbon centres. The reaction has multifaceted 
selectivity, in terms of both ring-size and relative and absolute stereochemistry. Up to nine 
stereocentres are formed in one step, resulting in rapid generation of molecular complexity 27, 28 
In the laboratory, cation-π cyclisations are initiated by the electrophilic activation of an alkene 
(Scheme 1). Brønsted29 and Lewis acids30 have been the most frequently used electrophiles but 
effective cyclisations have also been achieved with oxygen,31 iodine,32 sulfur,33 selenium,33 
mercury,34 and transition metals such as gold,35 iridium,36 palladium,37 and platinum.38  
Once initiated with an electrophile the build-up of positive charge results in attack of an 
intramolecular alkene,39, 27c forming a carbocycle and causing migration of the positive charge. 
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Subsequent ring formations can occur with up to five new rings possible.40 Termination of the 
cascade is achieved by elimination and/or attack by an internal or external nucleophile. To be 
synthetically useful, polyene cyclisations would ideally be terminated by one mechanism giving a 
single product.41 
 
Scheme 1 - Representation of a cation-π cyclisation 
The Stork-Eschenmoser hypothesis states that “when a cation-π cyclisation proceeds under 
stereoelectronic control (either as a ‘concerted’ process or, what is stereochemically equivalent, as a 
stepwise process via carbocationic intermediates that retain stereochemical information), then the 
stereochemical outcome will correspond to stereospecific trans-additions at C=C bonds. When 
extrapolated to the cyclisation of all-trans-polyolefinic isoprenoids, such a steric course produces 
the trans-anti-trans-configuration characteristic of the structure of the natural polycyclic terpenoids 
and steroids.”27, 42, 31a Therefore, developing a successful polyene cyclisation (forming multiple 
rings) relies on the stereoselective synthesis of alkenes, efficient initiation, propagation and control 
over termination.41a 
Of particular interest is the initiation of cation-π cyclisations with electrophilic bromine, where 
despite significant effort, challenges in stereoselective control still remain. Such a transformation 
would be of great value given the existence of hundreds of brominated natural products (Figure 
6) that could be accessed, as well as the potential ability to use the installed bromine atom as a 
handle to further elaborate the cyclised product.41b 
1.3 Brominated cyclic terpene natural products and their 
biosynthesis 
It is estimated that more than 16,000 natural products have been isolated and reported from 
marine organisms.43 Approximately 15-20% of all newly discovered marine natural products are 
organohalogens.44 These are carbon-based molecules containing fluorine, chlorine, bromine or 
iodine atoms (Figure 4). A particular class of these organohalogens have been isolated from species 
of the marine red algae, Laurencia (Figure 5).45 
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Figure 4 - Organohalogens in nature46 Figure 5 - Laurencia nidifica attached to a Porites lobata coral head.47 
They all possess a unique chemical motif – a six-membered carbocycle bearing a bromine atom 
and two adjacent methyl groups (shown in red, Figure 6). To date there are more than 135 
bromine-containing members of this natural product family.48 Although only a small number of 
these have been tested in biological assays many have potent biological activity, including anti-
tumour,49 anti-bacterial,50 anti-inflammatory51 and anti-HIV52 activity. For example, aplysistatin, 
isolated from an Australian South Pacific Ocean sea hare (Aplysia angasi) was found to significantly 
inhibit progression of murine lymphocytic leukemia.49 Majapolene B, isolated from Laurencia 
mujuscula (Harvey) Lucas, collected off Apo Island in the Philippines,50b showed moderate anti-
bacterial activity against a range of bacterial strains.50a Peyssonol A, a secondary metabolite 
obtained from the Red Sea marine algae Peyssonnelia species, has been shown to act as an allosteric 
inhibitor of the reverse transcriptases of HIV types 1 and 2.52b This family of natural products 
therefore has great potential in drug discovery.  
 
Figure 6 - Representative examples of sesqui- and diterpene metabolites isolated from Laurencia species, or their 
predators, which possess the enantiopure α,α-dimethylcyclohexyl bromide moiety 
Fluorine Chlorine Bromine Iodine
25 
 
These compounds are isolated from nature as single enantiomers and their biosynthesis is 
known to occur by the action of vanadium bromoperoxidase53, 46a – an abundant and robust 
enzyme found in all classes of marine algae. In the active site of vanadium bromoperoxidase, the 
vanadate(V) ion is coordinated to the protein scaffold by a single histidine residue positioned at 
the bottom of a deep active-site channel. Multiple amino acid side-chains hydrogen bond to the 
vanadate oxygen atoms (Figure 7).54, 53d 
 
Figure 7 - Representative example of the active site of native vanadium chloroperoxidase from Curvularia inaequalis. 
Possible hydrogen bonds are drawn as dashed lines.55, 53d 
Although the process is poorly understood it is proposed that the vanadate(V) first coordinates 
to hydrogen peroxide in a side-on bound fashion, producing a square-based pyramidal oxo-
peroxo-vanadium(V) intermediate (D, Scheme 2).56 In vanadium bromoperoxidases it is thought 
that a histidine residue alters the redox potential of the vanadium-peroxo complex D in such a way 
that the oxidation of chloride ions is no longer possible, providing chemoselectivity.54a Detection 
or isolation of the oxidised bromine intermediate E is hampered due to its reaction with organic 
substrates or with excess hydrogen peroxide to produce singlet oxygen, preventing its build-up in 
solution.57 Therefore the nature of the oxidised bromine intermediate as either enzyme-trapped, 
bound or freely diffusible depends on the nature of the organic substrate.58 Recent evidence has 
shown that bromide ion unambiguously binds within the active site of vanadium bromoperoxidase 
from the red algae Corallina piluliferad in the presence of its known substrates, phenol red and 
phloroglucinol.59 
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Scheme 2 - Proposed reaction mechanism for bromide oxidation by vanadium bromoperoxidases in the 
biosynthesis of (+)-3β-bromomanoyl oxide.54a 53a 
In nature vanadium bromoperoxidases accomplish bromonium ion-induced polyene 
cyclisations where a number of new C-C bonds, rings and quaternary stereocentres are formed 
stereoselectively, to give complex molecules from linear substrates. In the last 50 years, this 
reaction has been demonstrated in the chemical laboratory.  
1.4 History and precedent 
1.4.1 Polyene cyclisations triggered by direct bromination 
The first report of a bromonium-ion induced cation-π cyclisation from a synthetic laboratory 
came in 196660 when van Tamelen and Hessler found that the reaction of NBS with methyl 
farnesate 1 (Scheme 3) in a water-ethylene glycol mixture or THF solution gave rise to 12-15% 
yield of bromo-cyclised material, as observed by 1H NMR analysis of the crude reaction mixture, 
where mono-bromohydrins of the terminus alkene represented the major product. Isolated from 
this mixture, as a non-saponifiable fraction was bicycle 2 as a mixture of endo- and exocyclic 
alkenes in approximately 5% yield. It was suggested that the most likely mechanism for this 
reaction is the formation of a racemic bromonium ion 3 which cyclises in a synchronous fashion 
to the bicyclic product. 
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Scheme 3 - Brominative cyclisation of methyl farnesate 1 using NBS 
A decade later research into brominative polyene cyclisations continued. This was driven by an 
increasing number of halogenated mono-, sesqui-, and diterpenoids being isolated from the 
secondary metabolites of red algae,61, 45a sponges62 and sea hares.63, 45f Copper(II) acetate was used 
as an additive in tert-butanol and acetic acid to improve on van Tamelen’s conditions.64 Monocyclic 
adduct 4 was isolated in 12% yield (Scheme 4). 
 
Scheme 4 - Brominative cyclisation of methyl farnesate 1 using NBS and Cu(OAc)2 
Kato used homogeranonitrile 5 as a model polyene (Scheme 5) and under van Tamelen’s 
conditions it was converted to a bromohydrin adducts without formation of any cyclised product. 
Kato found that 2,4,4,6-tetrabromocyclohexa-2,5-dienone (TBCO) in the presence of a Lewis acid 
such as AlBr3 could be used to cyclise homogeranonitrile 5 into bromo-adduct 6, albeit in low yield 
(ca. 15%).65  
 
Scheme 5 - Brominative cyclisation of homogeranonitrile 5 using TBCO 
Without AlBr3, TBCO efficiently brominates homogeranonitrile to give dibromide 7.
66 It is 
expected by Kato that action of the Lewis acid on TBCO liberates a bromonium ion and the 
resulting tribromophenoxide-AlBr3 complex anion is less reactive towards the carbocation initially 
formed by attack of the olefin onto bromonium ion. Therefore ring formation by the neighbouring 
double bond occurs instead.65  
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When applying this method to a more complicated system (Scheme 6) Kato obtained without 
the aid of a Lewis acid a low (ca. 2%) but isolable yield of bromo-cycloadducts with the bromo-
cyclisation of nerolidol 8 into racemic snyderol 9.67 
 
Scheme 6 - Brominative cyclisation of (±)-nerolidol 8 using TBCO 
Use of the more polar solvent nitromethane produced 2% yield of each olefinic regioisomers α 
and β synderol 9, and also 5% of the bicyclic bromoether: 3-bromo-8-epicaparrapi oxide 10  
(Scheme 6).45h When (±)-geranyl-linalool 11 was also treated with TBCO under these conditions, 
remarkably isolable quantities (2%) of both 12 and 13 tricyclic bromo ethers were obtained.  
 
Scheme 7 - Brominative cyclisation of (±)-geranyl-linalool 11 using TBCO 
Kato et al. have demonstrated the use of TBCO in a number of natural product syntheses68 and 
have shown that it is a useful reagent for the brominative cyclisation of polyene precursors to 
synthesise up to three rings, in a presumed biomimetic fashion, albeit in low yields. 
Wolinsky and Faulkner later set out to synthesise the simplest naturally-occurring brominated 
chamigrene: 10-bromo-α-chamigrene (14, Scheme 8),69 which also contains the α,α-
dimethylcyclohexyl bromide moiety. Investigations were carried out into the use of reagent systems 
where no nucleophile was present to trap the presumed bromonium ion. The use of molecular 
bromine and stannic bromide in nitromethane on geranyl acetate 15 at 0°C for 5 minutes yielded 
16% of the desired cyclised bromoacetate 16 (Scheme 8). Large quantities of dibrominated 
materials were also isolated and so silver tetrafluoroborate was substituted for stannic bromide in 
order to sequester the bromide ions as they were produced. This improved the yield of 16 to 20%. 
Elimination of tertiary alcohol 16, ready for a second ring-cyclisation was carried out using tosic 
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acid. Unfortunately an inseparable mixture of undesired olefins 17 were returned in 77% yield 
which did not allow for further cyclisation to chamigrene 14. 
 
Scheme 8 - Bromo-cyclisation of geranyl acetate 15 using molecular bromine and silver tetrafluoroborate 
However, brominative cyclisation and acid catalysed rearrangement of geranylacetone 18 did 
give the desired tetrasubstituted olefin 19 (Scheme 9). Addition of a two carbon fragment via a 
Grignard reaction provided tertiary alcohol 20, allowing the second cyclisation to proceed to the 
desired 10-bromo-α-chamigrene 14 on treatment with tosic acid. 
 
Scheme 9 - Bromo-cyclisation of geranyl acetone 18 using molecular bromine and silver tetrafluoroborate 
In expanding the scope of this reaction, Hoye and Kurth carried out the bromolactonisation of 
homogeranic acid 21, using the same conditions, with the desire of synthesising brominated 
bicycles 22 and 23 (Scheme 10). However, as well as producing bromine containing adducts 22 
and 23, they found that the predominant reaction was the formation of norbromo lactones 24 and 
25.70  
 
Scheme 10 - Hoye and Kurth’s bromo-cyclisation of homogeranic acid 21 using molecular bromine and silver 
tetrafluoroborate 
This observation provided Hoye and Kurth with insight into the reaction’s mechanism. 
Investigation using different acids and conditions allowed them to determine if the undesired 
norbromo products 24 and 25 were arising via a competing cyclisation catalysed by acid, 
presumably generated as the brominative cyclisation proceeded. Hoye and Kurth found that 
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proton initiated cyclisation of homogeranic acid 21 led to the trans-fused lactone 24, the kinetically-
favoured product. This then isomerised to the thermodynamically favoured cis-fused lactone 25 in 
the presence of both Lewis and Brønsted acids. It was found that this cyclisation and isomerisation 
was favoured in nitromethane solvent as opposed to less polar solvents. However, isomerisation 
of bromide containing trans-22 to cis-23 only occurred to a minute extent under the same 
conditions. Both of these results can be rationalised by a common mechanism: ring-opening of 
trans lactones 22 and 24 (Scheme 11) to planar carbenium ion A which can ring-close to the 
thermodynamic cis- lactone C via attack on the opposite face of the carbenium ion by the carboxyl 
group (A to B). This requires a conformational change which would result in severe 1,3-diaxial 
strain (B) in the case of 22 and so this mechanism is comparatively unfavoured resulting in just 
trace amounts of 23 being isolated.  
 
Scheme 11 - Isomerisation of trans lactones to cis derivatives70 
Up until now, most methods of direct brominative cyclisation have been low-yielding. This 
must arise in part from the requirement of the reagent to react regioselectively with the olefin at 
the terminus of the polyene chain. The recent introduction of the powerful reagent 
bromodiethylsulfide bromopentachloroantimonate (BDSB, Scheme 12) by Snyder and Treitler—
a highly-activated source of electrophilic bromine, free from any additional nucleophilic species—
now allows for highly efficient bromonium ion induced cation-π cyclisations of a diverse set of 
polyenes derived from geraniol (such as 26) and farnesol (such as 27), in >55% yield, usually within 
5 minutes. Larger polyenes derived from farnesol required diastereoselective cyclisation of the 
third ring using methanesulfonic acid.48 This process is diastereoselective, forming a single product 
with the relative stereochemistry shown, however these cyclisations necessarily result in racemic 
cyclic adducts. 
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Scheme 12 - BDSB brominative polyene cyclisations48 
Bromonium ion-induced cyclisations using BDSB have recently formed part of a number of 
studies towards the synthesis of natural products. For example, the construction of alkenic 
regioisomers, bromophycolide A and D skeletons 28 (Scheme 13), via diastereoselective 
bromonium ion-induced cyclisation of triene 29 has been achieved in low yield with competitive 
elimination pathways to alkene isomers 30.71 
 
Scheme 13 - The use of BDSB in the synthesis of bromophycolide A and D skeletons 
The Braddock group have also used BDSB for an intramolecular bromonium ion assisted 
epoxide ring-opening reaction.72 Enantiomerically-enriched epoxide 31 (Scheme 14), when treated 
with BDSB, formed a number of constitutional isomeric halogenated C15-acetogenin medium-ring 
ether compounds that represent the core structures of a number of natural products from Laurencia 
species. 
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Scheme 14 - BDSB mediated synthesis of halogenated C15-acetogenin medium-ring ethers 
In an endeavour to render these reactions enantioselective, Snyder and co-workers prepared 
C2-symmetric chiral sulfonium bromide 32 (Scheme 15).
45b, 73 The use of this reagent with substrate 
26 led to the formation of the expected product in good yield (72%) but unfortunately as a racemic 
mixture. 
 
Scheme 15 - A chiral BDSB analogue 
1.4.2 Polyene cyclisations triggered by activation of a bromohydrin  
In 1982 Murai reported excellent yields (up to 94%) of bromo-cyclised adducts by the action 
of a Lewis acid on (racemic) bromohydrins. For example, bromohydrin 33 was cyclised to 
monocyclic bromo-adducts in 64% yield, (Scheme 16) of which 34 was isolated in 51% yield and 
elaborated to the antifungal agent, spirolaurenone 35 which possesses a unique spirolaurane 
skeleton.74 Although not explicitly stated in his paper, it is likely that this reaction proceeds through 
bromonium ion 36 by elimination of Lewis acid activated alcohol through neighbouring group 
participation of bromine. 
 
Scheme 16 - Brominative cyclisation of homogeranonitrile 5 using boron trifluoride diethyl etherate 
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This approach was further extended to the cyclisation of bromohydrin polyenes such as 37 to 
give bicyclic ring systems (38-41, Scheme 17). The formation of two rings required further 
activation of the alcohol as acetate 42, in order to obtain reasonable isolated yields of bicycle 40. 
This methodology was used as the key-step in the synthesis of racemic aplysin-20 (43), in 16 steps 
and 10% overall yield.75 
 
Scheme 17 - Murai’s total synthesis of (±)-aplysin-20 (43) 
Murai has demonstrated good yields for bromo-cyclisation of polyenes by the action of a Lewis 
acid on bromohydrin or acetate derivatives to give monocyclic and bicyclic adducts such as 34 and 
40 as necessarily racemic products. In 2004 Couladouros and Vidali76 used this methodology as 
part of a new, stereocontrolled method for the formation of trans-anti cyclogeranyl-oxepene 
systems such as 44 (Scheme 18). In this case, the Lewis acid activation of an enantiopure 
bromohydrin provided the key chiral building block 45 which underwent stereospecific SN2 attack 
onto a 1,2-unsymmetrically substituted epoxide 46. Ring-closing metathesis was employed to form 
the highly strained 7-membered oxepene ring before diversification into a number of natural 
products such as aplysistatin. 
 
Scheme 18 - Couladouros and Vidali’s synthesis of aplysistatin 
The asymmetric synthesis of enantiopure α,α-dimethylcyclohexyl bromide moiety 45 began 
with Sharpless asymmetric dihydroxylation of polyene 47 to give diol 48 in good regio- (61% yield) 
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and excellent enantioselectivity (>97% e.e.) (Scheme 19). Formation of the epoxide 49 and regio- 
and diastereoselective ring-opening with LiBr and PPTS in NMP was reported to produce 
bromohydrin 50 with good anti-Markovnikov selectivity and in excellent yield. Attempted direct 
SN2 displacement of tosylate 51 with bromide anion led to competing elimination to allyl alcohol 
52 in 15% yield. Couladouros and Vidali then activated the tertiary alcohol 50 towards cyclisation 
with tin(IV) chloride using Gosselin’s conditions,77 to give bromocyclodecane 53 in 60% yield and 
in optically active form. 
 
Scheme 19 - Couladouros and Vidali’s synthesis of an enantiopure bromohydrin 
For cyclisation of 50 to 53 there are two possible mechanistic scenarios. One involves 
cyclisation onto tertiary carbocation 54 (Scheme 20), whereas the other invokes a neighbouring 
group participation to form enantiopure bromonium ion 55 before cyclisation. Interestingly, 
Couladouros does not speculate on the mechanism, and does not invoke a bromonium ion. In any 
event, the mechanism will depend on the relative stabilities of the bromonium ion in comparison 
to the cationic intermediate which is inherently stabilised by its tertiary nature. 
 
Scheme 20 - Possible mechanisms for cyclisation of asymmetric bromohydrin 50 
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1.4.3 Enantioselective polyene cyclisations 
The first enantioselective biomimetic cyclisation of polyprenoids was reported in 1999 by 
Yamamoto, Ishihara and Nakamura, who combined a system of a Lewis acid and a chiral Brønsted 
acid.78 One equivalent of (R)-BzBINOL-SnCl4 (Scheme 21) was found to give the best yields for 
cyclisation of 2-geranyl phenol 56 to trans-decalin 57 at 92%. This was isolated with moderate 
enantio- and diastereoselectivity (54% e.e. and 19:1 d.r.). However, it was found that 57 was 
isolated with much better selectivity from the reaction of geranyl phenyl ether 58 even with only 
20 mol% of (R)-BzBINOL-SnCl4 to give 57 in 77% e.e. and 46:1 d.r.  
 
Scheme 21 - The first enantioselective cyclisation of polyprenoids 
This methodology was demonstrated in the asymmetric synthesis of (-)-chromazonarol acetate 
(Scheme 22), a minor constituent of the brown Pacific seaweed, Dictyopteris undulate.79 In this case 
one equivalent of (R)-iPrBINOL-SnCl4 gave the desired compound as the major diastereomer in 
44% e.e. and 40% overall yield.  
 
Scheme 22 - Asymmetric synthesis of (-)-chromazonarol acetate 
The substrate scope of this reaction was enhanced by the Yamamoto group when new BINOL 
ligands were tested in combination with SnCl4.
80 However, it wasn’t until very recently that Corey 
and Karavadhi discovered a method to improve the enantioselectivity of this reaction. They 
observed that a 1:1 complex of o,o’-dichloro-BINOL and antimony pentachloride in reaction with 
triene 59 gave tetracycle 60 in 84% e.e. with complete diastereoselectivity (Scheme 23). This was a 
consequence of the increased acidity of the BINOL ligand and a bulkier, stronger Lewis acid, 
antimony pentachloride. 
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Scheme 23 - Enantioselective proton-initiated polyene cyclisation 
Recently, Ishihara and Sakakura demonstrated the use of BINOL ligands in the development 
of polyene halo-cyclisation reactions. Initially, Ishihara found that racemic halo-cyclisation of 4-
(homogeranyl)toluene 61 was extremely efficient using NIS or NBS in the presence of a 
nucleophilic phosphine catalysts such as tributylphosphine or tri(4-methoxyphenyl)-phosphine (30  
mol%) in dichloromethane, producing 62a and 62b respectively in excellent yields (>80%, Scheme 
24). Albeit after diastereoselective cyclisation of the initially produced monocyclic adducts 63a and 
63b with chlorosulfonic acid.32  
 
Scheme 24 - Cyclisation of 61 with NXS and a nucleophilic phosphine catalyst 
The racemic bromo-cyclisation of 61 was later optimised by Ishihara and co-workers using 1,3-
dibromo-5,5,dimethylhydantoin, a more reactive brominating reagent than NBS and a highly active 
nucleophilic phosphine catalyst containing urea and bulky aryl groups, 64, to give 94% yield of 
62b  with excellent diastereoselectivity also being reported (95:5 d.r., Scheme 25).81 Acid catalysed 
cyclisation of the second ring was optimised using trifluoroacetic acid and additional Lewis acid, 
tin(IV) chloride. It is proposed that urea binds to succinimide that is produced during the course 
of the reaction, thus preventing it from reacting with the active catalytic species to produce anionic 
bromide which is responsible for dibromide containing by-products. 
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Scheme 25 - Bromo-cyclisation of 61 with DBH and a nucleophilic phosphine urea catalyst 
Attempts to render this reaction asymmetric using a BINOL derived catalyst 65 were 
unsuccessful (Scheme 26). The reaction of diene 61 with NBS and chiral catalyst 65 gave essentially 
full conversion to tricycle 62b after chlorosulfonic acid catalysed cyclisation. However, only minor 
asymmetric induction was observed (2% e.e.). 
 
Scheme 26 - Attempted asymmetric bromo-cyclisation using a chiral nucleophilic phosphine urea catalyst 
Ishihara and co-workers were however able to demonstrate the asymmetric iodo-cyclisation of 
diene 61 using chiral phosphoramidite 66 at stoichiometric loading to give iodide 62a. Remarkably, 
in toluene, 57% yield and 95% e.e. was observed (after treatment with chlorosulfonic acid, Table 
1, entry 1).  Interestingly, in dichloromethane no asymmetric induction was observed, although a 
95% yield of racemate 63a was isolated (entry 2). Similarly high enantioselectivities (>90% e.e.) 
were also found in the iodinative cyclisations of 3-(homogeranyl)toluene, 4-(homogeranyl)anisole 
and 4-(homofarensyl)toluene. However, when using NBS and catalytic quantities of chiral 
phosphoramidite 66, bromide 62b was only isolated with 4% enantiomeric excess and 29% yield 
(entry 3), which could only be improved to 75% yield and 36% e.e. with stoichiometric loading of 
a more bulky phosphoramidite ligand 67 (entry 4). 
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Table 1 - Asymmetric halo-cyclisation of diene 61 with NXS and a nucleophilic phosphine catalyst 
 
Entry NXS Nu. cat. (mol%) Solvent Product Yield (%) e.e. (%) 
1 NIS 66 (100) MePh 62a 57 95 
2 NIS 66 (100) CH2Cl2 62a 95 0 
3 NBS 66 (20) MePh 62b 29 4 
4 NBS 67 (100) MePh 62b 75 36 
Therefore, to access enantiomerically-enriched bromide and chloride products, which are more 
common in nature, Ishihara and co-workers converted the chiral iodides into the corresponding 
bromides through lithiation and stereo-retentive halide capture (Scheme 27). 
 
Scheme 27 - Lithiation and stereo-retentive bromide capture of enantiopure iodides 
Snyder has also recently employed a similar two-step mimic for asymmetric bromonium ion 
induced polyene cyclisations.34a Snyder developed methodology to synthesise chiral organomercury 
cyclic adducts which could then be substituted by bromine in a stereo-retentive fashion. 
 
Scheme 28 - Snyder’s two-step mimic for direct asymmetric bromonium ion induced polyene cyclisation 
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As a representative example, diene 68 was treated with mercury triflate and C2-symmetric chiral 
oxazoline ligand (L) to give cyclised product 69 (Scheme 28). Subsequent treatment with an excess 
of bromine in oxygenated pyridine, according to the procedure by Hoye and Kurth,82 generated 
the desired product 70 in 79% overall yield and 72% e.e. After recrystallisation of the intermediate 
organomercury 69, bromo-cyclised product 70 was afforded in 99% e.e and 53% yield. Although 
high yielding and enantioselective, this method requires stoichiometric quantities of toxic mercury 
salts. Also it can be noted that with electron rich aromatics such as 68, bromination of the aromatic 
ring is likely with the use of molecular bromine. 
Very recently there has been a number of metal-initiated enantioselective polyene cyclisation 
reactions reported by groups such as Toste,83 Carreira36 and Gagné.84 Toste et al. report a highly 
enantioselective gold(I)-catalysed polyene cyclisation in which transition metal-promoted alkyne 
activation serves as the cyclisation initiating event. Excellent yields were even obtained in the 
tricyclisation of dienyne 71 to form tetracycle 72 in 61% yield and 97% e.e. (Scheme 29). 
 
Scheme 29 - Gold(I)-catalysed enantioselective polycyclisation reaction 
Carreira et al. report the highly enantioselective initiation of allylic alcohols, catalysed by iridium 
and promoted by zinc triflate forming cyclic products in greater than 99.5% e.e. and with excellent 
yields. The Ir-catalysed cyclisation of 73 was shown to afford tetracyclic product 74 in 43% isolated 
yield and >99.5% e.e. as a single diastereomer (Scheme 30) and, with careful separation, isomeric 
trienes 75 in 30% yield. With an additional acid catalysed cyclisation, 75 was fully cyclised to 
tetracycle 74 in 75% isolated yield to give an overall combined yield of 65% for 74 and with 
identical enantioselectivity. It was concluded by Carreira et al. that the formation of tetracycle 74 
from triene 73 in such high stereoselectivity would suggest that this catalyst system has direct 
stereocontrol of the first cyclisation event. The subsequent ring closures are then stereospecific in 
accordance with the Stork-Eschenmoser hypothesis.  
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Scheme 30 - Iridium-catalysed enantioselective polyene cyclisation 
Very recently, asymmetric electrophilic platinum(II) cation-π cascades developed by Gagné and 
co-workers - which would normally be susceptible to β-hydride elimination to produce 76 or 7784 
– have been intercepted by a Pt-C fluorination  reaction to form asymmetric fluorinated bicycles 
78 and 79 (Scheme 31).85 The use of silver tetrafluoroborate, perfluorobenzonitrile and 
commercially available chiral paracyclophane derived ligand (S)-xylyl-phanephos (80) form the 
active species for this transformation: [(S)-(xylyl-phanephos)Pt(NCC6F5)2][BF4)2].  
 
Figure 8 - X-ray crystallographic structure of (S)-(xylyl-phanephos)PtCl284 
Addition of base (TMSOMe) facilitates cyclisation and an electrophilic fluorine source provides 
good enantioselectivity with up to 87% e.e. and 80% yield, where β-hydride elimination is 
responsible for the major by-products. 
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Scheme 31 - Catalytic enantioselective cyclisation and C3-fluorination of polyenes 
It can be noted that in the case of trienyl phenol 81, polystyrene-bound piperidine base was 
used instead of TMSOMe to improve the yields of tetracycle 79, however the enantioselectivity 
was greatly reduced to 10 % e.e. 
Although these examples of enantioselective polyene cyclisations by high-profile research 
groups such as Toste, Corey and others86 are not triggered by a bromonium ion, they demonstrate 
the high interest, importance and potential of polyene cyclisations. They suggest that if a cation-π 
cyclisation can be triggered by an enantiopure bromonium ion, then it is likely that the subsequent 
ring forming events will occur diastereoselectively. They also demonstrate the increasing difficulty 
in cyclising multiple rings, with the employment of acid-catalysed ring-closure steps necessary to 
form tetracyclic compounds. Recent advancements involving enantioselective iodonium ions, 
mercurinium ions and platinum(II)-induced cation-π cyclisations have provided access to chiral 
halogenated carbocycles in good yields, however there still remains a need for an enantioselective 
bromonium ion-induced cation-π cyclisation to yield the desired enantiopure bromo-cycles directly.87 
1.5 Configurational stability of bromonium ions 
A cyclic bromonium ion was first proposed by Roberts and Kimball in 1937 to account for the 
well-established anti-stereochemistry observed for the addition of molecular bromine to olefins.88 
The existence of a cyclic symmetrical species was proven by Winstein and Lucas in 1939 with the 
loss of optical activity in the reaction of erythro- and threo-3-bromo-2-butanols with hydrobromic 
acid where the term “bromonium ion” was first coined (Figure 9).89  
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Figure 9 - Winstein and Lucas proving the existence of a bromonium ion 
Olah et al. were the first to observe a bromonium ion by NMR.90 The first stable bromonium 
ion was isolated by Wynberg et al.91 using adamantylideneadamantane which was subsequently 
characterised crystallographically (Figure 10) and studied by Brown and co-workers.92 
 
 
Figure 10 - X-ray crystal structure of the bromonium ion derivative of adamantylideneadamantane92a 
The exact structure of bromonium ions in a broader context, depends strongly on any 
substituents and on the solvent, and it is understood that a continuum of ionic intermediates are 
possible, of which the cyclic bromonium ion and the open β-bromocarbocation are the extremes 
(Figure 11).93 It is also known that bromonium ions of adamantylideneadamantane can transfer to 
acceptor olefins, presumably without transfer of stereochemical information.92b, 94 
 
Figure 11 - Cyclic bromonium ion and open β-bromocarbocation extremes and the transfer of bromonium ion to 
acceptor olefins 
Denmark has further demonstrated that racemisation of enantiopure bromonium ions via 
olefin-olefin transfer is competitive with intermolecular capture by anionic nucleophiles.95  
The acetolysis of bromotosylate 82 in hexafluoroisopropanol—which provides a strong ionising 
medium of low nucleophilicity96—at room temperature with sodium acetate gave good yields and 
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complete retention of configuration. However, when alkene 83 was introduced into the reaction, 
bromoacetate 84 was produced with a diminished enantiomeric ratio (blue markers, Figure 12). 
With one equivalent of alkene the percentage retention of configuration was reduced to 26%. A 
large excess of sodium acetate (5 eq.) did not alter this affect significantly (red markers, Figure 12). 
 
 
Figure 12 - Racemisation of enantiopure bromonium ion via olefin-to-olefin transfer 
Since by definition a polyene cyclisation substrate will always contain alkene functional groups, 
it is not unreasonable to ask if such asymmetric cyclisations are therefore inherently compromised 
when not under enzymatic control. The close proximity of an intra- or intermolecular olefin may 
result in the transfer of an enantiopure bromonium ion to another alkene to give a racemic 
bromonium ion. This could increase the number of by-products and as it is a reversible process, 
the enantiomeric excess of the bromonium ion leading to the desired product could also be eroded 
(Scheme 32). 
 
Scheme 32 - Asymmetric brominative polyene cyclisation of (R)-nerolidol to (+)-3β-bromomanoyl oxide 
Previous research from the Braddock group has shown that an enantiopure bromonium ion 
can be prepared in situ and trapped with an intermolecular nucleophile. 
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1.6 Previous work in the Braddock group 
In the attempted synthesis of bromochloride 85 (Scheme 33) racemic styrene oxide 86 was ring-
opened with excellent regio-control to bromohydrin 87 by the action of HBr. Alcohol 87 was then 
treated with thionyl chloride.97 However, instead of the expected bromochloride 85, the 
corresponding regioisomer 88 was formed in excellent yield. This product must arise via the alkyl 
chlorosulfite 89, and intervention of a bromonium ion 90 via neighbouring group participation,89 
followed by attack of liberated chloride at the benzylic carbon.98 The structure of bromochloride 
88 was unambiguously confirmed by X-ray crystallography.  
 
Scheme 33 - Racemic styrene oxide reaction with HBr followed by thionyl chloride to benzylic chloride 88 
1.6.1 An asymmetric bromo-chlorination reaction 
The group then explored this sequence using an enantiopure epoxide (Scheme 34). Starting 
with enantiopure β-methylstyrene oxide 91, ring-opening of the epoxide to bromohydrin 92a 
proceeded smoothly via backside attack. Although some minor diastereoisomer 92b (ca. 20%) was 
obtained through the participation of the free benzylic cation, the stereochemical integrity of the 
homobenzylic stereocentre (marked with an asterisk in Scheme 34) was preserved as proven by 
the formation of the Mosher ester derivative (and comparison with the Mosher ester derived from 
racemic epoxide). On treatment with thionyl chloride the desired rearranged chlorohydrin 93—
evidently via enantiomerically pure bromonium ion 94—was obtained as a single enantiomer as 
determined by chiral HPLC (>98% e.e.). The structure of 93 was also unambiguously solved by 
X-ray crystallography.97  
 
Scheme 34 - The trapping of an enantiomerically pure bromonium ion using thionyl chloride 
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The group have also used PEG-sulfonate 95 to generate an enantiopure bromonium ion 94 by 
reacting it with TiCl4 (Scheme 35).
97 Under these conditions Lepore had previously reported that 
chlorination of PEG-sulfonate occurs via an SNi mechanism
99 and bromochloride 96 might have 
been expected to result. The group discovered that bromochloride 93 was obtained instead, which 
proved to be enantiomerically pure – evidently via enantiomerically pure bromonium ion 94 and 
trapping by chloride nucleophile.97  
 
Scheme 35 - The use of PEG-sulfonate and TiCl4 to generate an enantiopure bromonium ion 
1.6.2 An interesting rearrangement on standing 
In recent investigations by the group,100 bromobenzoate 97 was isolated from the reaction of 
cyclooctene epoxide 98 with NBS and 2,3,4,5-tetrafluorobenzoaic acid. Upon standing, neat, this 
compound was found to rearrange to 99, 100 and 101 (Scheme 36). This must proceed via 
neighbouring group participation of the bromine and loss of tetrafluorobenzoate. The resultant 
bromonium ion 102 can now be trapped by the earlier expelled tetrafluorobenzoate to form 100. 
Alternatively, transannular attack by the epoxide to give oxonium ion 103, and attack of 
tetrafluorobenzoate gives bicyclic adducts 99 and 101. 
 
Scheme 36 - Demonstration of 2,3,4,5-tetrafluorobenzoate as a labile leaving group100 
It was noted100 that this observation may be useful in designing further systems for the 
generation of enantiopure bromonium ions starting from enantiopure bromo-
tetrafluorobenzoates. The enantiopure bromonium ion could then be trapped by a nucleophile 
intramolecularly to form cyclic compounds.  
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1.7 Aims and objectives 
The overall aim of this project is to achieve the first polyene cyclisation triggered by an 
enantiomerically pure bromonium ion. To be successful, challenges in each of the fundamental 
steps of initiation, propagation and termination will need to be overcome (Scheme 37). In any 
initiation step, an enantiopure bromonium ion must be formed regioselectively at the terminus 
alkene of the polyene (in blue, Scheme 37). Currently, there is no widely applicable method for the 
formation of enantiopure bromonium ions by direct bromination of a simple trisubstituted alkene 
(even before considering the required regioselectivity of the process).87, 101  
 
Scheme 37 - Challenges for enantiospecific polyene cyclisation initiated by an enantiopure bromonium ion 
In the propagation step(s) intramolecular C-C bond formation must occur preferentially to 
intra- and/or intermolecular bromonium ion-to-alkene transfer102 and methods to analyse the 
extent of racemisation must also be developed. Termination needs to occur via a single mechanism, 
to give one polyene cyclisation product. The synthetic approach used to tackle these challenges is 
demonstrated in Scheme 38 and will require: 
A. Preparation of an enantiomerically pure bromine-containing substrate such as the 
bromohydrins shown in Scheme 38. These can be readily prepared by the anionic bromide 
ring-opening of an epoxide, the asymmetric synthesis of which can be accessed by a 
number of routes. 
B. Formation of an enantiopure bromonium ion by activation of the alcohol as a suitable 
leaving group, in the absence of a strong nucleophile, X-.  
C. Effective enantiospecific intramolecular trapping without erosion of enantiopurity by 
rapid bromonium ion-alkene exchange; whereby the rate of intramolecular trapping; k1 is 
greater than the rate of racemisation by olefin-olefin transfer; k2. 
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Scheme 38 - Overview of synthetic strategy 
In the first instance, racemic model systems will be utilised to develop the necessary synthetic 
methodology whilst chiral HPLC methods can be investigated to assess the extent of racemisation 
in a future asymmetric synthesis. This model system should: 
1. Provide substrates in good yields and in a small number of synthetic steps; 
2. Determine the required nature of the leaving group to form a bromonium ion; 
3. Determine the conditions and reagents needed to activate the leaving group; 
4. Provide chiral HPLC conditions for analysis of enantiomeric excess; 
5. Be reproducible in an asymmetric strategy and without degradation of enantiopurity. 
Realisation of the above chemistry will allow an asymmetric route to be undertaken and 
demonstrate that enantiomerically pure bromonium ions can be generated in a controlled fashion 
and be employed in synthesis. This methodology could then be applied in the biomimetic synthesis 
of naturally occurring sesqui-45a and diterpene45d,45g metabolites which possess the α,α-
dimethylcyclohexyl bromide moiety (highlighted in red in Figure 13). 
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Figure 13 - Representative disconnections for brominated polycyclic natural products 
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2 Results and discussion 
2.1 Synthesis of racemic substrates for mono-cyclisation 
The overall aim of this research was to develop general methodology for the asymmetric 
synthesis of natural products containing an α,α-dimethylcyclohexyl bromide moiety via a 
biomimetic bromonium ion-induced polyene cyclisation. However, when considering cation-π 
cyclisations of substrates containing an increasing number of isoprene units we anticipated 
increasing complexity arising from olefin selectivity and difficulties in the closure of multiple rings 
(Figure 14). 
 
Figure 14 - Homoprenyl, homogeranyl and homofarnesyl p-methoxybenzene substrates 
Initially we chose to investigate homoprenyl p-methoxybenzene (1), which allows for the 
investigation of cyclisation conditions without complications arising due to olefin selectivity. The 
cation-π cyclisation of this substrate will terminate by attack of the aromatic group; this was 
preferred over other nucleophilic groups because the remaining positive charge after cyclisation 
can only be quenched via one mechanism: rearomatisation (and therefore producing only one 
cyclisation product). The aromatic group also allows analysis by UV spectroscopy, which will be 
necessary for the determination of enantiopurity by chiral HPLC. Para-methoxy substitution of 
the aromatic ring also provides greater nucleophilicity for faster trapping of a bromonium ion 
during cyclisation and increases the polarity of the compound, aiding separation by analytical chiral 
HPLC.  
Homoprenyl p-methoxybenzene (1) was synthesised using methodology developed by 
Demuth.103 In our hands, 76% isolated yield was obtained by alkylation of prenyl bromide 2 with 
1.3 equivalents of p-methoxybenzyl Grignard reagent in the presence of 5 mol% Pd(PPh3)4 (Table 
2, entry 1) along with homodimer 4 in 13% yield. Increasing the number of equivalents of Grignard 
reagent from 1.3 to 1.5 did not improve the yield of 1 (entry 2) and on a larger scale (10 g of prenyl 
bromide), the catalytic loading of Pd(PPh3)4 could be reduced to 1.5 mol% without compromising 
the yield (80%, entry 3). 
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Table 2 - Synthesis of homoprenyl p-methoxybenzene (1) 
 
Entry 
2 
mmol 
3 
(eq.) 
Pd(PPh3)4 
(mol%) 
Yield 1a 
(%) 
α:γ 
Yield 4a 
(%) 
1 18 1.3 5.0 76 35:1 13 
2 4 1.5 5.0 73 11:1 18 
3 67 1.3 1.5 80 4:1 0 
4 67 1.1 1.0 73 55:1 nd 
5 34 0.95 1.0 78 50:1 nd 
nd = not determined. aIsolated yield after column chromatography 
In this reaction (Table 2, entry 3), the desired α-alkylated product α-1 was isolated with 
inseparable γ-1 in a 4:1 ratio. This undesired constitutional isomer is formed by SN2’ attack of the 
Grignard reagent at the more sterically hindered carbon of the intermediate (η3-allyl)Pd complex 
5 (Scheme 39) which can be supressed by decreasing the amount of Grignard reagent (1.1 or 0.95 
equivalents) and Pd(PPh3)4 (1 mol%) (entries 4 and 5). 
 
Scheme 39 - Potential products of Demuth’s allylic alkylation reaction 
Epoxidation of olefin 1 was achieved with mCPBA in dichloromethane to give epoxide 6 in 
81% yield (Scheme 40) together with isomeric epoxide 7 in 8% yield. This compound results from 
the epoxidation of γ-1 present in the starting material.  
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Scheme 40 - Epoxidation of homoprenyl p-methoxybenzene (1) 
Analysis of racemic epoxide 6 by chiral HPLC using available chiral columns (CHIRALCEL 
OD-H or CHIRALPAK AD) provided incomplete baseline separation of enantiomers. Therefore 
the enantiopurity of this compound cannot be determined in future asymmetric synthesis of 
epoxide 6. This simple two step procedure provided a quick route to over 8.5 grams of pure 
racemic epoxide 6. 
2.1.1 Anionic bromide epoxide ring-opening 
Attention then turned to conditions for the installation of bromide by epoxide ring-opening 
where two regioisomeric bromohydrin products are possible; 8a and 8b (Table 3). There are 
several reported methods for regioselective ring-opening of epoxides, for example, Morimoto104 
carried out the regioselective ring-opening of trisubstituted epoxide 9 using magnesium bromide 
etherate in the total synthesis of (+)-intricatetraol,105 giving the Markovnikov product 10a in 45% 
yield. Morimoto also carried out the ring-opening of epoxide 9 to give anti-Markovnikov addition 
10b using dilithium tetrabromonickelate106 in THF in 76% yield. Magnesium bromide etherate was 
also used by Krauss71 to carry out the ring-opening of a trisubstituted epoxide in polyene cyclisation 
substrate 11. In this case, tetrabutylammonium bromide was added to suppress polyene cyclisation, 
from the action of Lewis acid on the epoxide. This method gave predominantly the Markovnikov 
product 12 in 88% with a ratio of regioisomers 5:1. 
  
Scheme 41 - Regioselective ring-opening of epoxides 
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In this work on bromonium ion-induced cation-π cyclisations, both bromohydrin regioisomers 
will re-converge onto the same bromonium ion. For this reason, regioselective epoxide ring-
opening is not a priority, and there is not necessarily any need for them to be separated. Our aim 
however, was to discover a practically simple method for the isolation of each bromohydrin 
regioisomer, 8a and 8b in high yield. This would allow conditions for the activation of secondary 
and tertiary alcohols towards cyclisation to be investigated separately. 
Table 3 - Anionic bromide reagents tested for use in the ring-opening of epoxide 6 
 
Entry Reagents 
Solvent  
(T /°C, t /h) 
Recovered 
6 
Yield (%)  
8a + 8ba 
8a:8bb 
1 (n-hexyl)4NBr 
HFIP 
(58, 16) 
12 0 N/A 
2 
Bu4NBr, 
Mg(NO3)2 
CH2Cl2 
(40, 6) 
35 39 1:2 
3 PPh3/Br2 
CH2Cl2 
(r.t. 16) 
0 42 2:1 
4 
PPh3/Br2 
(excess PPh3) 
CH2Cl2 
(r.t. 16) 
0 50 2:1 
5 Me2SBr
+Br- 
MeCN 
(r.t., 0.5) 
0 46 2:1 
6 LiBr, PPTS 
NMP 
(r.t., 3) 
6 71c 1:1 
aIsolated yield after chromatography, bdetermined by inspection of the 1H NMR spectrum,  cfrom reaction of (R)-6 
To this end, epoxide 6 was reacted with tetrahexylammonium bromide in 
hexafluoroisopropanol which acts as a powerful hydrogen-bond donor,107 previously used in work 
by Denmark (Table 3, entry 1).95 HFIP was anticipated to assist in activation of the epoxide oxygen 
and the observed reaction products indicated that this assumption was correct. However, 
competitive elimination, semi-pinacol rearrangement or cyclisation processes were faster than 
attack by bromide anion giving: cycloadduct 13 (20%, Scheme 42), allyl alcohol 14 (14%), aldehyde 
15 (8%) and ketone 16 (28%). 
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Scheme 42 - Rearrangement of epoxide 6 with (hexyl)4NBr in HFIP 
Tetrabutylammonium bromide was then used in conjunction with catalytic quantities of Lewis 
acid, magnesium nitrate (Table 3, entry 2). This methodology was originally developed by Suh et 
al.108 who found that magnesium nitrate catalysed the regioselective ring-opening of a number of 
primary epoxides and one trisubstituted cyclohexene oxide 17 (Scheme 43). 
 
Scheme 43 - Regioselective ring-opening of trisubstituted epoxide 17 using magnesium nitrate Lewis acid 
Suh’s work showed that bromide attacks preferentially at the least hindered carbon of a 
trisubstituted epoxide which is activated by magnesium nitrate. Accordingly epoxide 6 was heated 
at reflux for 6 hours with n-Bu4N
+Br- and Mg(NO3)2, giving 39% yield of bromohydrin 8a and 8b 
in a 1:2 ratio in preference for the anti-Markovnikov adduct as found by Suh et al. It must be noted 
that the desired bromohydrin regioisomers 8a and 8b could be separated by column 
chromatography, however bromohydrin 8b was contaminated with allyl alcohol 14 in 10% yield. 
Ketone 16 was also isolated in 7% yield (Scheme 44).  
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Scheme 44 - Ring-opening of epoxide 6 using n-Bu4N+Br- and Mg(NO3)2 
Palumbo, Ferreri and Caputo:109 reported the use of a 1:1 mixture of triphenylphosphine and 
molecular bromine which react to give a partially ionic complex110 that preferentially attacks the 
less-substituted carbon atom of trisubstituted epoxide 18 (Scheme 45) leading them to postulate a 
SN2 mechanism. In later experiments by the same group,
111 trisubstituted cholesterol based 
epoxides (19) was shown to give trans-diaxial ring-opening of the epoxide to give 20, consistent 
with an SN2 mechanism. 
 
Scheme 45 - Anionic bromide epoxide ring-opening of 1-methylcyclohexene oxide 18 and trisubstituted cholesterol 
based steroid 19 using Ph3P/Br2 
In our hands these reaction conditions gave bromohydrins 8a and 8b in an overall yield of 42% 
with a ca. 2:1 ratio favouring Markovnikov addition (Table 3, entry 3). Unfortunately, considerable 
quantities of aryl bromides 21a and 21b were also isolated (Scheme 46) with secondary bromide 
8b being contaminated with aryl bromide 21a. 
 
Scheme 46 - PPh3/Br2 epoxide ring-opening of 6 
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These aromatic bromination by-products were presumably formed by the presence of un-
complexed molecular bromine in the reaction mixture. Subsequently, the use of excess 
triphenylphosphine reduced the yield of undesired aryl bromide products to ca. 10% (Scheme 47) 
and improved the yield of the desired bromohydrin adducts 8a and 8b to 50% (Table 3, entry 4).  
 
Scheme 47 - PPh3/Br2 epoxide ring-opening of 6 with excess of PPh3 
A conceptually similar reagent, (bromodimethyl)sulfonium bromide has been employed by Das, 
Krishnaiah and Venkateswarlu.112 Its reaction with primary, 1,2-disubstituted cyclic and trans-
epoxides gives bromohydrins in up to 98% yield with no observed side products and high 
regioselectivities for attack at the least hindered carbon. Anionic bromide ring-opening of 
trisubstituted epoxide 22 for example was reported under these conditions to give anti-
Markovnikov adduct 23 in 78% yield.  
 
Scheme 48 - (Bromodimethyl)sulfonium bromide ring-opening of trisubstituted epoxide 
Discovered by Meerwein,113 (bromodimethyl)sulfonium bromide was synthesised as a light-
orange crystalline solid by the original method114 and reacted with epoxide 6 using conditions by 
Das et al.112 Bromohydrins 8a and 8b were in produced in 46% yield, in a 2:1 ratio (Scheme 49 & 
Table 3, entry 5). 
 
Scheme 49 - Ring-opening of epoxide 6 using Me2SBr+Br- 
Couladouros and Vidali in their research on the stereocontrolled synthesis of trans-fused 
oxepene-cyclogeranyl systems76 (Chapter 1.4.2, page 34) achieved regioselective ring-opening of 
enantiopure trisubstituted epoxide 24 using lithium bromide and camphorsulfonic acid in 
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hexamethylphosphoramide, giving the desired anti-Markovnikov adduct 25 in 53% yield with allyl 
alcohol 26 in 18% yield (Table 4, entry 1). 
Table 4 - Couladouros and Vidali bromide ring-opening of epoxide conditions 
 
Entry H+ Solvent Yield 25 (%) Yield 26 (%) 
1 CSA HMPA 53 18 
2 PPTS NMP 85 <5 
 
The formation of the elimination product 26 was reduced to less than 5% by the use of milder 
conditions, namely lithium bromide and PPTS in N-methyl-2-pyrrolidone. This gave an improved, 
85% yield of bromohydrin 25 with less than 5% yield of 26. In our hands these conditions 
produced bromohydrins 8a and 8b in 71% overall yield in a ratio of ca. 1:1 (Table 3, entry 6) and 
ketone 16 (12%). Bromohydrin 8b could only be isolated contaminated with ca. 12-15% allyl 
alcohol 14 (Scheme 50). The method of Couladorous76 using inexpensive lithium bromide became 
the method of choice to access both regioisomeric bromohydrins in high yield. 
 
Scheme 50 - Ring-opening of epoxide 6 using LiBr, PPTS and NMP 
2.1.2 Characterisation of bromohydrin regioisomers 
Once separated and purified bromohydrin regioisomers 8a and 8b can be distinguished by 
characteristic 1H and 13C NMR resonances. Figure 15a and Figure 16a show the 13C NMR 
resonances of carbon atoms bearing a heteroatom for each bromohydrin regioisomer. Below are 
the corresponding 13C DEPT NMR spectrums (Figure 15b and Figure 16b). From this data for 
the first bromohydrin regioisomer, (Figure 15, a and b) it can be deduced that the carbon resonance 
at 78.7 ppm bears a proton, whereas the carbon resonance at 75.6 ppm is a quaternary carbon. For 
the second bromohydrin regioisomer (Figure 16, a and b) there is a quaternary carbon at 72.5 ppm 
and a tertiary carbon at 70.3 ppm. 
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Figure 15 - a) 13C NMR spectrum; b) 13C DEPT NMR 
spectrum; c) 13C high resolution spectrum of bromine 
isotope effect of bromohydrin 8a. 
Figure 16 - a) 13C NMR spectrum; b) 13C DEPT 
NMR spectrum; c) 13C high resolution spectrum of 
bromine isotope effect of bromohydrin 8b. 
Figure 15c and Figure 16c show high resolution analysis of the 13C NMR resonances at 75.6 
ppm and 70.3 ppm for each regioisomer, the patterns shown are characteristic of a carbon bearing 
a bromine atom, a consequence of the two naturally-occurring isotopes of bromine, 79Br and 81Br, 
with 50% abundance of each, and their effect on the 13C NMR chemical shift of the carbons 
attached to each isotope. If bromine is present on a given carbon the 13C NMR resonance will 
appear as two signals of equal intensity separated by ca. 2 ppb.115  
Furthermore, with the aid of 13C HSQC NMR experiments it is possible to identify the 
characteristic 1H NMR resonances of a proton alpha to a secondary alcohol (in bromohydrin 8a) 
and a proton alpha to a bromine atom (in bromohydrin 8b). The proton alpha to the hydroxyl 
group was determined to have a 1H NMR resonance at 3.43 ppm (Figure 17) and the proton alpha 
to a bromine atom has a 1H NMR resonance at 3.98 ppm. 
Figure 17 - 1H and 13C NMR resonances of bromohydrin regioisomers 8a and 8b 
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With careful chromatography samples of bromohydrin 8a and 8b could also be analysed by 
chiral HPLC. In the event of erosion of e.r. in the asymmetric synthesis of bromo-esters this may 
prove diagnostic. 
  
Figure 18 - Chiral HPLC chromatogram showing 
separation of enantiomers of bromohydrin (±)-8a 
Figure 19 - Chiral HPLC chromatogram showing 
separation of enantiomers bromohydrin (±)-8b 
Isolation and characterisation of pure tertiary bromide 8a would allow us to demonstrate the 
formation of a bromonium ion in future cyclisations. This regioisomer must necessarily proceed 
through bromonium ion 27 in order for the bromide to shift from its tertiary position in 8a to a 
secondary position in cyclised product 29 (Scheme 51), whereas secondary bromide 8b could 
cyclise via tertiary carbocation 28 (investigated in Chapter 2.2.4). 
 
Scheme 51 - Cyclic bromonium ion and open β-bromocarbocation extremes of cyclisation intermediates 
2.1.3 Esterification 
The alcohols present in bromohydrins 8a and 8b require activation as a suitable leaving group 
in order to form a bromonium ion, in the absence of another nucleophile, to trigger clean reaction 
pathways to cyclisation.  
Secondary tosylate 30 was successfully synthesised using 4-toluenesulfonic anhydride in 
pyridine (Scheme 52). Unfortunately, the product was found to be unstable to chromatography. 
As tertiary tosylate esters are likely to be more reactive, it was concluded that tosylate esters of 8a 
and 8b would be unsuitable as cyclisation substrates. 
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Scheme 52 - Synthesis of secondary-tosylate 30 
Based on previous work within the Braddock group (1.6.2, page 45) it was decided that 
tetrafluorobenzoate esters could be a facile leaving group, stable enough for isolation by column 
chromatography. The synthesis of secondary tetrafluorobenzoate ester 31a was first attempted by 
forming the acid chloride of 2,3,4,5-tetrafluorobenzoic acid using oxalyl chloride and catalytic 
DMF (Scheme 53). Subsequent reaction with secondary alcohol 8a and stoichiometric DMAP 
gave the desired tetrafluorobenzoate ester 31a in very low yield (4%) along with epoxide 6 (33%), 
ketone 16 (19%) and recovered starting material 8a (7%).  
 
Scheme 53 - Formation of tetrafluorobenzoic acid chloride and esterification of secondary alcohol 8a 
Secondary alcohol 8a was instead esterified using Steglich esterification116 using a small excess 
of tetrafluorobenzoic acid (1.2 eq), DCC (1.3 eq) and a substoichiometric amount of DMAP (30 
mol%) over one hour gave the desired tetrafluorobenzoate ester 31a in 88% yield (Table 5, entry 
1). The more sterically hindered tertiary alcohol 8b gave 42% yield of ester 31b under the same 
conditions over sixteen hours (entry 2). Increasing the number of equivalents of tetrafluorobenzoic 
acid and DCC employed to two and three equivalents, respectively, gave an improved yield of 69% 
of the tertiary tetrafluorobenzoate ester 31b as a mixture with allyl ester 33 (entry 3). Allyl ester 33 
was isolated as the esterification product of allyl alcohol 14 present in the starting material. 
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Table 5 - Steglich esterification 
 
Entry Substrate Product t /h 
ROH 
(eq.) 
DCC 
(eq.) 
Yield 
(%) 
1 8a 31a 1 1.2 1.3 88 
2 8b 31b 16 1.2 1.3 42 
3 8b 31b 16 2 3 69a 
4 8a 32a 16 1.2 1.3 95 
5 8b 32b 48 6 9 0 
a Containing ca. 10% allyl tetrafluorobenzoate 33 
 
For comparison in cyclisation studies, the more atom-economical acetate esters 32a and 32b 
were also targeted for synthesis using Steglich esterification. Acetylation of secondary alcohol 8a 
using acetic acid (1.2 eq.) and DCC (1.3 eq.) over sixteen hours gave 95% yield of the desired 
acetate ester 32a (Table 5, entry 4). However, reaction of the more sterically hindered tertiary 
alcohol 8b with acetic acid (2 eq.) and DCC (3 eq.) gave poor conversion after 16 h and despite 
two further additions of the two reagents after 16 h each none of the desired acetate ester 32b was 
observed (Table 5, entry 5). Therefore alternative conditions were investigated for the synthesis of 
tertiary acetate 32b (Table 6). 
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Table 6 - Investigating tertiary alcohol acetylation conditions 
 
Entry Reagent (eq.) T (°C) t (h) Yield (%) 
1 
AcCl (1.3×2),  
NEt3 (3×2), DMAP (0.3) 
0 to r.t 16 then 2 17 
2 
AcCl (2×3), NBS 
(2×0.05) 
40 8 then 16 32a 
3 
Ac2O (25),  
NEt3 (19), DMAP (0.1) 
0 to r.t. 16 29 
4 AcOH (1), TFAA (6) r.t. 2 63 
a Contaminated with 21% yield of allyl acetate 34 
 
The use of acetyl chloride and triethylamine with catalytic DMAP overnight produced none of 
the desired tertiary acetate 32b (Table 6, entry 1), however, when a second equivalent of acetyl 
chloride and triethylamine was added the desired product was isolated in 17% yield after 2 hour. 
It has been reported that NBS can act as an acid catalyst for acetylation of alcohols using acetic 
anhydride.117 It was shown by Rezaei et al. that NBS could be used as an effective catalyst 
specifically for the synthesis of tertiary esters using acyl halides in good yield.118 In our hands, when 
tertiary alcohol 8b was heated at reflux with catalytic NBS and acetyl chloride for 16 h a mixture 
of acetate ester 32b and allylic acetate 34 were isolated in 32% and 21% yield, respectively (Table 
6, entry 2).  
Acetic anhydride was then used in a large excess with triethylamine and catalytic DMAP (Table 
6, entry 3) which gave 29% isolated yield of desired acetate ester 32b after 16 h at room 
temperature. 
The use of acetic acid and trifluoroacetic anhydride was first demonstrated by Bourne et al. in 
the acetylation of a range of aromatic carboxylic acids.119 The scope and limitations of the reaction 
were later investigated with more hindered acids but more importantly, good yields were observed 
with the esterification of hindered alcohols such as tert-butanol.120 This method was later used in 
the synthesis of (±)-Aplysin-20.75 Under these conditions tertiary acetate ester 32b was 
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accomplished in 72% isolated yield after 3 hours at room temperature (Table 6, entry 4). These 
reaction conditions provided pure 32b, free from 34 for analysis by chiral HPLC. 
Cyclisation substrates 31a, 31b, 32a, and 32b have now been synthesised in good yield and all 
four sets of enantiomers were shown to be separable by chiral HPLC (see Figure 20-Figure 23). 
This allows the determination of enantiomeric excess of these compounds in a future asymmetric 
route (2.3.1, page 77). 
  
Figure 20 - Chiral HPLC chromatogram showing 
separation of enantiomers of tetrafluorobenzoate ester 
(±)-31a 
Figure 21 - Chiral HPLC chromatogram showing 
separation of enantiomers of tetrafluorobenzoate ester 
(±)-31b 
  
Figure 22 - Chiral HPLC chromatogram showing 
separation of enantiomers of acetate ester (±)-32a 
Figure 23 - Chiral HPLC chromatogram showing 
separation of enantiomers of acetate ester (±)-32b 
2.2 Investigation of mono-cyclisation reaction conditions 
It is now necessary to investigate conditions and reagents to promote the formation of a 
bromonium ion for tetrafluorobenzoate esters 31a and 31b, and acetate esters 32a and 32b. This 
investigation will allow us to establish the required nature of the leaving group. 
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2.2.1 Solvolysis 
As the Braddock group has previously observed the spontaneous formation of a bromonium 
ion on standing from an isolable 1-bromo-2-tetrafluorobenzoate (1.6.2, 45).100 It was reasoned that 
31a and 31b may also spontaneously generate a bromonium ion by solvolysis. Accordingly, a range 
of solvents and conditions were explored using 31a and/or 31b. 
 Table 7 - Attempted cyclisation of 31a or 31b into 29 under various solvolytic conditions 
 
     Yield (%) 
Entry Substrate Solvent T (°C) t (h) 
Recovered 
SM 
29 33 35 36 
1 31a CDCl3 61 3 100
a 0 0 0 0 
2 31a CD3NO2 100 3 100
a 0 0 0 0 
3 31a HFIP 60 16 0 0 26 b 39b 0 
4 31b HFIP 60 16 complicated mixture of components 
5 31a NFTB 45 16 100a 0 0 0 0 
6 31b NFTB 45 16 28 complicated mixture of components 
7 31a HCO2H 101 6 complicated mixture of components 
8 31b HCO2H 101 6 complicated mixture of components 
9 31a IL 90 → 120 16 & 2 95 trace 0 0 0 
10 31b IL 90 4 34 19 0 0 6 
a inspection of the 1H NMR spectrum after work-up revealed no reaction and only recovered starting material; 
binseparable mixture of components 
   
Initially, secondary tetrafluorobenzoate ester 31a was left standing in deuterated chloroform 
overnight, inspection of the 1H NMR spectrum showed that no reaction had occurred. Both 
heating the same sample at reflux for 3 h (Table 7, entry 1) and exchanging the solvent for 
deuterated nitromethane as a polar solvent and heating at reflux for 3 h gave no product (entry 2). 
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As previously discussed (1.5, Figure 12, page 41) hexafluoroisopropanol is a well-known polar 
solvent121 of high ionising power, low nucleophilicity96 and is a powerful hydrogen-bond donor.107 
It is capable of strongly solvating anions but not cations, and so carbocations and cationic radicals 
persist in solution. This property makes HFIP an optimal solvent for the promotion of 
neighbouring group participation in solvolysis reactions which generate cationic halonium ions.122 
HFIP has therefore been used in cationic cyclisation reactions123 and as discussed previously 
Denmark95 has shown that enantiopure bromonium ions can be generated from 1,2-
bromotosylates in HFIP, which are then trapped in the presence of stoichiometric quantities of 
nucleophile (Scheme 54). The solvolysis of enantiomerically enriched (4R,5S)bromo-tosylate 37 
with a solution of nucleophile (NaOAc, or MeOH) in HFIP produced the products 38 or 39 in 
high yields and high enantiopurity.  
 
Scheme 54 - Denmark solvolytic substitution with (4R,5S)-37 
HFIP has also been used by Jamison et al.124 to facilitate bromonium ion initiated poly-epoxide 
ring-opening of alkene 41 and maximised the directing influence of the methyl groups to form the 
cyclised product 42 (Scheme 55).  
 
Scheme 55 - Jamison et al. bromonium ion initiated poly-epoxide ring-opening cascade 
Accordingly, HFIP could reasonably be foreseen to promote bromonium ion formation and 
cyclisation of bromo-tetrafluorobenzoate esters 31a and 31b. However utilising HFIP as a solvent 
at 60°C (Table 7, entry 3) gave non-bromine containing compounds 35 (39%) and 33 (26%, 
Scheme 56). These must result from solvent assisted bromide separation to produce tertiary 
carbocation 43 (which may be stabilised anchimerically by the benzoate), this could then cyclise to 
form 35 or eliminate to form 33. Under the same conditions tetrafluorobenzoate ester 31b (Table 
7, entry 4) produced a complex mixture of products. 
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Scheme 56 - Cyclisation of tetrafluorobenzoate 31a using HFIP at reflux 
The use of nonafluoro tert-butanol (NFTB) as the solvent was also unsuccessful at promoting 
clean cyclisation of 31a/31b to product 29. No reactivity was observed in reaction with secondary 
tetrafluorobenzoate ester 31a (Table 7, entry 5). Only low conversion was observed of 31b to a 
mixture of non-bromine containing cyclised and un-cyclised tetrafluorobenzoate esters (entry 6). 
Formic acid was also used by Denmark95 in the solvolysis of enantiomerically enriched bromo-
tosylates 37 (Scheme 54) and so it could reasonably be foreseen to promote bromonium ion 
formation and cyclisation of bromo-tetrafluorobenzoate esters 31a and 31b. However the reaction 
produced a very complicated mixture of products, presumably a number of formate esters, 
tetrafluorobenzoate esters, and bromide containing compounds (Table 7, entries 7 and 8). 
Research into the use of ionic liquids in organic synthetic chemistry is being pioneered by the 
Welton group at Imperial College.125 The use of 1-butyl-1-methylpyrrolidinium 
bis[(trifluoromethyl)sulfonyl]imide (IL) as a solvent was investigated to promote bromonium ion 
formation and cyclisation of bromo-tetrafluorobenzoate esters 31a and 31b as the ionic nature of 
the liquid possibly stabilises any charged intermediates formed. Unfortunately, no reactivity was 
observed at elevated temperatures, for the cyclisation of secondary tetrafluorobenzoate ester 31a 
(Table 7, entry 9). However, when IL was used as a solvent in the cyclisation of tertiary 
tetrafluorobenzoate ester 31b, 19% yield of the desired cyclised product 29 was obtained along 
with 6% yield of the allyl bromide 36 (Table 7, entry 10). 
Minimal success was achieved using solvolysis to promote bromonium ion formation and 
cyclisation of bromo-tetrafluorobenzoate esters 31a and 31b, and attention turned to the attempted 
cyclisation of 31a/31b using stoichiometric quantities of oxophilic Lewis acids. 
2.2.2 Oxophilic Lewis acids 
A selection of four oxophilic Lewis acids in dichloromethane at low temperatures were chosen 
for the attempted cyclisation of tetrafluorobenzoate esters 31a/31b to brominated bicycle 29 
(Table 8).  
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Table 8 - Lewis acid effect on cyclisation 
 
     Yield (%) 
Entry Substrate Reagents T (°C) t (h) 
Recovered 
SM 
29 36 44 
1 31a BF3.OEt2 -40 0.5 100 0 0 0 
2 31b BF3.OEt2 -40 0.5 80
 a 0 20a 0 
3 31a TiCl4 (2 eq) -78 1 100 0 0 0 
4 31b TiCl4 (2 eq) -78 1 5 55 0 12 
5 31a Me2AlCl -78 to r.t. 16 20 33 0 23 
6 31b Me2AlCl -78 to r.t. 4 0 56 0 6 
7 31a TMSOTf -78 6 95 0 0 0 
8 31b TMSOTf -78 6 0 44 0 0 
9 32b TMSOTf -78 16 0 43 0 0 
10 30 TMSOTf -78 6 0 48 0 0 
11 31b 
TMSOTf (2.1 eq) 
DTBP (1 eq) 
-78 to r.t. 96 100 0 0 0 
All reactions were carried out with 1.1 eq. of Lewis acid unless stated otherwise. adetermined by inspection of the 1H 
NMR spectrum 
.  
Boron trifluoride etherate was ineffective for cyclisation of substrate 31a (Table 8, entry 1) 
under these conditions, and the starting material was recovered. Reaction of tertiary 
tetrafluorobenzoate ester 31b however, gave 20% yield of eliminated product 36, although no 
bromo-cyclisation was observed (entry 2). Titanium tetrachloride was able to effect the desired 
cyclisation of tertiary tetrafluorobenzoate ester 31b in 55% yield (entry 4) with 12% yield of 
inseparable bromochloride 44. Regioisomeric bromochloride 44 was identified by the 
characteristic 1H NMR absorbance for a proton alpha to a bromine atom at 4.03 ppm, which was 
bonded to a carbon atom at 65.0 ppm in the 13C NMR spectrum by analysis of the HSQC NMR 
spectrum. Titanium tetrachloride was ineffective at cyclisation of secondary ester 31a (entry 3). 
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Dimethylaluminium chloride affected the desired cyclisation of both tetrafluorobenzoate 
regioisomers 31a and 31b in good yield, 33% and 56% yield respectively, however both reactions 
also produced inseparable chloride 44 (entries 5 and 6).  
Trimethylsilyl triflate showed promising activity having cleanly promoted the bromo-cyclisation 
of tertiary tetrafluorobenzoate ester 31b in 44% yield (entry 8), but not secondary 
tetrafluorobenzoate ester 31a (entry 7). TMSOTf was also found to initiate the cyclisation of 
acetate ester 32b in 43% yield (entry 9) and bromo-tosylate 30 in 48% yield (Synthesis: Scheme 
52). Also produced in reaction of bromo-tosylate 30 was 18% yield of ketone 16 (entry 10). 
However, tosylate esters of 8a and 8b would be unsuitable as cyclisation substrates as sulfonate 
esters are too unstable for purification by column chromatography. 
  
Scheme 57 - TMSOTf catalysed cyclisation of secondary-tosylate 30 
For the successful cyclisation of tertiary tetrafluorobenzoate 31b using TMSOTf, control 
experiments containing non-nucleophilic base: 2,6-di-tert-butylpyridine were carried out (entry 11). 
The loss of reactivity signified that TMSOTf was not active in the original reaction and instead it 
was the presence of triflic acid which must be promoting the reaction. Based on this result, 
investigations into the use of triflic acid as a cyclisation initiator began. 
2.2.3 Triflic acid 
The use of 30 mol% catalytic loading of triflic acid was tested on both secondary and tertiary 
tetrafluorobenzoate esters 31a and 31b. Pleasingly, both regioisomers were found to cyclise 
smoothly to the desired product 29 (Table 9, entries 2 and 3). Tertiary tetrafluorobenzoate ester 
31b reacted over 16 h at room temperature to give bicycle 29 in 51% isolated yield (entry 2). 
However, no conversion was observed for secondary tetrafluorobenzoate ester 31a over the same 
period (entry 1). After heating the reaction mixture at reflux for 6 h in dichloromethane, full 
conversion to bicycle 29 was accomplished in 73% isolated yield (entry 3). 
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Table 9 - Investigation of triflic acid loading on cyclisation of tetrafluorobenzoate esters 31a and 31b 
 
Entry Substrate 
TfOH 
(mol%) 
T (°C) t (h) % Conversiona 
1 31a 30 r.t. 16 0 
2 31b 30 r.t. 16 79 (51) 
3 31a 30 40 6 97 (73) 
4 31a 10 40 16 81 (65) 
5 31a 5 40 16 20 (15) 
aAs determined by inspection of the 1H NMR spectrum after aqueous work-up. Figure in parentheses is isolated 
yield after column chromatography. 
The catalyst loading of triflic acid could be reduced to 10 mol% without compromising the 
yield of the reaction (65%, Table 9, entry 4), however, 5 mol% catalyst loading of triflic acid was 
less effective (15% entry 5). 
Having successfully triggered a cation-π cyclisation with bromo-tetrafluorobenzoate esters 31a 
and 31b with catalytic quantities of triflic acid, the question posed was whether bromohydrins 8a 
and 8b would also be suitable substrates under these conditions. To analyse the use of these earlier 
substrates, bromohydrin 8a and 8b were treated with 30 mol% triflic acid in dichloromethane at 
reflux for 3 hours (Table 10, entry 1 and 2). 
Table 10 - Triflic acid mediated cyclisation on bromohydrins 8a and 8b 
 
Entry Substrate 
TfOH  
(mol%) 
T (°C) t (h) 
Yield 29 
(%) 
Yield 16 
(%) 
1 8a 30 40 3 57 30 
2 8b 30 40 3 67 14a 
3 8a 10 40 16 34 66 a 
4 8a 5 40 16 31 69 a 
adetermined by 1H NMR analysis of crude reaction mixture 
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In the reaction of secondary alcohol 8a the desired bromo bicycle 29 was isolated in 57% yield 
(entry 1), whereas tertiary alcohol 8b gave an improved yield of 67% (entry 2). The major by-
product of both reactions was found to be ketone 16 which was isolated in 30% yield from reaction 
of bromohydrin 8a and identified by 1H NMR analysis of the crude reaction mixture from 
bromohydrin 8b (entry 2). Unfortunately, lower than 30 mol% loadings of triflic acid with 
secondary alcohol 8a gave ketone 16 as the major product (entries 3 and 4). 
In summary, conditions for activation of bromo-tetrafluorobenzoate esters 31a and 31b and 
also bromohydrins 8a and 8b towards bromo-cyclisation have been optimised using catalytic triflic 
acid. However, a number of questions regarding the mechanism of this reaction still remain. 
2.2.4 Mechanistic investigation 
As mentioned previously, (Scheme 20) the activation of tertiary alcohol or ester derivatives and 
any subsequent cyclisation can invoke one of two intermediates, either a tertiary carbocation or 
cyclic bromonium ion. In order to probe whether bromine neighbouring group participation was 
required for cyclisation to occur in tertiary substrates such as 8b or 31b, it was necessary to 
synthesise the tertiary alcohol 45 without bromine. Attempts to synthesise this compound from 
bromohydrin 8b via a radical dehalogenation reaction using tributyltin hydride and 
azobisisobutyronitrile in anhydrous toluene were unsuccessful and the thermal degradation 
products epoxide 6 and ketone 16 were isolated in 87% and 4% yields (Scheme 58). This 
unexpected reaction outcome proved to be reproducible. 
 
Scheme 58 - Treatment of bromohydrin 8b with tributyltin hydride 
However, oxymercuration-reduction of homoprenyl p-methoxybenzene (1) yielded 65% of the 
desired tertiary alcohol 45 (Scheme 59). This could be activated as a tetrafluorobenzoate ester using 
2 equivalents of 2,3,4,5-tetrafluorobenzoic acid and 3 equivalents of DCC, catalytic DMAP in 
dichloromethane at room temperature overnight to give the desired tetrafluorobenzoate ester 46 
in 83% yield. 
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Scheme 59 - Oxymercuration reduction of homoprenyl p-methoxybenzene 1 
Reaction of both tertiary alcohol 45 and tetrafluorobenzoate ester 46 with catalytic triflic acid 
gave excellent yields of cyclohexane 47 (Scheme 60). 
 
Scheme 60 - Cyclisation of des-bromo tertiary alcohol 45 and tertiary tetrafluorobenzoate ester 46 
This shows that cyclisation of tertiary leaving groups with triflic acid can certainly occur without 
neighbouring group participation by bromine. As the yield is higher than the respective bromine-
containing compounds 8b and 31b, it is possible that the bromine may even be sterically hindering 
the cyclisation. This demonstrates the stability of the tertiary carbocation in the fact that it can be 
readily formed using triflic acid and trapped by an intramolecular nucleophile. 
After consideration of the substitution of the aromatic ring it became apparent that attack of 
the aromatic onto bromonium ion 48 may occur at either the meta- or the para-positions relative to 
the methoxy group (Scheme 61). Direct attack of the meta-position relative to the methoxy group 
would furnish bicycle 29 after rearomatisation, attack of the more favoured para-position would 
give a spiro quinone type intermediate 49, which would rearrange and re-aromatise via the same 
carbocation 50 to give the desired bicycle 29. 
 
Scheme 61 - Possible mechanisms of attack of a para-methoxy substituted aromatic 
In an attempt to trap any spiro quinone type intermediate such as 51 (Scheme 62), silyl ether 52 
was sought.  
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Scheme 62 - Cyclisation of silyl ether 52 to a spiro quinone 51 
The use of boron tribromide for demethylation of 1 failed to give the desired phenol 53 and 
instead catalytic, proton initiated cyclisation under these reaction conditions gave bicycle 54 in 
quantitative yield.  
 
Scheme 63 - Boron tribromide demethylation of 1  
When the demethylation reaction was instead carried out with three equivalents of 2,6-di-tert-
butylpyridine (DTBP)—a non-nucleophilic proton scavenger—the desired phenol 53 was isolated 
in quantitative yield. Silylation of 53 with chlorotrimethylsilane in pyridine produced the desired 
silyl ether 52 in 78% yield, but again the silyl ether was found to be unstable to chromatography 
and so was used directly after work-up in bromo-cyclisation reaction with Snyder’s reagent: 
BDSB.48 
With one equivalent of BDSB in nitromethane at -14°C for 1 h, TMS ether 52 gave bromo-
bicyclic phenol 55 in 52% isolated yield over two steps. The cyclisation of phenol 53 gave the same 
product in 72% under the same bromo-cyclisation reaction conditions. There was no evidence for 
the presence of a compound such as a spiro-quinone 51, in either reaction. Therefore it seems 
likely that if such an intermediate were to be formed it rearranges to the observed bicyclic phenol 
55.  
  
Scheme 64 - Mechanistic studies using phenol 53 and its trimethylsilyl ether derivative 52 
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To conclude, it cannot be ruled out that cyclisation of tertiary leaving groups such as those in 
bromohydrin 8a and tetrafluorobenzoate ester 31b are proceeding through a tertiary carbocation. 
However, secondary leaving group substrates must necessarily proceed through NGP of bromine. 
Further experimentation would be needed to determine if cyclisation proceeds through attack of 
the aromatic from the para- position, as products such as spiro quinone 51 could not be isolated. 
2.3 Enantioselective synthesis of mono-cyclisation substrates 
and reactions 
So far, the synthesis of a range of racemic substrates has been optimised and the conditions 
needed for activation of the leaving group towards cyclisation have been identified. It was then 
necessary to investigate the reactions in an asymmetric synthesis and determine the enantiomeric 
ratio of the products. Sharpless asymmetric dihydroxylation provides access to both R and S-
enantiomeric diols, and these 1,2-diols can then be converted to epoxides via Corey conditions.126  
Initially, scalemic diol (S)-56 was synthesised from alkene 1 using Sharpless’ AD-mix α127 in 92% 
isolated yield (Scheme 65). The absolute configuration of diol (S)-56 was assigned on the basis of 
the Sharpless mnemonic.127-128 
 
Scheme 65 - Sharpless asymmetric dihydroxylation using AD-mix α 
The enantiomeric ratio was 92:8 (Figure 25) as determined by chiral HPLC separation of 
enantiomers and comparison with a racemic sample (Figure 24). Racemic diol 56 was synthesised 
using modified Sharpless asymmetric dihydroxylation conditions, whereby the chiral ligand was 
substituted by achiral quinuclidine, a method developed by Warren et al.129 Quantitative yields of 
(±)- 56 were obtained (Scheme 66).  
 
Scheme 66 - Dihydroxylation of homoprenyl p-methoxybenzene (1) to give racemic diol 56 
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Figure 24 - Chiral HPLC chromatogram showing 
separation of enantiomers of diol (±)-56 
Figure 25 - Chiral HPLC chromatogram showing 
enantiopurity of (S)-56 
Mesylation of diol (S)-56 at the less hindered secondary alcohol and treatment with base 
produced epoxide (R)-6 in 76% yield.  
 
Scheme 67 - Mesylation and base mediated closing to epoxide (R)-6 
Ring-opening of epoxide (R)-6 with lithium bromide and pyridinium p-toluenesulfonate in N-
methylpyrrolidone produced bromohydrins (R)-8a and (S)-8b in 71% overall yield (Scheme 68).  
 
Scheme 68 - Ring-opening of epoxide (R)-6 with lithium bromide 
The enantiomeric ratio of bromohydrin regioisomers, 8a and 8b was determined by chiral 
HPLC analysis (Figure 26 and Figure 27) to be 91:9 which is comparable to the enantiomeric ratio 
of diol (S)-56 at 92:8. This discrepancy is likely to be in the margin of error. 
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Figure 26 - Chiral HPLC chromatogram showing 
enantiopurity of bromohydrin (R)-8a 
Figure 27 - Chiral HPLC chromatogram showing 
enantiopurity of bromohydrin (S)-8b 
Esterification of bromohydrin regioisomers (R)-8a and (S)-8b as tetrafluorobenzoate esters was 
achieved using Steglich conditions.116 Bromohydrin (R)-8a was reacted with a small excess of 
2,3,4,5-tetrafluorobenzoic acid and DCC over 4 h in excellent yield, 88% for the synthesis of 
secondary tetrafluorobenzoate ester (R)-31a (Table 11, entry 1). Bromohydrin (S)-8b was reacted 
with two equivalents of tetrafluorobenzoic acid and three equivalents of DCC. Under these 
conditions tertiary tetrafluorobenzoate ester (S)-31b was isolated in 62% with ca. 15% of allyl 
tetrafluorobenzoate ester 33 (entry 2). 
Table 11 - Steglich esterification 
 
Entry Substrate Desired Product DCC (eq.) Acid (eq.) t (h) Yield (%) 
1 (R)-8a (R)-31a 1.3 1.2 4 88 
2 (S)-8b (S)-31b 3 2 16 62 a 
3 (R)-8a (R)-32a 1.3 1.2 62 52 
 acontaining ca. 15% allyl tetrafluorobenzoate 33 
The synthesis of secondary acetate (R)-32a (entry 3) using the Steglich method (1.3 eq. DCC, 
1.2 eq. acetic acid) over 62 h gave a low 52% yield, showing that this reaction could be capricious 
when forming acetate esters, possibly due to the volatility of the carboxylic acid. The previous 
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optimised conditions for synthesis of racemic tertiary acetate 32b using acetic acid and 
trifluoroacetic anhydride in dichloromethane at room temperature for 3 hours provided clean 
tertiary acetate (S)-32b in 73% yield. 
 
Scheme 69 - Acetylation of tertiary alcohol (R)-8b using mixed anhydride 
With access to scalemic tetrafluorobenzoate esters (R)-31a and (S)-31b, and acetate esters (R)-
32a and (S)-32b in good yield it is necessary to determine the enantiomeric ratio of each bromo-
ester before carrying out any cyclisation reactions with triflic acid. This is to determine if the route 
following Sharpless asymmetric dihydroxylation was enantiospecific and if cyclisation of the 
bromo esters with triflic acid is also enantiospecific. For an accurate enantiomeric ratio to be 
determined via chiral HPLC separation the following is required: 
 Baseline separation of enantiomers. 
 A sample which is free from impurities present in greater quantities than the minor 
enantiomer. 
 Retention times of enantiomers which are equal to those of a racemic sample.  
This was complicated by the presence of alkene-containing impurities mainly in tertiary esters 
(S)-31b and (S)-32b, although some samples of (R)-32a were also contaminated. These impurities 
were difficult to remove by column chromatography and even in small proportions relative to 
desired material were enough to affect baseline separation of enantiomers and the ability to identify 
the minor enantiomer. When it was not possible to obtain analytically pure samples by careful 
chromatography a further reaction was needed to remove the impurities. Epoxidation with 
mCPBA was chosen in order to react with olefinic impurities and produce more polar oxidation 
products which would be separable from the desired bromo-esters. This was carried out 
successfully, for example, a 1:0.75 mixture of (S)-31b and 33 was reacted with mCPBA to give 
analytically pure (S)-31b in 19% yield and a 4% yield of the corresponding epoxide 57. 
 
Scheme 70 - Removal of allyl tetrafluorobenzoate 33 by reaction with mCPBA 
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Figure 28 shows the enantiomeric ratios of both tetrafluorobenzoate ester regioisomers (R)-31a 
and (S)-31b (chromatograms b and d) and acetate esters (R)-32a and (S)-32b (chromatograms f 
and h) as determined by chiral HPLC chromatography in comparison to a racemic reference 
samples (chromatograms a, c, e and g).  
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Figure 28 - Chiral HPLC chromatograms showing separation of enantiomers in a) (±)-31a, b) (R)-31a, c) (±)-
31b, d) (S)-31b, e) (±)-32a, f) (R)-32a, g) (±)-32b, h) (S)-32b 
With enantiomeric ratios of all the substrates proven to be 92:8 ± 1, in line with that achieved 
by Sharpless asymmetric dihydroxylation in the first step of this synthesis it is now possible to 
investigate activation of these esters in order to generate enantiopure bromonium ions. We can 
then be confident that any erosion of enantiomeric excess will have occurred under cyclisation 
conditions. 
2.3.1 Enantiospecific mono-cyclisation 
In order to determine the enantiopurity of cyclisation reactions carried out with scalemic 
substrates a racemic sample of bromocyclohexane 29 was needed. This was obtained by direct 
BDSB-mediated cyclisation of alkene 1 giving (±)-29 in 63% yield in 15 minutes (Scheme 71). 
 
 
Scheme 71 - BDSB bromo-cyclisation of homoprenyl p-methoxybenzene (1) and chiral HPLC analysis of bicycle 
(±)-29 
Cyclisation of secondary tetrafluorobenzoate (R)-31a with 30 mol% TfOH at reflux in 
dichloromethane proceeded quantitatively to bromo-bicycle (S)-29 (Table 12, entry 1). This 
process was completely enantiospecific as determined by chiral HPLC analysis (Figure 29). Tertiary 
tetrafluorobenzoate (S)-31b was also efficiently cyclised under these conditions, in excellent 
conversion and without racemisation at reflux (entry 2).  
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Table 12 - Investigation of triflic acid loading on cyclisation of tetrafluorobenzoate esters (R)-31a and (S)-31b and 
acetate esters (R)-32a and (S)-32b 
 
Entry Substrate e.r. T (°C) t (h) % Conversiona e.r.b 
1 (R)-31a 92:8 40 3 97 (84) 91:9 
2 (S)-31b 93:7 40 4 94 (67) 92:8 
3 (R)-32a 92:8 40 3 92 (53) 84:16 
4 (S)-32b 92:8 r.t. 5 35 (30c) nd 
aAs determined by inspection of the 1H NMR spectrum after aqueous work-up. Figure in parentheses is isolated 
yield after column chromatography. bAs determined by HPLC analysis by reference to a racemic sample. cIsolated as 
a mixture of products 
  
Figure 29 - Chiral HPLC chromatogram showing the 
enantiopurity of (S)-29 for entry 1 Table 12 
Figure 30 - Chiral HPLC chromatogram showing the 
enantiopurity of (S)-29 for entry 3 Table 12 
Secondary acetate ester (R)-32a was also efficiently cyclised under these conditions (entry 3) 
with a slight erosion in enantiomeric ratio of the product observed by chiral HPLC analysis (Figure 
30). In the 1H NMR spectrum of the crude product mixture small quantities of alkene (ca. 2-5%) 
were observed, and presumably some erosion of enantiomeric ratio is occurring by transfer of 
bromonium ion to these olefins.95 Tertiary acetate ester (S)-32b gave complex and varied mixtures 
of product and rearranged compounds at room temperature (entry 4). This demonstrates that a 
non-nucleophilic counterion, such tetrafluorobenzoate is required for clean cyclisation to (S)-29. 
The reaction profiles of tetrafluorobenzoate derivatives cyclised using triflic acid at reflux were 
extremely clean, gave complete conversion to desired product 29, without the formation of alkene 
products and without erosion of enantiopurity. So, tetrafluorobenzoate derivatives of either (R)-
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8a or (S)-8b bromohydrins represent excellent choices for the formation of scalemic bromonium 
ions. 
It became apparent that in a practical synthesis of (S)-29 it would be desirable to esterify 
bromohydrins (R)-32a and (S)-32b without separation and so a full synthesis of (S)-29 was set out 
without separation of these regioisomers. 
2.3.2 Demonstration of practical utility  
To show the preparative utility of this method alkene 1 was dihydroxylated using AD-mix β 
which gave (R)-56 in 99% yield, and with an improved enantiomeric ratio of 97:3 e.r. over AD-
mix α. Epoxide formation as before gave (S)-6 in 53% isolated yield.  
  
Scheme 72 - Synthesis of the opposite enantiomer (S)-6 epoxide 
 
Figure 31 - Chiral HPLC analysis of (R)-56 
Anionic bromide ring-opening of epoxide (S)-6 produced bromohydrins (S)-8a and (R)-8b 
which were isolated as a mixture in 72% yield and converted to tetrafluorobenzoate esters (S)-31a 
and (R)-31b in 95% overall yield (Scheme 73). 
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Scheme 73 - Synthesis of tetrafluorobenzoate esters (S)-31a and (R)-31b without separation of regioisomers 
Triflic acid catalysed cyclisation of the mixture in dichloromethane at reflux over 3 h gave (R)-
29 in high yield without racemisation of the products (84%, 96:4 e.r.). 
  
Scheme 74 - Cyclisation of a mixture of regioisomeric tetrafluorobenzoate esters (S)-31a and (R)-31b 
 The epoxide ring-opening method produces ca. 9% of allyl alcohol 14, which is carried through 
in the esterification to give allyl tetrafluorobenzoate ester 33. This material can be removed by 
treating the mixture with mCPBA followed by chromatography. If the cyclisation is conducted in 
the presence of the allylic ester, (R)-29 is obtained in lower yield (53%) with slight erosion of e.r. 
(92:8), presumably some leakage of ee is occurring by bromonium ion-to-olefin transfer.95  
2.3.3 Investigation into racemisation in the cyclisation of acetate esters 
It was at this point, when substrates of both enantiomeric series, from AD-mix α and β, that 
the cyclisation of scalemic acetate esters with catalytic triflic acid was investigated further. Table 
13, entries 1 and 5 detail the cyclisation of acetate esters (R)-32a and (S)-32b, derived from 
dihydroxylation using AD-mix α, that were previously discussed in Chapter 2.3.1.  
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Table 13 - Investigation of triflic acid loading on cyclisation of scalemic acetate esters 32a and 32b 
 
Entry Substrate e.r. T (°C) t (h) % Conversiona e.r.b 
1 (R)-32a 92:8 40 3 92 (53) 84:16 
2 (S)-32a 96:4 40 3 86 (59) 89:11 
3 (S)-32a 96:4 40 2 100 (78) 96:4 
4 (S)-32a 96:4 40 2.5 97(66) 96:4 
5 (S)-32b 92:8 r.t. 5 35 (30) nd 
6 (R)-32b 96:4 40 2 92 (30) 72:28 
7 (R)-32b 96:4 40 2 95 (39) 89:11 
8 (R)-32b 96:4 40 2 85 (56) 90:10 
aAs determined by inspection of the 1H NMR spectrum after aqueous work-up. Figure in parentheses is isolated 
yield after column chromatography. bAs determined by HPLC analysis by reference to a racemic sample. 
Secondary acetate ester (R)-32a, discussed previously (Table 12, entry 3) and re-examined here 
(Table 13, entry 1) cyclised efficiently in 3 h at reflux. However, erosion of enantiomeric ratio of 
the product was observed, from 92:8 to 84:16 e.r. This was accounted for by the presence of small 
quantities of alkene produced during the reaction which caused erosion of enantiomeric ratio by 
bromonium ion-to-olefin transfer.95 
This was also the case in entry 2 where secondary acetate ester (S)-32a derived from 
dihydroxylation using AD-mix β, with enantiomeric ratio of 96:4, showed a lower enantiomeric 
ratio of 89:11 in its cyclisation with triflic acid, the crude 1H NMR spectrum also contained 7% of 
alkene. 
However, two subsequent runs using (S)-32a, gave quantitative conversion with undiminished 
e.r.’s where no alkene was apparent in the crude 1H NMR spectrum (entries 3 and 4). Evidently, 
using this substrate produces variable quantities of alkene during the reaction which cause 
unpredictable erosion of enantiomeric ratio. 
Tertiary acetate ester (S)-32b discussed previously (Table 12, entry 4) and re-examined here 
(entry 5) gave complex and varied mixtures of product and rearranged compounds. However, 
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three runs were also carried out using the opposite enantiomer (R)-32b (e.r. 96:4). (R)-32b giving 
essentially the same results in which the product (R)-29 was observed in all cases, along with 
varying amounts of starting acetate 32b, secondary acetate 32a, elimination products and ketone 
16. Enantiomer ratios of the isolated product (R)-29 were recorded as 72:28, 89:11 & 90:10 in each 
case. Not surprisingly, the formation of many different side products has led to variable erosion 
of enantiomeric excess. 
It has very clearly been demonstrated that the presence of alkenes in cyclisation reactions, either 
from the starting material or produced during the reaction, has a profound effect on the 
enantiomeric ratio of the products and so the use of pure tetrafluorobenzoate esters is critical. As 
an activated leaving group they provide clean conversion to desired cyclised products without 
undesirable alkene by-products which results in completely enantiospecific reactions.  
2.3.4 Are shorter routes possible? 
The Appel reaction is used to convert primary and secondary alcohols to halides using 
triphenylphosphine and tetrahalomethane in high yield and under mild conditions.130  In the 
example of bromination, triphenylphosphine reacts with tetrabromomethane to give CBr3
- which 
deprotonates the alcohol (Scheme 75), the resulting alkyl oxide attacks at phosphorus to form an 
oxyphosphonium intermediate 58. This activated alcohol is reactive towards attack by the resulting 
bromide anion to give the desired alkyl bromide.  
  
Scheme 75 - Generalised Appel bromination reaction 
There are examples of Appel reactions being carried out on tertiary alcohols131 and so it was 
proposed that in the case of a 1,2-bromohydrin 8b, under these reaction conditions, that the 
activated alcohol may undergo intramolecular cyclisation (Scheme 76). The reaction of diol 56 with 
triphenylphosphine and tetrabromomethane could also be expected to give bromohydrin (Scheme 
76). Therefore reaction of diol 56 with two equivalents of triphenylphosphine and 
tetrabromomethane could provide the desired cyclised product in one step. 
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Scheme 76 - Postulated Appel reaction of diol 56 
Accordingly, (±)-56 was reacted with 2.5 equivalents of tetrabromomethane and 2.6 equivalents 
of triphenylphosphine at room temperature overnight. Unfortunately none of the desired cyclised 
product 29 was isolated. Instead allyl bromide 36 was isolated as the major product in 49% yield 
(Scheme 77), presumably this results from the bromination of diol 56 to give bromohydrin 8b. 
Activation of the tertiary alcohol and elimination would then provide allyl bromide 36.  
 
Scheme 77 - Appel reaction of diol (±)-56 with two equivalents of tetrabromomethane and triphenylphosphine 
In order to investigate the first step in this reaction, from diol 56 to presumed bromohydrin 
8b, (±)-56 was reacted with only 1.2 and 1.3 eq. of tetrabromomethane and triphenylphosphine 
respectively. This gave both bromohydrin regioisomers 8a and 8b in 24% overall yield (Scheme 
78). This supports our previous hypothesis that they are intermediates to allyl bromide 36 in the 
previous reaction and although, the conversion was low, heating may improve the yields of 
bromohydrin. 
  
Scheme 78 - Appel reaction of diol (±)-56 with one equivalent of tetrabromomethane and triphenylphosphine 
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In order to investigate the second part of the reaction, from bromohydrin to allyl bromide, 
bromohydrin (±)-8a was reacted under the same conditions, but there was no reaction at room 
temperature overnight. Adding an extra equivalent of each reagent, triphenylphosphine and 
tetrabromomethane gave ketone 16 as the major product in 29% yield and allyl bromide 36 in 8% 
yield. (Scheme 79).  
 
Scheme 79 - Reaction of bromohydrin (±)-8a under Appel conditions. 
From these reactions it appears possible to react a 1,2-diol under Appel conditions to synthesise 
allyl bromide 36 (Scheme 77) or bromohydrin (albeit in low yields, Scheme 78). However using 
these conditions to enact a bromo cyclisation was not possible.  
The synthesis of tertiary acetates has been carried out using acetic acid and trifluoroacetic 
anhydride in dichloromethane. It was proposed that the substitution of trifluoroacetic anhydride 
with triflic anhydride would further promote cyclisation by the formation of triflic acid in the 
reaction. Accordingly a mixture of bromohydrin regioisomers was reacted with acetic acid and 
triflic anhydride at room temperature for 5 hours (Scheme 80) 
 
Scheme 80 - Bromohydrin cyclisation via acetylation 
Interestingly, the major component isolated from the reaction was Friedel–Crafts adduct 59 in 
57% yield, where the desired brominated bicycle 29 was not present in the product mixture. 
Evidently, bromo-cyclisation of the bromohydrin regioisomers had indeed been induced. 
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However, further reaction of the desired product with the reagent combination led to Friedel-
Crafts acetylation. If further investigation was explored it would be interesting to see if triflic 
anhydride can enact the cyclisation of alcohols (S)-8a and (R)-8b without the presence of acetic 
acid. 
Although the synthesis of tetrafluorobenzoate cyclisation substrates requires a number of 
reaction steps, the substrates have been proven to undergo clean, efficient, and most importantly 
enantiospecific cyclisation reactions. The production of pure scalemic cyclisation products was 
deemed far more beneficial than a shorter route and so these avenues were no longer pursued.. 
2.3.5 Experimental mono-cyclisation reactions with added alkene 
For the development of a polyene cyclisation triggered by an enantiopure bromonium ion it is 
vital to know if the enantiospecific cyclisation onto bromonium ion will be compromised by 
competitive bromonium ion transfer to alkenes.95 Alkenes, which are necessarily present in 
potential polyene substrates. Accordingly, catalytic triflic acid was added to secondary 
tetrafluorobenzoate ester (R)-31a in the presence of one equivalent of 1-methylcyclohexene and 
no reaction of (R)-31a was observed even after prolonged heating and a total addition of 60 mol% 
of triflic acid, instead 1-methylcyclohexene was reacting with the acid to give high molecular weight 
hydrocarbons. 
The cyclisation of secondary acetate ester (S)-32a (e.r. 96:4) was however successful in the 
presence of one equivalent of 1-methylcyclohexene (Scheme 81) with the desired 
bromocyclohexane (R)-29 isolated in 35% yield with an essentially undiminished e.r. of 94:6. 
Therefore no racemisation had occurred in the formation of desired product 29 via bromonium 
ion-to methylcyclohexene transfer. Friedel–Crafts alkylation adduct (R)-60 was also formed in 53% 
yield. 
  
Scheme 81 - Mono-cyclisation in the presence of alkene. 
To analyse the enantiomeric ratio of (R)-60 a racemic sample was synthesised via the reaction 
of bromo bicycle (±)-29 with 1-methylcyclohexene and stoichiometric triflic acid, which gave (±)-
60 in 40% yield together with 56% recovered starting material (Scheme 82). Unfortunately (±)-60 
was not separable on the available chiral HPLC columns. However it can be assumed by the high 
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enantiomeric ratio of (R)-29 obtained from the previous reaction that it is likely to be the same 
case for (R)-60. 
 
Scheme 82 - Synthesis of Friedel-Crafts adduct (±)-60 
We have shown that the enantiomeric ratio of bicycle (R)-29 from bromonium ion-induced 
cation-π cyclisation of secondary acetate (S)-32a is not diminished by the presence of an added 
alkene under these conditions. Thus, for a bi-cyclisation, with substrates bearing a necessarily 
present alkene, it can be expected that their cyclisation will be wholly enantiospecific. However 
the presence of an acid-sensitive trisubstituted alkene in bi-cyclisation substrates renders the use 
of Brønsted acids to subsequently generate bromonium ions undoubtedly problematic. 
2.4 Bi-cyclisation substrates 
Bromonium ion-induced cation-π cyclisation of substrates bearing a single olefin have been 
successfully carried out and the mechanism of the reaction investigated. This synthetic 
methodology was then applied to polyene substrates containing two alkenes where two C-C bonds 
are formed during bromonium ion-induced cyclisation. Figure 32 demonstrates this for the 
cyclisation of nerolidol to bromo-epicaparrapi oxide.  
 
Figure 32 - Polyene cyclisation of nerolidol to (-)-3b-bromo-8-epicaparrapi oxide 
Polyene 61 (Figure 33) was selected as the basic carbon framework for investigation of the first 
polyene cyclisation triggered by an enantiopure bromonium ion. The para-methoxy substituted 
aromatic in the compound will provide a UV chromophore necessary for chiral HPLC analysis. 
An enantiopure bromonium ion was to be formed on the terminus alkene (in blue), with the 
second, internal alkene (in red) acting as the propagating olefin, and the polyene cyclisation was to 
be terminated by the aromatic moiety.    
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Figure 33 - Polyene 61 and its enantiopure bromonium ion-induced polyene cyclisation 
2.4.1 Synthesis of analytically pure polyene 61 
Diene 61 could be prepared by the method of Demuth and co-workers via palladium(0) 
catalysed coupling of commercially available p-methoxybenzyl magnesium chloride with geranyl 
bromide.103 In our hands variable and significant quantities of the branched regioisomer γ-61 were 
also observed which was inseparable by simple column chromatography. In multiple runs the ratio 
of α:γ-61  was found to vary unpredictably from 37:1 to 15:1 (Table 14).   
Table 14 - Pd(PPh3)4 catalysed alkylation of geranyl bromide 62 using commercial Grignard reagent 
 
Entry 
62 
(mmol) 
Yield 61 
(%) 
α:γa 
1 1.0 83 37:1 
2 2.5 62 35:1 
3 4.6 65 15:1 
aAs determined by 1H NMR analysis of isolated product 
For larger-scale reactions (over 5 mmol) it was more economical to synthesise p-methoxybenzyl 
chloride from the corresponding benzyl alcohol 63 (Scheme 83) and then react this with 
magnesium turnings to form the Grignard reagent. 
 
Scheme 83 - Synthesis of p-methoxybenzyl chloride 
Synthetic Grignard reagent was employed for the alkylation of geranyl bromide using Demuth 
conditions103 (Table 15) and inseparable branched regioisomer γ-61 was again isolated with the 
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desired product: α-61 in a ratio of 1:18 (entry 1). The use of 0.9 equivalents of Grignard reagent 
(entry 2) and palladium(0) catalyst sourced from Strem gave poorer regioselectivity (9:1 α:γ-61).  
Table 15 - Pd(PPh3)4 catalysed alkylation of geranyl bromide 62 with synthetic Grignard reagent 
 
Entry 
62 
(mmol) 
3 (eq.) 
Pd(PPh3)4 
(mol%) 
Pd(PPh3)4 
Source 
Yield 61 
(%) 
α:γa 
1 2.5 1.5 5 Aldrich 63 18:1 
2 8.1 0.9 5 Strem 89 9:1 
3 100.6 1.1 5 Strem 48 3:1 
4 0.2 1.1 100 Synthetic 0 n/a 
5 0.7 1.1 1 Synthetic 29 10:1 
6 24.2 0.95 1 Synthetic 77 36:1 
aAs determined by 1H NMR analysis of isolated product 
When further reactions were carried out using a 9:1 mixture of linear to branched chain isomers 
it was found that the branched isomers were inseparable at all stages of the synthesis, culminating 
in the contamination of cyclisation products with a 7,5,6-membered tricycle 64, (Scheme 84) 
formed from bromonium ion-induced cyclisation of γ-61. This impurity obscured the desired 
minor enantiomer signal in the HPLC analysis and so high purity diene α-61, free from branched 
γ-61, was therefore found to be essential for subsequent HPLC enantiomeric excess determination 
of products. 
 
Scheme 84 - Formation of unwanted by-product 64 from γ-61 
On a 100 mmol scale of geranyl bromide 62 with 1.1 equivalents of Grignard reagent, even 
poorer regioselectivities of 3:1 α:γ-61 were observed (entry 3). When freshly prepared tetrakis 
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palladium was investigated at stoichiometric loading only homo-coupling by-product 4 was 
isolated (entry 4). Two further runs using synthetic Pd(PPh3)4 at catalyst loadings of 1 mol% 
continued to give unpredictable ratios of α:γ-61 (10:1 and 36:1, entries 5 and 6) and so another 
method for this alkylation was sought. 
Dilithium tetrachlorocuprate(II) is frequently used as a catalyst in the reaction of Grignard 
reagents with electrophiles.132 It has been reported to undergo highly regioselective substitution of 
geranyl bromide to give exclusively α- (SN2) substitution without any γ- (SN2’) substitution products 
detectable by NMR.133 In our hands p-methoxybenzyl magnesium chloride was reacted with 
geranyl bromide in the presence of 4 mol% Li2CuCl4 catalyst at -20°C for 1.5 h (Scheme 85) to 
give a 66% yield of the desired product 61. The regioselectivity of the reaction was poor with an 
α:γ ratio of 2:1. 
 
Scheme 85 - Li2CuCl4 catalysed Grignard alkylation of geranyl bromide  
Synder10a has described the non-catalysed coupling of the same Grignard reagent with geranyl 
diethyl phosphate, a method originally reported by Butsugan et al.134 Geranyl diethyl phosphate 66 
can be synthesised by reaction of geraniol 65 and diethyl chlorophosphate in 92% isolated yield 
(Scheme 86). 
 
Scheme 86 - Synthesis of geranyl diethyl chlorophosphate 
For comparison, geranyl dimethyl phosphate 67135 was also investigated as an alternative 
substrate for Grignard alkylation. Geranyl dimethyl phosphate can be synthesised by reaction of 
geraniol and dimethyl chlorophosphate via the same method and although analysis of the 1H NMR 
of the crude reaction mixture showed good conversion to the desired dimethyl phosphate, 
purification by chromatography led to decomposition on silica. Both geranyl diethyl and dimethyl 
phosphates could however be used as crude mixtures in subsequent alkylation reactions. 
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Table 16 - Investigation of non-catalysed Grignard alkylations of geranyl alkyl phosphates using the Butsugan 
method.134 
  
Entry Substrate Mg (eq.) Solvent 
Yield 61 
(%) 
α:γa 
1 66  4 THF Quant. 17:1 
2 66  4 THF 82 8:1 
3 66  10 THF 90 15:1 
4 66  10 Et2O 13 3:1 
5 67  4 THF 19 0:1 
aAs determined by 1H NMR analysis of isolated product 
Two reactions using the literature procedure10a and geranyl diethyl phosphate gave excellent 
yields of 61 (quantitative and 82% yield, entries 1 and 2, Table 16) and reasonable regioselectivities 
of α:γ products (17:1 and 8:1). The use of greater quantities of magnesium turnings did not affect 
the yield or regioselectivity of the reaction (90% yield and 15:1 α:γ, entry 3). The use of diethyl 
ether in the formation of the Grignard reagent and subsequent alkylation reaction gave poor yields 
and regioselectivity (13% yield, 3:1 α:γ, entry 4). This is likely due to the precipitation of MgCl2 and 
the formation of dialkylmagnesium compounds in the Grignard formation step. Synthesis of the 
Grignard reagent in THF and then exchanging the solvent for diethyl ether was also attempted, 
but unfortunately the reagent was not soluble in diethyl ether and so 1,4-dioxane was considered 
as an alternative however its melting point of 12°C would not allow for temperature control in the 
reaction and so was expected to give poor regioselectivity. The use of crude geranyl dimethyl 
phosphate 67 and the literature conditions10a gave 19% yield of γ-61 and none of the desired α-61 
product (entry 5).  
With no improvement in regioselectivity found using different geranyl alkylation substrates, 
catalysts or conditions, attention turned to reagents which may react selectively at the primary 
olefin over the trisubstituted alkenes. This will create derivatives of the undesired branched 
regioisomer, γ-61, which could be separated from the linear polyene (α-61) by column 
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chromatography. A hydroboration-oxidation reaction for example, could be envisaged to react 
with the less hindered primary alkene of γ-61 to give an alcohol 68 (Scheme 87) which would be 
more polar than linear diene α-61 and so separable by standard chromatography. 
 
Scheme 87 - Proposed hydroboration of diene mixture α- and γ-61 
Accordingly a 3:1 mixture of α- and γ-61 was stirred with 0.5 equivalents of borane at room 
temperature over 6 h (Scheme 88), unfortunately, no conversion of the starting materials was 
observed by 1H NMR analysis of the crude reaction mixture even after doubling the number of 
equivalents of borane. 
 
Scheme 88 - Unsuccessful hydroboration-oxidation of 61 
The use of sodium perborate oxidation, as described by Denmark for the hydroboration-
oxidation of terminal double bonds,136 led to a small improvement in the regioisomeric ratio from 
3:1 to 4.2:1 (Scheme 89). This ratio was determined by 1H NMR analysis of the crude reaction 
mixture following heating with 3 equivalents of borane at reflux for 3 h and subsequent oxidation 
with sodium perborate and sodium hydroxide solution at 50°C for 4 h. 
 
Scheme 89 - Hydroboration and NaBO3 oxidation of 61 
 Evidently, with the use of 3 equivalents of borane, the reagent was reacting poorly with α- and 
γ-61 and in an attempt to push the reaction to completion a 3:1 mixture of α- and γ-61 was heated 
at reflux with 9 equivalents of borane in THF for 4 h (Scheme 90). Standard oxidation with 
hydrogen peroxide and sodium hydroxide gave non-alkene containing products. 
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Scheme 90 - Hydroboration/oxidation of 61 to non-alkene containing products 
After limited success using reagents which selectively react with primary alkenes, an alternative 
approach was investigated. The mixture of two constitutional isomers could both be reacted to 
give more polar products which may be separable by standard column chromatography. To this 
end, the demethylation of α- and γ-61 in a 3:1 ratio was carried out with previously used conditions 
for the synthesis of compound 53 (Scheme 91). However after column chromatography a mixture 
of compounds was isolated. It was apparent from the 1H NMR that full conversion to aromatic 
phenols had occurred, but there were a considerable number of alkyl absorbances between 0.8-2.8 
ppm and no primary alkenes, this suggested that protonation of the primary alkene and various 
cyclisations had occurred to produce inseparable alkyl products. The same product distribution 
was also observed when five equivalents of DTBP was used. 
 
Scheme 91 - Boron tribromide demethylation of α- and γ-61 
Yamamoto and co-workers carried out the demethylation of aryl methyl ether 61 using 
ethanethiol and sodium hydride in DMF.137 These conditions gave full conversion to the desired 
phenols 69, (Scheme 92) however α- and γ-69 could not be separated by column chromatography 
 
Scheme 92 - Ethanethiolate demethylation of α- and γ-61 
Having explored the selective synthesis of α-61, reactions of primary alkenes and the synthesis 
of more polar derivatives with minimal success, it became apparent that α- and γ-61 would have to 
be separated directly. Numerous solvent systems for standard silica gel column chromatography 
had already been investigated as well as preparative HPLC within our laboratory. Samples of the 
3:1 mixture were supplied to AstraZeneca to investigate the use of supercritical fluid 
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chromatography and their library of chiral HPLC columns. Unfortunately, none of their analytical 
chiral HPLC columns separated the two constitutional isomers and samples returned after super 
critical fluid chromatography contained the same ratio of isomers. 
The power of silver nitrate-impregnated silica gel column chromatography has been 
demonstrated in the separation of hydrocarbons bearing various alkenes, which are inseparable via 
standard techniques due to their high Rf in non-polar solvents.
138 Using this technique pure samples 
of both α- and γ-61 were obtained for characterisation, however, the expense of silver nitrate was 
prohibitive for isolation of pure α-61 on a larger scale. 
We proposed that as linear and branched constitutional isomers, α- and γ-61 will differ most in 
their volatility, and distillation could be a likely method to purify these mixtures. In order to be 
successful, over 10 mL of α- and γ-61 was needed for Vigreux distillation to give satisfactory 
separation of fractions. Butsugan’s method134 was selected for large-scale synthesis of α- and γ-61 
as the reaction reliably provided good selectivity for the desired linear polyene and the starting 
materials could be obtained cheaply from geraniol and 4-methoxybenzyl alcohol, subsequently two 
80 mmol scale reactions were carried out (Scheme 93), which gave a total of 26.7 g of 61 in an 
overall ratio of 26:1. 
 
Scheme 93 - Large scale synthesis of α- and γ-61 for use in distillation  
 By carrying out fractional distillation of the combined diene mixtures using a vacuum-jacketed 
Vigreux column, the purity of 61 could be improved to >98%, this involved heating the mixture 
under vacuum (0.003 mmHg) at 200°C and collecting the fraction at 70°C. This fraction was 
enriched in branched isomer γ-61 and the distillation residue remaining was linear diene α-61 with 
a mass of 8.2 g. 
2.4.2  Optimisation of Sharpless asymmetric dihydroxylation 
To generate enantiopure bromohydrins at the terminus of the diene, regioselective, asymmetric 
dihydroxylation would be required. Ligands such as the Corey-Noe-Lin ligand139  (Table 17) give 
improved yields of dihydroxylation at the terminus alkene in comparison to the standard 
(DHQD)2-PYDZ ligand found in AD-mix β.
126 For example in the regioselective asymmetric 
dihydroxylation of farnesyl acetate, AD-mix β provides 34% yield of the desired diol whereas the 
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Corey-Noe-Lin ligand increases the yield to 60% and the ligand has therefore been used in the 
synthesis of a number of natural products.71, 140 The development of the Corey-Zhang ligand gave 
further improvements up to 72% yield for the same substrate141 and the ligand was later used in 
the synthesis of Germanicol,30f Lupeol,142 Serratenediol.143 and Glisoprenin A.144 
Table 17 - Regioselective dihydroxylation ligands 
 
 
Entry Ligand Yield (%) 
1 (DHQD)2-PYDZ 34 
2 Corey-Noe-Lin 60 
3 Corey-Zhang 72 
Shi epoxidation145 using a sugar-derived catalyst has also been found to give good 
regioselectivity in polyprenoid substrates by Wiemer and co-workers,146 diene substrates 
undergoing highly enantioselective Shi epoxidation of the terminus alkene in 48% yield (Scheme 
94) which was later improved to 63% yield by epoxidation of an earlier geraniol derivative.147  
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Scheme 94 - Regioselective Shi epoxidation of polyprenoid substrates. 
(DHQD)2PHAL, found in AD-mix β, is significantly sterically demanding that a slight 
preference for the less encumbered olefins nearer the terminus occurs even in substrates such as 
squalene148 and has been used to good effect in a number of recent natural product syntheses.149 
Therefore good selectivity for dihydroxylation at the terminus alkene was also assumed for diene 
substrate 61 using AD-mix β.127 In the event, dihydroxylation of diene 61 with AD-mix β and 
methane sulfonamide at room temperature gave good regioselectivity furnishing the desired diol 
(R)-70 in 52% yield, (72% based on recovered starting material, Figure 34) with only a trace of 
dihydroxylation occurring at the central diol. The absolute configuration of diol (R)-70 was 
assigned on the basis of the Sharpless mnemonic.127-128 Although AD-mix is not as high yielding as 
the use of Corey-Zhang ligand or Shi epoxidation, AD-mix provides a cheap and commercially 
available reagent which can be used in a simple procedure, thus providing significant practical 
benefits over more complex reagents. Optimisation of the reaction conditions can be carried out 
to reduce the quantity of major by-product tetraol 70a to obtain a good yield based on recovered 
starting material. 
Tetraol 70a, the major by-product of the reaction was then further investigated. A rudimentary 
analysis of the conversion of starting material to desired product and tetraol over a 24 h period 
demonstrated that tetraol is formed in 11% yield within 1 h and only increases to 21% after 24 h. 
This was carried out by analysis of UV chromatograms from LCMS experiments at various 
intervals of the reaction. 
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Entry 
Time 
(h) 
61 
(%) 
70a 
(%) 
(R)-70 
(%) 
 
1 1 79 11 10 
2 4 56 11 33 
3 5.5 48 11 42 
4 24 28 20 52 
Figure 34 - Initial investigation into the conversion of diene 61 during Sharpless asymmetric dihydroxylation  
We felt confident, as the proportion of tetraol 70a after 24 hours was 21% that stirring the 
reaction for longer periods of time could improve the conversion of diene 61. As tetraol 70a was 
formed in 11% yield within one hour and was unchanged for the next four and a half hours, we 
felt that over-dihydroxylation may be occurring as the starting materials are first mixed. To control 
this we initiated the reaction at 0°C and allowed it to warm to room temperature slowly over three 
days. As this is a biphasic reaction involving water and tBuOH, it is important to have all the 
reagents mixing thoroughly at room temperature before cooling the reaction mixture to 0°C. This 
prevents the solvent from freezing at 0°C at which point the diene starting material can be added. 
Under these conditions a 63% isolated yield of diol (R)-70 was obtained (84% BRSM, Table 18, 
entry 1). 
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Table 18 - Investigation of conditions for Sharpless asymmetric dihydroxylation of diene 61 
 
Entry 
AD-mix β 
(gmmol-1) 
CH3SO2NH2 
(eq.) 
T (°C) 
t 
(h) 
Recovered 
61 (%) 
Yield 
70a (%) 
Yield 
(R)-70 (%)a 
1 1.4 1 0 to r.t. 72 25b 12b 63 (84b) 
2 0.7 1 r.t. 72 13b 37b 50 (57b) 
3 1.4 0.5 r.t. 72 54b 2b 25 (54b) 
4 1.4c 1 0 to r.t. 16 7 nd 31 (33) 
a Figure in parentheses is percentage yield based on recovered starting material. bBased on LCMS analysis of crude 
reaction mixture. cAdditional 1 mol% K2OsO4.2H2O and 2 mol% (DHQD)2PHAL. nd = not determined. 
Slowing down the reaction by using half the number of equivalents of AD-mix or methane 
sulfonamide, over 72 hours, gave reduced yields of 50% and 25% of diol (R)-70 (entries 2 and 3). 
Adding an extra 1 mol% of potassium osmate and 2 mol% of ligand (entry 4) gave 31% isolated 
yield of diol (R)-70 (33% BRSM). Presumably such forcing conditions led to over-dihydroxylation 
to tetraol 70a. Carrying out the Sharpless asymmetric dihydroxylation reaction at 0°C and warming 
to room temperature gave both the highest yield of diol (R)-70 (63%) and the highest yield based 
on recovered starting material (84%). Therefore these conditions were selected for future 
dihydroxylation reactions.  
In these test reactions diene 61 was used with a low linear to branched chain ratio of 13:1. It 
has to be noted that for the dihydroxylation reactions discussed thus far (excluding entry 4, Table 
18) the linear to branched chain ratio of the product diol (R)-70 had reduced to 5:1 in the product. 
Evidently, while the linear diol α-70 could further dihydroxylate to tetrol 70a, thus depleting the 
amount of (R)-70, the terminal alkene of the branched isomer diol γ-70 was more resistant to 
further dihydroxylation. This accumulation of the branched isomer in this reaction made it even 
more imperative that the starting material was of high purity. This dramatic effect can be shown 
in the following example: when 5 g of diene 61 with a linear to branched chain ratio of 3:1 was 
reacted under our standard Sharpless asymmetric dihydroxylation conditions, the reaction went to 
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full conversion and a 34% yield of 70 was isolated, however the mixture of isomers had the 
opposite ratio of linear to branch chain diols, 3:1 in favour of the branched diol, γ-70. 
Subsequently, 8.2 g of high purity (>98% or 60:1 α:γ) diene 61, was divided into three reactions 
and carried out at 0°C and warmed to room temperature overnight to produce diol (R)-70 in good 
yield based on recovered starting material (42-60%, Table 19), with isolated yields from 25-40%. 
The main by-products were tetraol 70a, isolated in 25% yield (entry 2), and trace quantities of 
undesired regioisomer (R,R)-70b (3% isolated yield, entry 1). 
Table 19 - Sharpless asymmetric dihydroxylation using high purity diene 61 
 
Entry 61 (g) 
Recovered 
61 (%) 
Recovered 
61 (α:γ) 
Yield 
70a (%) 
Yield (R,R)-
70b (%) 
Yield 
(R)-70 (%)a 
70 
(α:γ) 
1 1 33 124:1 nd 3 40 (60) 
118:
1 
2 4.1 40 205:1 25 nd 25 (42) 98:1 
3 3 34 60:1 nd nd 37 (56) 63:1 
a Figure in parentheses is percentage yield based on recovered starting material 
The Sharpless asymmetric dihydroxylation of diene 61 was found to be highly enantioselective, 
diol (R)-70 from entry 2, Table 19 had an enantiomeric ratio of 99:1 (Figure 36) determined by 
chiral HPLC analysis in comparison to a racemic sample (Figure 35). As the asymmetric 
dihydroxylation was highly enantioselective (99:1 e.r.) identifying the minor enantiomer in chiral 
HPLC analysis became difficult as impurities that represent even 1% of the mixture can obscure 
judgement, it was therefore critical that diol 70 is synthesised in at least 99% purity. 
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Figure 35 - Chiral HPLC chromatogram showing 
separation of enantiomers of (±)-70 
Figure 36 - Chiral HPLC chromatogram showing 
separation of enantiomers in (R)-70 
Racemic diol (R)-70 was synthesised using modified Sharpless asymmetric dihydroxylation 
conditions, whereby the chiral ligand was substituted by achiral quinuclidine, a method developed 
by Warren et al.129 A consequence of using quinuclidine, a less sterically-encumbered ligand than 
(DHQD)2PHAL, is that the reaction times are much shorter and so racemic diol (±)-70 was 
isolated in 19% yield after just two hours (Scheme 95). 
 
Scheme 95 - Racemic dihydroxylation of diene 60 
Interestingly, as a direct consequence of the accumulation of the branched isomer in the 
product diol (R)-70, recovered starting material has a much higher purity, from 60:1, linear to 
branch chain ratio in diene 61 to over 100:1 in product diol (R)-70 for cases entries 1 and 2, Table 
19. It was hoped that combining these two batches of recovered starting material and subjecting 
them to Sharpless asymmetric dihydroxylation would result in even higher purity diol (R)-70. 
However this was not the case and diol (R)-70 was isolated in 26% yield (31% based on recovered 
starting material, Scheme 96) with a linear to branched chain ratio of 44:1.  
  
Scheme 96 - Sharpless asymmetric dihydroxylation of ultra-high purity recovered diene 61 
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The remaining recovered starting material was dihydroxylated to give a total of 4 g of diol 70, 
this represents a 43% overall yield of diol (R)-70 from 8.2 g of diene 61. 
For access to the S enantiomer, diene 60 can be treated with AD-mix α to give (S)-70 in 19% 
yield (Scheme 97) and 94:6 enantiomeric ratio (Figure 37). Under these conditions a 16% yield of 
central diol regioisomer (S,S)-70b was also isolated and none of the over dihydroxylation product 
70a was observed. Evidently, (DHQ)2PHAL is less regioselective for dihydroxyulation at the 
terminus alkene of diene 61. 
 
Scheme 97 - Asymmetric dihydroxylation of diene 60 to (S)-70 using AD-mix α 
 
Figure 37 - Chiral HPLC chromatogram showing separation of enantiomers in (S)-70 
2.4.3 Synthesis of enantiopure bromohydrin derivatives  
Diol (R)-70 was converted to epoxide (S)-71 by the Corey et al. method126 in 83% isolated yield 
(Scheme 98).  
 
Scheme 98 - Stereospecific formation of epoxide (S)-71 
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Stereospecific epoxide ring-opening of (S)-71 by bromide anion provided the separable 
regioisomeric bromohydrins (S)-72a and (R)-72b in 71% overall yield (Scheme 99). The 
regioisomeric bromohydrins (S)-72a and (R)-72b were assigned on the basis of their distinctive 
chemical shifts at 3.40 and 3.95 ppm in their 1H NMR spectra respectively, see chapter 2.1.2 page 
56. 
 
Scheme 99 - Synthesis of enantiopure bromohydrins (S)-72a and (R)-72b 
In the work on mono-cyclisation reactions (2.3.1, page 77) enantiopure bromonium ions were 
generated from 2,3,4,5-tetrafluorobenzoate derivatives, followed by activation with catalytic triflic 
acid. Whilst we could synthesise tetrafluorobenzoate esters of 72a and 72b, unfortunately acid-
sensitive trisubstituted alkenes present in these substrates would make the use of triflic acid to 
generate bromonium ions incompatible. In experimental mono-cyclisation reactions with added 
alkene (Chapter 2.3.5, page 85), tetrafluorobenzoate derivatives did not undergo cyclisation with 
triflic acid, which instead protonated the added alkene. Acetate derivatives did however show that 
racemisation was not occurring in the presence of added alkenes.  
The acetate derivatives, (S)-73a and (R)-73b were synthesised for testing alongside 
tetrafluorobenzoate derivatives, (S)-74a and (R)-74b. It was hoped that a suitable Lewis acid would 
enact the required cyclisation of either acetate or tetrafluorobenzoate derivatives. However 
tetrafluorobenzoate esters are expected to produce cleaner and enantiospecific cyclisation 
reactions, based on work previously investigated on mono-cyclisations. 
A mixture of acetates (S)-73a and (R)-73b were synthesised using the Bourne method119a with 
acetic acid and trifluoroacetic anhydride in 45% isolated yield (Scheme 100) but it was observed 
that there was a reduction in the ratio of regioisomers in the acetate products compared to starting 
material (S)-72a and (R)-72b, from 1:1.5 to 1:1.2. This is likely a result of the lower reactivity of 
the more hindered tertiary alcohol (R)-72b toward esterification. 
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Scheme 100 - Acetylation of bromohydrins (S)-73a and (R)-73b 
 Tetrafluorobenzoates (S)-74a and (R)-74b were synthesised using Steglich esterification116 with 
2,3,4,5-tetrafluorobenzoic acid in 92% yield and 60% yield (Scheme 101) from alcohols (S)-72a 
and (R)-72b respectively. 
 
 Scheme 101 - Synthesis of enantiopure tetrafluorobenzoate derivatives (S)-73a and (R)-73b 
2.5 Investigation of enantiospecific bi-cyclisation reaction 
conditions 
Attempted bromonium ion-initiated cyclisation of acetates and tetrafluorobenzoates (S)-73a, 
(R)-73b, (S)-74a or (R)-74b with catalytic quantities of triflic acid, led, as predicted (vide supra), to 
extensive decomposition. Previous attempts to generate bromonium ions from bromo-
tetrafluorobenzoates 31a and 31b by solvolysis were unsuccessful (see chapter 2.2.1 page 63) and 
so such conditions were not pursued on these bi-cyclisation substrates.  
Previously, oxophilic Lewis acids such as titanium(IV) chloride and dimethylaluminium 
chloride had been successfully used to carry out the mono-cyclisation of bromo-
tetrafluorobenzoates (R)-31a and (S)-31b in the model system. TiCl4 however, was rejected as a 
potential mediator of bi-cyclisation as hydrochloric acid would be generated during the course of 
the reaction, whereas alkyl aluminium reagents lead to rigorously proton free-solutions150 and so 
Me2AlCl was expected to be more beneficial.  
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Reaction of a mixture bromo-acetates (S)-73a and (R)-73b with dimethylaluminium chloride 
gave a 27% yield of the desired cyclisation adduct 75 (Scheme 102), however this component of 
the reaction mixture was not isolated as a pure product and contained other unknown un-cyclised 
by-products. Furthermore, 27% of the starting material was also recovered. 
 
Scheme 102 - Cyclisation of bromo-acetates (S)-73a and (R)-73b using dimethylaluminium chloride 
Similarly, cyclisation of a mixture of tetrafluorobenzoate esters (S)-74a and (R)-74b using 
dimethylaluminium chloride gave 11% yield of cyclisation adduct 75 after extensive 
chromatography. Non-cyclised bromochloride 76 was observed as the major product in 26% yield, 
evidently competing intermolecular attack of anionic chloride on bromonium ion was occurring. 
  
Scheme 103 - Cyclisation of tetrafluorobenzoates (S)-74a and (R)-74b by dimethylaluminium chloride 
Initial studies with stoichiometric quantities of Yb(OTf)3 were ineffective at triggering 
cyclisation of a mixture of (S)-74a and (R)-74b  at reflux overnight in dichloromethane and even 
the addition of a second equivalent of Yb(OTf)3 and heating at 131°C in chlorobenzene for a 
second night failed to produce the desired cyclisation products and 15% of the starting material 
was recovered (entry 1, Table 20). The use of Eu(fod)3 in chlorobenzene at 60°C overnight with 
the addition of a second equivalent, and heating at 131°C was also ineffective at initiating the 
cyclisation with starting material being recovered in 10% yield (entry 2). Heating a solution of both 
regioisomeric tetrafluorobenzoates at 150°C for 1 h under microwave irradiation was also 
ineffective, starting material was recovered in 22% yield (entry 3). 
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Table 20 - The use of Lewis acids, ytterbium triflate and Eu(fod)3 for the cyclisation of tetrafluorobenzoates (S)-74a 
and (R)-74b   
 
Entry LA LA (eq.) Solvent T (°C) t (h) 
Recovered  
(S)-74a (R)-74b (%) 
1 Yb(OTf)3 1 + 1 
CH2Cl2 
PhCl 
40 
131 
16 
16 
15 
2 Eu(fod)3 1 + 1 PhCl 
60 
131 
16 
16 
10 
3 Eu(fod)3 1 PhCl 150 (MW) 1 22 
The use of stoichiometric quantities of trimethylaluminium were not effective in mediating the 
desired cyclisation, instead, decomposition of both of the substrates (S)-74a and (R)-74b was 
observed. 
So far, the Lewis acid which has shown the most promise is dimethylaluminium chloride. To 
reduce competing reaction pathways, the chloride in the Lewis acid was replaced with a non-
nucleophilic counterion. Tetrafluorobenzoate esters have acted as good leaving groups in mono-
cyclisation reactions with high yields, where no tetrafluorobenzoate containing by-products were 
observed. Therefore, dimethylaluminium tetrafluorobenzoate was prepared by adding a solution 
of one equivalent of 2,3,4,5-tetrafluorobenzoic acid in dichloromethane at -78°C to a solution of 
trimethylaluminium, evolution of methane gas was observed, signifying the formation of the 
reagent, which was used at -78°C for attempted cyclisation of a mixture of tetrafluorobenzoate 
substrates (S)-74a or (R)-74b. However, no reaction was observed overnight at room temperature 
and addition of two further equivalents of reagent and heating at reflux overnight, returned 82% 
recovered starting material. 
Formation of tris(tetrafluorobenzoate)aluminium using three equivalents of tetrafluorobenzoic 
acid to one trimethylaluminium and heating at reflux with a mixture of tetrafluorobenzoate 
substrates (S)-74a and (R)-74b for 2 h again gave 83% recovered starting material. It is apparent 
that alkylaluminium tetrafluorobenzoate Lewis acids are not reactive enough for cyclisation of 
bromo-tetrafluorobenzoate substrates, or trimethylaluminium may not be coordinating to the ester 
but instead methylating the ester to form 1-(2,3,4,5-tetrafluorophenyl)ethanone. 
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The use of stoichiometric dimethylaluminium triflate – first reported in the 1980s151 and 
infrequently used152 – on each of bromide (S)-74a and (R)-74b provided clean conversion to 
cyclised adducts. The desired cyclised product 75 was isolated in 9% and 26% yield respectively 
(Table 21, entries 1 and 2), in both cases 75 was formed as a 3:1 mixture of diastereoisomers.  
Table 21 - Dimethylaluminium triflate activated cyclisation of bromo-tetrafluorobenzoates (S)-74a and (R)-74b 
 
Entry Substrate X (eq.) 
Recovered  
(S)-74a (R)-74b (%) 
Yield 77 
(%) 
Yield 75 
(%) 
1 (S)-74a 1.2 44 0 9 
2 (R)-74b 1.2 9 35 26 
3 (S)-74a 2.5 42 23 13 
4 (R)-74b 2.5 0 24 34 
5 (S)-74a 5 0 19 25 
6 (R)-74b 5 0 55 11 
5 (S)-74a 7.5 0 17 19 
In the cyclisation of (R)-74b (entry 2) a mixture of inseparable endo- and exocyclic alkenes 77 
were also isolated in 35% yield and identified by inspection of the alkene region of their 1H NMR 
spectrum (Figure 38). Two monocycles with endocyclic trisubstituted alkenes [δH 5.27 (br. S, 1H) 
and 5.20 (br. S, 1H)] were evident. As well as two monocycles with exocyclic methylene groups 
[δH 5.03 (s, 1H), 4.79 (s, 1H) and 4.91 (s, 1H), 4.72 (s, 1H)]. Both endo- and exocyclic alkene mono-
cycles had a diastereomeric ratio of 3:1 and their endo:exocyclic ratio was 1.5:1. 
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Figure 38 - 1H NMR Spectrum of 77, a mixture of endo- and exocyclic diastereomers 
Monocyclisation adducts of this type have been ring-closed with chlorosulfonic acid in 2-
nitropropane by Ishihara et al.,32, 81, 153 however, in our hands no reaction was observed under these 
conditions with mono-cycles 77 after 4 h at room temperature and after 24 h at room temperature 
polymerisation of the mixture had occurred. Carrying out the acid catalysed second ring-closure 
on crude cyclisation material also led to polymerisation at -78°C for 4 h. 
The use of 2.5 equivalents of dimethylaluminium triflate improved the yield of 75 from both 
substrates, (S)-74a and (R)-74b to 13% and 34% respectively (entries 3 and 4). In the case of entry 
4, clean and complete conversion of (R)-74b was observed with mono-cyclised adducts 
representing 24% yield.  
Increasing the number of equivalents of dimethylaluminium triflate to 5 improved the yield of 
bromide 75 from secondary tetrafluorobenzoate (S)-74a to 25% (entry 5), however this was not 
the case for cyclisation of tertiary tetrafluorobenzoate (R)-74b whose yield of 75 dropped to 11% 
(entry 6). Increasing the number of equivalents further to 7.5 did not improve the yield of 75 from 
(S)-74a (entry 7). 
The highest yield of cyclisation for (S)-74a of 25% was obtained using 5 equivalents of 
dimethylaluminium triflate, whereas for (R)-74b only 2.5 equivalents was needed to obtain a 34% 
yield, evidently the secondary tetrafluorobenzoate is less readily activated than the tertiary 
tetrafluorobenzoate. In both these reactions inspection of the 1H NMR spectrum of the crude 
reaction mixtures showed clean conversion of all starting material to mono- and bicyclisation 
products. The relatively low isolated yields were a result of the difficult purification of these non-
polar compounds by column chromatography. 
Ha 
Hb 
Hc Hc 
Hd Hd 
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It is unclear in cyclisation reactions initiated by Me2AlOTf which alkyl aluminium species is the 
defacto initiator of the reaction. We know that trimethylaluminium is an inactive species and 
Al(OTf)3 will not provide proton-free solutions however methylaluminium ditriflate may also be 
present in the reaction mixture. To investigate if MeAl(OTf)2 was the active species secondary 
tetrafluorobenzoate (S)-74a was reacted with 2.4 equivalents of MeAl(OTf)2, as prepared from 
trimethylaluminium and 2 equivalents of triflic acid, at room temperature overnight. Unfortunately 
decomposition of substrates was observed. 
Other alkylaluminium Lewis acids and conditions were tested using secondary 
tetrafluorobenzoate (S)-74a, these include: 
 2.5 equivalents of Me2Al(OTf) in polar solvents such as tBuNO2 led to decomposition; 
 carrying out the cyclisation using Me2Al(OTf) at elevated temperatures in 1,2-dichloroethane 
led to oxidation of the para-methoxyphenyl ring in the substrate and also to alkylation with 
1,2-dichloroethane; 
 the use of 2.9 equivalents of Me2Al(NTf2), as prepared from trimethylaluminium and 1 
equivalent of bis(trifluoromethane)sulfonimide, in dichloromethane at reflux for 6 h, gave 
trace quantities of 75. 
The desired product of the cyclisation 75 was isolated as a mixture of two diastereoisomers 
which were not separable by column chromatography, but could be separated by preparative 
HPLC. This enabled the enantiomeric purity of each to be determined, without interference from 
the other, as 98:2.  
  
Figure 39 - Chiral HPLC chromatogram showing 
separation of enantiomers of the desired diastereomer 
(2R,4aR,10aS)-75 
Figure 40 - Chiral HPLC chromatogram showing 
separation of enantiomers of undesired diastereomer 
(2R,4aS,10aR)-75 
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The chiral HPLC chromatogram of the desired diastereomer was compared to a racemic 
sample. This was prepared by the direct action of BDSB on diene 61 as described by Synder48 to 
provide racemic tricyclic bromide (±)-75 (Scheme 104) in 68% yield as a single diastereoisomer, 
which in our hands proved to be crystalline. An X-ray crystal structure (Figure 41) of tricyclic 
bromide (2R*,4aR*,10aS*)-75 confirms the formation of a trans-fused decalin ring system and the 
equatorial positioning of the bromine atom.  
 
 
Scheme 104 - BDSB mediated cyclisation of polyene 
61 into racemic tricyclic bromide (±)-75. 
Figure 41 - The crystal structure of (±)-75 
 
With the relative configuration of (2R,4aR,10aS)-75 being established by X-ray crystallography 
(Figure 41), the assignment of absolute configuration follows from an R-configured bromonium 
ion.  The relative configuration of the minor diastereoisomer can be established by dehalogenation 
of a 3:1 mixture of diastereomers 75. This was carried out by radical dehalogenation using 
trimethylsilyl silane in essentially quantitative conversion (43% isolated yield, Scheme 105). A single 
diastereomeric trans-decalin-78 was obtained with a 3:1 enantiomeric ratio. This allows assignment 
of the absolute configurations as (4aR,10aR)-78 and (4aS,10aS)-78 from (2R,4aR,10aS)-75 and 
(2R,4aS,10aR)-75 respectively.  The absolute configurations were confirmed by comparison of the 
sign of optical rotation for the 3:1 enantiomeric mixture of (4aR,10aR)-78 and (4aS,10aS)-78 with 
the rotation already reported for (+)-(4aS,10aS)-78.154 
  
Scheme 105 - Correlation of absolute and relative configurations by reduction of a 3:1 diastereomeric bromide 
mixture 75 to trans-decalin 78. 
Evidently, the bromonium ion-initiated cyclisations described (Table 21) are proceeding via 
enantiomerically pure bromonium ions without erosion of enantiopurity by intramolecular or 
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intermolecular bromonium ion-to-alkene transfer.87a A chair-like conformation C (Figure 42) can 
be invoked in the cyclisation leading to (2R,4aR,10aS)-75, and a boat-like conformation B in the 
cyclisation leading to (2R,4aS,10aR)-75. Both have the same R-configured absolute configuration 
of the bromonium ion.  
 
Figure 42 - Chair-like C and boat-like B geometries in the cyclisations leading to (2R,4aR,10aS)-75 and 
(2R,4aS,10aR)-75 respectively. 
The enantiospecific cyclisation of tertiary bromide (S)-74a has to occur by the formation of an 
R-configured enantiomerically pure bromonium ion, due to the change in position of Br-C bond. 
Cyclisation of secondary bromide (R)-74b may instead be occurring directly via a tertiary 
carbocation. As the product distributions for each substrate are identical by analysis of the 1H 
NMR spectrum of the crude reaction mixture, a single common intermediate such as a bromonium 
ion must be implicated. 
2.6 Towards an enantiospecific tri-cyclisation 
Having successfully carried out the first bromonium ion-induced polyene cyclisation of a diene 
substrate, the natural progression was to carry out the bromonium ion-induced cyclisation of a 
triene substrate. To this end, triene 79 was synthesised via palladium(0)-catalysed alkylation of 
farnesyl bromide using conditions reported by Demuth and co-workers103 in 72% yield with the 
desired α-alkylated product isolated with inseparable branched regioisomer γ-79 in a ratio of 17:1. 
Unfortunately, the boiling point of 79 was expected to be too high for vacuum distillation using 
standard stirrer hotplate temperatures (≤300°C). 
  
Scheme 106 - Synthesis of homo-farnesyl p-methoxybenzene 79 
Triene 79, as a 17:1 mixture of constitutional isomers was dihydroxylated using Sharpless’ AD-
mix β127 (Scheme 107) on a 7.6 g scale as the reaction was likely to be low yielding due to 
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regioselectivity problems, as discussed previously (Chapter 2.4.2, page 93). The desired 
regioisomeric diol 80a was isolated in 15% yield with branched diol γ-80a in a ratio of 20:1 with 
regioisomeric diol 80b in 17% yield. Evidently, the central alkene is just as accessible to 
dihydroxylation as the terminus alkene. Starting material was recovered in 31% yield (2.4 g) with 
an α:γ ratio of 23:1. The absolute configuration of diol (R)-80a and 80b were assigned on the basis 
of the Sharpless mnemonic.127-128 
 
Scheme 107 - Sharpless asymmetric dihydroxylation of homo-farnesyl p-methoxybenzene 79 
The enantiomeric ratio of 80a was determined to be 99:1 by chiral HPLC separation of 
enantiomers (Figure 43) in comparison to a racemic sample (Figure 44). Visible in these 
chromatograms are a  minor impurity, branched chain diol γ-80a. 
  
Figure 43 - Chiral HPLC chromatogram showing 
separation of enantiomers of (R)-80a 
Figure 44 - Chiral HPLC chromatogram showing 
separation of enantiomers of (±)-80a 
Racemic diol (±)-80a was synthesised using modified Sharpless asymmetric dihydroxylation 
conditions, whereby the chiral ligand was substituted by achiral quinuclidine, a method developed 
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by Warren et al.129 As a consequence of using quinuclidine, a less sterically encumbered ligand than 
(DHQD)2PHAL, the reaction time is much shorter, racemic diol (±)-80a was isolated in 13% yield 
after four hours (Scheme 108). 
 
Scheme 108 - Racemic dihydroxylation of homo-farnesyl p-methoxybenzene 79 
Diol (R)-80a was ring-closed to epoxide (S)-81 via mesylation and reaction with potassium 
carbonate in 54% yield (Scheme 109). Progress on tri-cyclisation substrate (S)-81 was halted at the 
more stable epoxide, as bromohydrins in our hands were found to undergo photolytic 
dehalogenation over time. 
  
Scheme 109 - Synthesis of epoxide (S)-81 
Racemic bromonium ion-induced polyene cyclisation of 79 was carried out using Snyder’s 
BDSB reagent48 with a second acid catalysed ring closure step using methane sulfonic acid in 24% 
overall yield. 
 
Scheme 110 - BDSB initiated tri-cyclisation of polyene 79 
 This provided a racemic sample for chiral HPLC analysis of the enantiomers. This can be used 
to determine future enantiospecific cyclisation reactions. 
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Figure 45 - Chiral HPLC chromatogram showing separation of enantiomers in (±)-82 
When carrying out a bi-cyclisation reaction using Me2AlOTf on tetrafluorobenzoate derivatives 
such as 74a or 74b, mono-cyclisation products accounted for 17-55% yield. When considering a 
tri-cyclisation reaction using these conditions, mono- and bi-cyclisation products are expected to 
account for the majority of the reaction products where the desired tricycle 82 may only be isolated 
in trace amounts. Development of our cyclisation conditions will have to be carried out to promote 
multiple C-C bond forming events. 
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3 Conclusion 
The overall aim of this project was to achieve the first polyene cyclisation triggered by an 
enantiomerically pure bromonium ion. The chemistry developed in this investigation was expected 
to demonstrate that enantiomerically pure bromonium ions can be generated in a controlled 
fashion and be employed in synthesis. The methodology could then be applied to the biomimetic 
synthesis of naturally occurring sesqui-45a and diterpene45d,45g metabolites which possess the α,α-
dimethylcyclohexyl bromide moiety. 
Initial studies on a model system bearing a single olefin 1 (Scheme 111), showed that 
enantiopure bromohydrins (8a and 8b) can be efficiently synthesised utilising Sharpless 
asymmetric dihydroxylation methodology. Activation as tetrafluorobenzoate esters (31a and 31b) 
was shown, in comparison to acetate derivatives, to provide substrates which undergo clean, 
enantiospecific and regioselective cyclisation under the action of catalytic triflic acid. Bromo-
bicycle 29 was therefore synthesised in excellent yield and high enantiomeric excess. 
 
Scheme 111 - Triggering a cation-π cyclisation with an enantiopure bromonium ion 
The isolation of each bromohydrin regioisomer separately allowed us to demonstrate that in 
the cyclisation of 31a an enantiomerically pure bromonium ion must be invoked. Although the 
cyclisation of 31b may instead proceed via a tertiary carbocation, as was indeed the case for des-
bromo substrate 46 (Scheme 112), the near identical product distributions for each substrate 
suggests a single common intermediate such as a bromonium ion. 
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Scheme 112 - Cyclisation of des-bromo tetrafluorobenzoate 46 via tertiary carbocation 
In preliminary studies using diene 61 it became apparent that high purity α-61, free from 
branched diene γ-61, was essential for subsequent dihydroxylation reactions and accurate HPLC 
enantiomeric excess determination. The branched isomer was inseparable at all stages of the 
synthesis by standard chromatography techniques and was found to obscure enantiomer signals in 
chiral HPLC analysis after cyclisation. Extensive investigation into the selective synthesis of α-61 
was carried out and reaction conditions were optimised. Large scale synthesis and fractional 
vacuum distillation was found to remove the branched diene γ-61 which provided a small number 
of grams of >98% purity α-61 for investigation. 
  
Scheme 113 - Synthesis of high purity diene α-61 
Sharpless asymmetric dihydroxylation of diene 61 was optimised using AD-mix β and standard 
conditions. Diol 70 was synthesised in reproducible yields in the range of 25-40% and with 
excellent enantioselectivity 99:1 e.r. Synthesis of bromo-tetrafluorobenzoate derivatives 74a and 
74b (Scheme 114) via the same methodology developed on the model system provided activated 
alcohols for investigation of cyclisation conditions. Although triflic acid was shown to be 
unsuitable for these olefinic substrates, Lewis acid: dimethylaluminium triflate was found to 
successfully enact the cyclisation. 
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Scheme 114 - Enantiospecific bromonium ion-induced cyclisation of 74a and 74b by the action of Me2AlOTf 
Although clean and complete conversion of 74a and 74b to cyclised adducts was achieved with 
Me2AlOTf, unfortunately, full conversion to the desired tricycle 75 was not. Mono-cyclisation 
adducts 77 accounted for 19% and 24% of the product mixtures. Closing of the final ring via acid 
catalysed cyclisation was attempted unsuccessfully using known literature conditions. Bromo 
tricycle 75, was isolated as a 3:1 mixture of diastereomers, evidently in this case a boat transition 
state has a similar energy to that of the more favourable chair transition state. 
After preparative HPLC separation of both diastereomers of 75 were shown to be of high 
enantiopurity: 98:2 e.r. Therefore we have demonstrated that enantiopure bromonium ions can be 
generated in the presence of alkene without racemisation via bromonium ion-to-olefin transfer and 
used in the synthesis of polyene cyclisation products. 
In the beginning we set out to overcome challenges in each of the fundamental steps of 
initiation, propagation and termination. Using this methodology an enantiopure bromonium ion 
can be formed regioselectively by taking advantage of Sharpless asymmetric dihydroxylation which 
is selective for the terminus alkene of the polyene. In propagation intramolecular C-C bonds were 
formed to give tricycle 75 in high enantiopurity, but with low diastereoselectivity. Unfortunately 
challenges in termination of this cyclisation via one mechanism, to give the desired tricyclic product 
diastereoselectivity, still need to be addressed. 
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4 Future Work 
In the development of the first polyene cyclisation triggered by an enantiopure bromonium ion 
a number of hurdles were overcome and novel methodology developed. However there still 
remains challenges and new avenues to explore.  
4.1 Optimisation of bi-cyclisation reaction 
In order to improve the overall yield of polycyclic product 75 in the cyclisation of geranyl based 
substrates such as 74a, alternative Lewis acid-leaving group combinations could be explored. 
Although 2,3,4,5-tetrafluorobenzoate derivatives were championed in this work, higher yields may 
be achieved with other benzoate derivatives such as pentafluorobenzoate, 4-nitrobenzoate, 3,5-
dinitrobenzoate or 4-trfluoromethylbenzoate. 
 
Figure 46 - Suggested leaving groups for development of bromonium ion-induced polyene cyclisation 
These suggested leaving groups can be tested with Lewis acids already investigated in this 
project such as Yb(OTf)3, Eu(fod)2 and Me2AlOTf, or unexplored Lewis acids such as Sc(OTf)3. 
Sulfonate esters could also act as good leaving groups. Bromo-tosylate 30 was investigated as a 
cyclisation substrate in model systems and cyclised successfully using TMSOTf (Scheme 115). 
Although it is likely that adventitious triflic acid was the active catalyst, bromo-tosylates show 
potential as cyclisation substrates. Other sulfonate esters could be synthesised and investigated 
such as methanesulfonate and trifluoromethanesulfonate. 
  
Scheme 115 - Activation of bromohydrins as tosylate esters 
4.2 Expansion of substrate scope 
Other factors which may improve cyclisation yields include the nucleophilicity of the 
intramolecular aromatic which terminates the cyclisation. 4-Methoxybenzene has been used 
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throughout this study however the substrate scope could be broadened to different substitution 
patterns.  2-Methoxy substitution 83, for example would be better positioned for stabilisation of 
the cationic intermediate (Scheme 116). Dimethoxy substitution would increase the nucleophilicity 
further, such as in substrates 84 and 85. Dimethyl aniline 86 would take this hypothesis even 
further.  
 
Scheme 116 - Broadening of substrate scope to different aromatics 
To find the boundaries in scope of this methodology, less nucleophilic aromatics could be 
investigated such as 4-chloro substitution 87. It should be noted that aromatic substation should 
still provide enough polarity for separation of enantiomers of cyclisation products by chiral HPLC 
analysis. Other electron withdrawing groups to be tested could include cyano- and trifluoromethyl 
88 and 89. 
As discussed previously, future work will involve the progression of farnesyl substrate (S)-81a 
to bromohydrins using methodology developed in this thesis (Scheme 117). Activation of the 
bromohydrins as tetrafluorobenzoate esters and triggering with Me2AlOTf will likely produce only 
mono- and bicyclic products. Cyclisation of three rings will require a second acid catalysed 
cyclisation step which as of yet hasn’t been proven in this work.  
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Scheme 117 - Development of farnesyl substrate 81a 
It may also be of interest to understand the product distribution of cation-π cyclisations carried 
out on olefins that aren’t trisubstituted. A disubstituted terminus alkene will produce two 
stereocentres which will be under stereospecific control of the enantiopure bromonium ion. It will 
be of interest to know if this affects the diastereoselectivity. 
4.3 Synthesis of natural products 
 Far more interesting may be to investigate the bromonium ion-induced cyclisation of 
substrates with different functional groups terminating the reaction. Phenols such as cymopol 
(Scheme 118) would undergo cyclisation to the natural product 4-isocymobarbatol.68d Nerolidol 
could cyclise to give bromomanoyl oxide or α-snyderol. The synthesis of these natural products 
would pose new challenges. Activation of the intermediary bromohydrin may result in 
esterification of the cyclisation terminating alcohols. In such a case the terminating alcohols may 
need protecting before this step. Trimethylsilyl ether functionality may prove beneficial as 
deprotection is likely to occur under cyclisation conditions. 
 
Scheme 118 - Bromonium ion-induced polyene cyclisation in the biomimetic synthesis of natural products 
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The use of a boc protected alcohol in the synthesis of peyssonol A (Scheme 118) will act as a 
trigger for the bromonium ion-induced cyclisation. This will favour termination of the cyclisation 
via one mechanism and give tricycle 90 as the major product. This product can be hydrolysed and 
the diol further functionalised to peyssonol A.  
It may be the case that any combination of substrate, Lewis acid-leaving group combination 
may produce improved yields and diastereoselectivity.  
4.4 The synthesis of enantiopure bromo-chlorides 
With a simple modification of the protocol an enantiopure fluorohydrin,155 chlorohydrin or 
iodohydrins could be synthesised. It would be interesting to investigate the activation of such 
substrates as tetrafluorobenzoate esters and to cyclise with Me2AlOTf to form halocyclic analogues 
of 29 and 75. 
The reaction of enantiopure bromohydrin 8b with thionyl chloride to give enantiopure 
bromochloride 91a has been carried out in 11% yield (Scheme 119). Unfortunately this was isolated 
with inseparable regioisomeric bromochloride 91b and elimination by-products 36 and 92. 
Optimisation of this reaction could give rise to methodology for the asymmetric synthesis of 
bromo-chlorides such as 91a, a common motif found in a wide variety of halogenated natural 
products.104, 156 
  
Scheme 119 - Synthesis of enantiopure bromo-chlorides 
Carrying out this research into bromonium ion-induced cation-π cyclisations has therefore 
opened up the door to a number of different avenues of research. Long may it continue.  
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5 Experimental 
5.1 General Experimental 
Reagents: Tetrakis(triphenylphosphine)palladium(0) was prepared according to the procedure by 
Coulson et al.157 and stored under nitrogen, without light in the fridge. 4-Methoxybenzyl chloride 
was prepared from 4-methoxybenzyl alcohol according to a procedure by Yadav et al.158 
Bromodiethylsulfide pentachloroantimony bromide (BDSB) was prepared according to the 
procedure by Snyder and Treitler.41b Methanesulfonamide was purified by recrystallization from 
EtOH. NBS was purified by recrystallization from water. Pyridine was distilled from CaH2. 
Triethylamine was distilled from CaH2 onto activated 4Å molecular sieves.  All other regents were 
obtained from commercial sources and used as received. 
Solvents: All reactions were carried out in anhydrous solvents unless used in combination with 
H2O. CH2Cl2, Et2O, THF and toluene were dried by passing through a column of alumina beads. 
N-Methyl-2-pyrrolidone was purified by distillation and stored over 4Å molecular sieves. 
Extraction solvents and chromatography eluents were used as received. MeOH and CH2Cl2 were 
HiPerSolv grade, EtOH was AnalaR grade, and Et2O, EtOAc, and petroleum ether 40-60 (referred 
to as pet. ether) were GPR grade. n-Hexane and i-PrOH for analytical HPLC were HPLC grade 
and used as received.  
Experimental techniques: Reactions were carried out in oven-dried glassware under an inert 
atmosphere of nitrogen, unless otherwise stated. Air and moisture sensitive reagents were 
transferred by syringe. Reaction temperatures other than room temperature were recorded as 
aluminium alloy heating block, or bath temperatures. 4Å Molecular sieves were activated by 
grinding into a powder and heating under vacuum and then cooling under nitrogen. The phrase, 
concentrated under reduced pressure, refers to rotary evaporation. Brine refers to a saturated 
aqueous solution of NaCl. Column chromatography was performed on silica gel, particle size 40-
63 μm unless otherwise stated. Chiral HPLC was performed on CHIRALCEL OD-H, OJ or 
CHIRALPAK AD columns detecting at 284 nm. Retention times (tR) are reported in minutes. 
Analytical TLC was performed on Kieselgel 60 F254 pre-coated aluminium-backed plates which 
were visualised by ultraviolet light (350 nm) and chemical staining using potassium permanganate 
solution. Silver nitrate doped silica gel was obtained after slurrying silica in aqueous AgNO3 
solution (0.1 M, 4 mLg-1 silica) and concentrating under reduced pressure azeotroping with toluene 
until dryness. 
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Characterisation: Fourier transform IR spectra were recorded neat using an ATR-IR 
spectrometer. 1H, 13C and 19F NMR spectra were recorded on Bruker AV400 and AV500 
spectrometers at 400 MHz and 500 MHz, and 100 MHz and 125 MHz, and 377 (AV500 only) 
MHz respectively.  Chemical shifts (δ) are quoted in parts per million (ppm) and are referenced to 
the residual solvent resonance. Coupling constants (J) are quoted in Hertz (Hz). Low resolution 
MS (EI, CI), GCMS and HRMS, were recorded by the Imperial College Department of Chemistry 
Mass Spectrometry Service. 
Compound naming: Compounds in this experimental section are named according to IUPAC 
recommendations on nomenclature. 1H NMR resonances are assigned using the numbering system 
outlined below. For linear substrates, numbering will begin at the terminus alkene and end at the 
benzylic position and each of the aromatic 1H NMR resonances will be labelled “a” and “b” as 
shown in Figure 47. 
 
Figure 47 - Representative compound numbering system for linear substrates in assignment of 1H NMR 
throughout the experimental section 
For cyclic structures, IUPAC nomenclature will be used.  
 
Figure 48 - IUPAC compound numbering system for cyclic structures 
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5.2 1-Methoxy-4-(4-methylpent-3-en-1-yl)benzene (1) 
 
Prepared according to the procedure used by Zhao and Loh159 and developed by Demuth.103  
To a stirred solution of magnesium turnings (2.4 g, 100 mmol) in anhydrous THF (50 mL) was 
added a few drops of p-methoxybenzyl chloride and a few drops of 1,2-dibromoethane to activate 
the magnesium. The reaction could also be started by gentle heating. Subsequently a solution of p-
methoxybenzyl chloride (11.3 mL, 83 mmol) in anhydrous THF (50 mL) was added dropwise over 
30 min maintaining the reflux. After complete addition reflux was continued for 2 h. The mixture 
was then added dropwise to a freshly prepared solution of 1-bromo-3-methylbut-2-ene (8.0 mL, 
67 mmol) and tetrakis(triphenylphosphine)palladium(0) (1.13 g, 0.98 mmol, 1.5 mol%) in THF (50 
mL) at 0°C. The reaction mixture was allowed to warm to room temperature, stirred for 16h and 
quenched with ice water (100 mL).  The mixture was extracted with Et2O (2 × 100 mL), washed 
with water (100 mL), brine (100 mL), dried over Na2SO4, concentrated under reduced pressure 
and chromatographed (5-15% Et2O in pet. ether) to afford the title compound 1 as a mixture of 
constitutional isomers with 1-(2,2-dimethylbut-3-en-1-yl)-4-methoxybenzene (γ-1) in ratio 4:1 
(10.2 g, 54 mmol, 80%) as a colourless oil. 1-(2,2-Dimethylbut-3-en-1-yl)-4-methoxybenzene (γ-1) 
can be identified by characteristic 1H NMR absorbances at 5.90 (dd, J = 17.5, 10.8 Hz, 1H), 4.96 
(dd, J = 10.6, 1.5 Hz, 1H) and 4.90 (dd, J = 17.4, 1.4 Hz, 1H) ppm. 
Rf = 0.33 (10% EtOAc in pet. ether); IR νmax 2914, 2855, 2835, 1612, 1585, 1511, 1441, 1376, 
1300, 1243, 1176, 1109, 1038, 825, 760, 720, 700 cm-1, sp2 CH and C=C stretches not observed; 
1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 8.6 Hz, 2H, Hb), 6.87 (d, J = 8.6 Hz, 2H, Ha), 5.21 (t, 
J = 7.1 Hz, 1H, H2), 3.83 (s, 3H, OCH3), 2.62 (app. t, J = 7.8 Hz, 2H, H4), 2.31 (app. q, J = 7.8 
Hz, 2H, H3), 1.74 (s, 3H, C1(CH3)), 1.61 (s, 3H, C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 
157.7, 134.6, 132.1, 129.3, 123.8, 113.7, 55.3, 35.2, 30.3, 25.7, 17.7 ppm; MS (CI+, NH3) m/z 191 
[M + H]+; HRMS (CI+, NH3) calc’d for C13H19O [M + H]
+ 191.1436, found 191.1434. 
5.3 (-)-(S)-5-(4-Methoxyphenyl)-2-methylpentane-2,3-diol [(S)-
56] 
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Diol (S)-56 was prepared according to the method of Sharpless,127 to a stirred solution of alkene 
1 (2.0 g, 10.5 mmol , 1 eq.) and methanesulfonamide (1.0 g, 10.5 mmol, 1 eq.) in water (20 mL) 
and tert-butanol (20 mL) was added AD-mix α (14.7 g, 1.4 gmmol-1) at room temperature and 
stirred vigorously for 16 h. The reaction mixture was quenched with saturated aqueous Na2SO4 
solution (60 mL), extracted with EtOAc (2 × 100 mL), washed with brine (100 mL), dried over 
Na2SO4, concentrated under reduced pressure and chromatographed (50-60% EtOAc in pet. 
ether) to afford the title product (S)-56 (2.17 g, 92%).  
Colourless oil; Rf = 0.37 (50% EtOAc in pet. ether); [α]D
24 -27.6 (c 1.4, CH2Cl2); IR νmax 3700-
3050, 2933, 1612, 1584, 1512, 1465, 1382, 1300, 1244, 1177, 1077, 1036, 936, 823 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.16 (d, J = 8.6 Hz, 2H, Hb), 6.86 (d, J = 8.6 Hz, 2H, Ha), 3.81 (s, 3H, OCH3), 
3.40 (d, J = 10.5 Hz, 1H H2), 2.90 (ddd, J = 14.3, 9.6, 5.2 Hz, 1H, H4), 2.65 (ddd, J = 13.8, 9.3, 
7.2 Hz, 1H, H4), 1.81-1.72 (m, 1H, H3), 1.69-1.59 (m, 1H, H3), 1.21 (s, 3H, C1(CH2)), 1.17 (s, 3H, 
C1(CH2)) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.9, 134.0, 129.4, 113.9, 77.8, 73.2, 55.3, 33.7, 
32.0, 26.6, 23.2 ppm; MS (CI+, NH3) m/z  242 [M + NH4]
+; HRMS (CI+, NH3) calc’d for 
C13H24NO3 [M + NH4]
+ 242.1756, found 242.1756; HPLC (CHIRALCEL OD-H; 10% IPA in n-
hexane; 1.0 mL/min) tR  = 7.5 min (major), 9.6 min (minor) – 92:8 e.r. (84% ee). 
A reference sample of (±)-diol 56 was prepared following a modified procedure of Warren.129 
A solution of potassium ferricyanide (2.60 g, 7.9 mmol), potassium carbonate (1.09 g, 7.9 mmol), 
K2OsO4.2H2O (29 mg, 0.079 mmol), quinuclidine (9 mg, 0.079 mmol, 3 mol%) and 
methanesulfonamide (250 mg, 2.63 mmol) in water (5 mL) and tert-butanol (5 mL) was warmed 
slightly and stirred until all the solids had dissolved and then allowed to cool to room temperature. 
Alkene 1 (500 mg, 2.63 mmol) was added and the mixture was stirred vigorously for 16 h. 
Anhydrous sodium sulfite (3.8 g, 30.2 mmol) was added and the mixture was stirred for 1 h, diluted 
with water (75 mL) and extracted with CH2Cl2 (3 × 75 mL). The combined organics were washed 
with aq. NaOH (2M, 100 mL), dried over Na2SO4, concentrated under reduced pressure and 
chromatographed (50-60% EtOAc in pet. ether) to afford (±)-56 (594 mg, 100%) as a white solid; 
m.p. 58-62 ˚C; HPLC (CHIRALCEL OD-H; 10% IPA in n-hexane; 1.0 mL/min) tR  = 7.4 min, 
9.3 min. 
5.4 (+)-(R)-5-(4-Methoxyphenyl)-2-methylpentane-2,3-diol [(R)-
56] 
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According to the method of Sharpless,127 to a stirred solution of alkene 1 (1.5 g, 7.9 mmol) and 
methanesulfonamide (750 mg, 7.9 mmol) in water (15 mL) and tert-butanol (15 mL) was added 
AD-mix β (11.0 g, 1.4 gmmol-1) and stirred vigorously for 16 h. The reaction mixture was quenched 
with saturated aqueous Na2SO4 solution (40 mL), extracted with EtOAc (2 × 75 mL), washed with 
brine (75 mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed 
(50:50-60:40 EtOAc:PE) to afford the title product (R)-56 (1.76 g, 99%) as a white solid. m.p. 42-
44°C; [α]D
24 +31.8 (c 1.1, CH2Cl2). HPLC (CHIRALCEL OD-H; 10% IPA in n-hexane; 1.0 
mL/min) tR  = 7.5 min (minor), 9.6 min (major) – 97:3 e.r. (94% ee). All other data identical to that 
of diol (S)-56. 
5.5 (±)-3-[2-(4-Methoxyphenyl)ethyl]-2,2-dimethyloxirane [(±)-
6] and (±)-2-[1-(4-methoxyphenyl)-2-methylpropan-2-
yl]oxirane (7) 
 
To a stirred solution of alkene 1 as a mixture of constitutional isomers with 1-(2,2-dimethylbut-
3-en-1-yl)-4-methoxybenzene (γ-1) in ratio 4:1 (10.2 g, 54 mmol, 1 eq) in CH2Cl2 (250 mL) at 0 °C 
was added meta-chloroperoxybenzoic acid (13.9 g, 80 mmol 1.5 eq) in one portion and stirred 
overnight. The reaction was quenched with saturated aqueous solution of Na2SO3 (250 mL), 
extracted and washed with saturated aqueous solution NaHCO3 (250 mL), brine (250 mL), dried, 
concentrated under reduced pressure and chromatographed (10% EtOAc in pet. ether) to afford 
the title product 7160 (8.8 g, 81%) and isomeric epoxide 7 (843 mg, 8%). 
Epoxide 6: Colourless oil; Rf = 0.36 (10% EtOAc in pet. ether); IR νmax 2960, 2928, 2859, 2835, 
1612, 1584, 1512, 1462, 1378, 1299, 1243, 1177, 1113, 1035, 909, 871, 760, 731, 703 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.14 (d, J = 8.6 Hz, 2H, Hb), 6.86 (d, J = 8.6 Hz, 2H, Ha), 3.81 (s, 3H, OCH3), 
2.85-2.75 (m,  2H, H4), 2.72-2.63 (m, 1H, H2), 1.93-1.74 (m, 2H, H3), 1.29 (s, 3H, C1(CH3)) 1.16 
(s, 3H, C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.9, 133.5, 129.4, 113.8, 63.9, 58.5, 55.3, 
31.8, 31.0, 24.8, 18.6 ppm; MS (CI+, NH3) m/z 224 [M + NH4]
+; HRMS (CI+) calc’d for C13H22NO2 
[M + NH4]
+ 224.1651. Found: 224.1660. 
Isomeric epoxide 7: Colourless oil; Rf = 0.44 (10% EtOAc in pet. ether); IR νmax 2958, 2931, 
1711, 1612, 1583, 1512, 1466, 1302, 1245, 1179, 1073, 913, 824, 760 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.10 (d, J = 8.5 Hz, 2H, Hb), 6.84 (d, J = 8.7 Hz, 2H, Ha), 3.81 (s, 3H, OCH3), 2.88-2.51 
(m,  3H, H4, H2), 1.08 (d, J = 6.9 Hz, 2H, H1), 0.91 (s, 3H, C3(CH3)) 0.82 (s, 3H, C3(CH3)) ppm; 
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13C NMR (100 MHz, CDCl3) δ 158.0, 131.5, 130.0, 113.2, 59.0, 55.2, 45.5, 44.3, 34.5, 23.3, 21.7 
ppm; MS (CI+) m/z 224, [M + NH4]
+; HRMS (CI+) calc’d for C13H22NO2 [M + NH4]
+ 224.1651. 
Found: 224.1654.  
5.6 (+)-(R)-3-[2-(4-Methoxyphenyl)ethyl]-2,2-dimethyloxirane 
[(R)-6] 
 
Using a modified procedure of Corey,126 to a stirred solution of (S)-diol 56 (2.0 g, 8.9 mmol, 1 
eq.) and triethylamine (2.46 mL, 17.7 mmol, 2 eq.) in CH2Cl2 (40 mL) at 0°C was added 
methanesulfonyl chloride (0.89 mL, 11.5 mmol, 1.3 eq). After 0.5 h the mixture was warmed to 
room temperature and stirred for 3 h. Additional triethylamine (7.4 mL 53 mmol, 6 eq.) was added, 
the reaction mixture was stirred for 16 h and poured into a suspension of K2CO3 (20 g, 145 mmol, 
16 eq.) in methanol (80 mL). The reaction mixture was stirred for 5 h, concentrated, diluted with 
water (100 mL), extracted with EtOAc (3 × 100 mL), washed with 10% aqueous CuSO4 solution 
(200 mL) and brine (200 mL), dried over Na2SO4, concentrated under reduced pressure and 
chromatographed (5-15% EtOAc in pet. ether) to afford the title product (R)-6 (1.39 g, 76%) as a 
colourless oil; [α]D
24 +12.6 (c 1.1, CH2Cl2). 
5.7 (-)-(S)-3-[2-(4-Methoxyphenyl)ethyl]-2,2-dimethyloxirane 
[(S)-6] 
 
Following the method used for the preparation of epoxide (R)-6, (R)-56 (1.76 g, 7.9 mmol) was 
converted into (S)-epoxide (S)-6 (858 mg, 53%) as a colourless oil: [α]D
24 -14.8 (c 1.7 CH2Cl2). 
5.8 (+)-(R)-4-Bromo-1-(4-methoxyphenyl)-4-methylpentan-3-ol 
[(R)-8a] and (-)-(S)-3-bromo-5-(4-methoxyphenyl)-2-
methylpentan-2-ol [(S)-8b] 
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Following the method of Couladouros and Vidali,76 to a solution of epoxide (R)-6 (1.39 g, 6.75 
mmol, 1 eq) in N-methyl-2-pyrrolidone (2 mL) was added LiBr (763 mg, 8.77 mmol, 1.3 eq) and 
PPTS (1.69 g, 6.75 mmol, 1 eq) and stirred at room temperature. for 3 h. The reaction was 
quenched with a saturated aqueous solution of NaHCO3 (100 mL), extracted with EtOAc (2 × 
100 mL), washed with brine (100 mL), dried, concentrated under reduced pressure and 
chromatographed (10-20% EtOAc in pet. ether) to yield first ketone 16160 (172 mg, 12%), second, 
bromohydrin (R)-8a (648 mg, 33%), and third, bromohydrin (S)-8b (1.06 g, 45%) containing ca. 
12-15% allyl alcohol 14.161 A sample of analytically pure (S)-8b was obtained by careful 
chromatography. Samples of (±)-8a and (±)-8b were prepared from (±)-6 using the above 
procedure. Bromohydrin (±)-8a: HPLC (CHIRALCEL OD-H; 1% IPA in n-hexane; 1.0 mL/min) 
tR  = 5.9 min, 7.1 min. Bromohydrin (±)-8b: HPLC (CHIRALCEL OD-H; 1% IPA in n-hexane; 
1.0 mL/min) tR  = 5.4 min, 6.1 min (major) 
Bromohydrin (R)-8a: Colourless oil; [α]D
24 +28.5 (c 1.4, CH2Cl2); Rf  = 0.64 (10% EtOAc in pet. 
ether); IR νmax 3600-3200, 2933, 1611, 1584, 1512, 1455, 1387, 1300, 1244, 1177, 1105, 1072, 1035, 
972, 824, 741, 704, 532 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.17 (d, J = 8.6 Hz, 2H, Hb), 6.87 (d, 
J = 8.7 Hz, 2H, Ha), 3.82 (s, 3H, OCH3), 3.46 (dd, J = 10.4, 1.8 Hz, 1H, H2), 2.94 (ddd, J = 14.0, 
9.4, 4.8 Hz, 1H, H4), 2.63 (ddd, J = 13.8, 9.0, 7.6 Hz,  1H, H4), 2.20 (br. s, 1H, OH), 1.92 (dddd, 
J = 13.7, 9.4, 7.6, 2.1 Hz, 1H, H3), 1.81 (s, 3H, C1(CH3)), 1.78-1.67 (m, 1H, H3) 1.74 (s, 3H, 
C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.9, 133.8, 129.4, 113.9, 78.7, 75.6 (CBr), 55.3, 
33.9, 31.7, 31.2, 28.7 ppm; MS (CI+) m/z 306, 304 [M + NH4]
+; HRMS (CI+) calc’d for 
C13H23NO2
79Br [M + NH4]
+ 304.0912. Found: 304.0918; HPLC (CHIRALCEL OD-H; 1% IPA 
in n-hexane; 1.0 mL/min) tR  = 6.4 min (minor), 8.0 min (major) - 91:9 e.r. (81% e.e.). 
Bromohydrin (S)-8b: Colourless oil; [α]D
24 -42.0 (c 1.1, CH2Cl2); Rf = 0.50 (10% EtOAc in pet. 
ether); IR νmax 3600-3150, 2934, 2835, 1612, 1584, 1512, 1464, 1369, 1336, 1300, 1244, 1177, 1105, 
1035, 964, 906, 822, 773, 704, 567, 552, 533, 527 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.17 (d, J = 
8.6 Hz, 2H, Hb), 6.88 (d, J = 8.6 Hz, 2H, Ha), 3.98 (dd, J = 11.4, 2.1 Hz, 1H, H2), 3.82 (s, 3H, 
OCH3), 3.00 (ddd, J = 13.9, 8.4, 4.4 Hz, 1H, H4), 2.68 (ddd, J = 13.9, 8.4, 8.3 Hz, 1H, H4), 2.26 
(br. s, 1H, OH), 2.23-2.13 (m, 1H, H3), 2.11-2.00 (m, 1H, H3) 1.34 (s, 3H, C1(CH3)), 1.33 (s, 3H, 
C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 158.1, 132.7, 129.5, 114.0, 72.5, 70.5, 55.3, 35.9, 
33.6, 26.6, 26.0 ppm; MS (CI+) m/z 306, 304 [M + NH4]
+; HRMS (CI+) calc’d for C13H23NO2
79Br 
[M + NH4]
+ 304.0912, found: 304.0915; HPLC (CHIRALCEL OD-H, 1% IPA in n-hexane, 1.0 
mL/min) tR  =  7.6 min (major), 8.3 min (minor) - 91:9 e.r. (82% e.e.). 
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5.8.1 1-(4-Methoxyphenyl)-4-methylpentan-3-one (16) 
 
Colourless oil. Rf = 0.58 (20% EtOAc in pet. ether); IR νmax 2969, 2935, 2834, 1708, 1612, 1584, 
1512, 1464, 1409, 1383, 1364, 1300, 1243, 1177, 1110, 1071, 1034, 1001, 963, 729, 705 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.15-7.09 (m, 2H, Hb), 6.87-6.83 (m, 2H, Ha), 3.81 (s, 3H, OCH3), 
2.89-2.83 (m, 2H, H4), 2.79-2.74 (m, 2H, H3), 2.59 (sep, J = 6.9 Hz, 1H, H1), 1.10 (s, 3H, 
C1(CH3)), 1.08 (s, 3H, C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 214.0, 157.9, 133.4, 129.3, 
113.9, 55.3, 42.3, 41.0, 29.0, 18.1 ppm; MS (CI+) m/z  224 [M + NH4]
+; HRMS (CI+) calc’d for 
C13H22NO2 [M + NH4]
+ 224.1651, found: 224.1651. 
5.8.2 5-(4-Methoxyphenyl)-2-methylpent-1-en-3-ol (14) 
 
Colourless oil. Rf = 0.50 (10% EtOAc in pet. ether); IR νmax 3421, 2935, 1612, 1513, 1456, 1246, 
1178, 1036, 900, 830 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 8.6 Hz, 2H, Hb), 6.86 (d, J 
= 8.7 Hz, 2H, Ha), 5.01-4.98 (m, 1H, CH2=C), 4.91-4.88 (m, 1H, CH2=C), 4.11 (t, J = 6.4 Hz, 1H, 
H2), 3.82 (s, 3H, OCH3), 2.74-2.57 (m, 2H, H4), 1.90-1.83 (m, 2H, H3), 1.77 (s, 3H, C1(CH3)), 
1.29 (br. s, 1H, OH) ppm; 13C NMR (100 MHz, CDCl3) δ 157.8, 147.5, 134.0, 129.3, 113.8, 111.2, 
55.3, 36.8, 31.0, 29.7, 17.6 ppm; MS (CI+) m/z  224 [M + NH4]
+; HRMS (CI+) calc’d for C13H22NO2 
[M + NH4]
+ 224.1651, found: 224.1650. 
5.9 (-)-(S)-4-Bromo-1-(4-methoxyphenyl)-4-methylpentan-3-ol 
[(S)-8a] and (+)-(R)-3-bromo-5-(4-methoxyphenyl)-2-
methylpentan-2-ol [(R)-8b] 
 
Following the method of Couladouros and Vidali,76 to a solution of (S)-epoxide 3 (858 mg, 4.17 
mmol) in N-methyl-2-pyrrolidone (1.2 mL) was added LiBr (471 mg, 5.41 mmol) and PPTS (1.05 
g, 4.17 mmol) and stirred at room temperature for 4 h. Additional LiBr (72 mg, 0.83 mmol) and 
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PPTS (209 mg, 0.83 mmol) was added and stirred for a further 2 h. The reaction was quenched 
with saturated aqueous NaHCO3 solution (50 mL), extracted with EtOAc (2 × 50 mL), washed 
with brine (50 mL), dried over Na2SO4, concentrated under reduced pressure and 
chromatographed (10:90-20:80 EtOAc:PE) to yield a 4:5 mixture of bromohydrins (S)-8a and (R)-
8b (860 mg, 72%) as a colourless oil containing ca. 9% allyl alcohol 14.161 Bromohydrins (S)-8a: 
[α]D
24 -27.0 (c 0.8, CH2Cl2). Bromohydrin (R)-8b: [α]D
24 +51.0 (c 1.5, CH2Cl2). The spectral data for 
(S)-8a and (R)-8b were identical to those of (R)-8a and (S)-8b. 
5.10 Epoxide ring-opening with HFIP and (n-hexyl)4N+Br- 
To a stirred solution of epoxide (±)-6 (50 mg, 0.24 mmol, 1 eq) and activated 4 Å molecular 
sieves in HFIP for 1 h, was added n-hexyl4N
+Br- (385 mg, 0.89 mmol, 3.65 eq) and heated at reflux 
overnight. The reaction mixture was diluted with EtOAc (10 mL), filtered through a silica plug, 
washed with brine (50 mL), concentrated under reduced pressure and chromatographed (5-25% 
EtOAc in pet. ether) to afford ketone 16160 (14 mg, 28%) and aldehyde 15162,160 (4 mg, 8%) as a 4:1 
mix, as a colourless oil,  bicycle 13163,160 (10 mg, 20%) and allyl alcohol 14161 (7 mg, 14%). 
5.10.1 4-(4-Methoxyphenyl)-2,2-dimethylbutanal (15) 
 
Rf = 0.58 (20% EtOAc in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 9.50 (s, 1H CHO), 7.09 
(d, J = 8.6 Hz,  2H, Hb), 6.83 (d, J = 2H, Ha), 3.81 (s, 3H, OCH3), 2.53-2.47 (m, 2H, H4), 1.82-
1.76 (m, 2H, H3), 1.15 (s, 6H, C2(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 206.0, 157.9, 133.9, 
129.2, 113.9, 55.3, 45.9, 39.6, 29.8, 29.7, 21.4 ppm; MS (CI+) m/z  224 [M + NH4]
+. 
5.10.2 (±)-7-Methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-
2-ol (13) 
 
Colourless oil. Rf = 0.42 (20% EtOAc in pet. ether); IR νmax 3397, 2935, 1611, 1574, 1504, 1464, 
1282, 1242, 1034, 856, 808, 708 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 8.4 Hz, 1H, H5), 
6.91 (d, J = 2.7 Hz, 1H, H6), 6.37 (dd, J = 8.4, 2.6 Hz, 1H, H8), 3.82 (s, 3H, OCH3), 3.78 (dd, J = 
8.7, 3.1 Hz, 1H H2), 2.97-2.77 (m, 2H, H4), 2.03 (tdd, J = 9.7, 6.6, 3.4 Hz, 1H, H3), 1.99-1.90 (m, 
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1H, H3), 1.36 (s, 3H, C1(CH3)), 1.32 (s, 3H, C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 158.0, 
145.6, 129.6, 126.7, 112.4, 111.4, 75.6, 55.3, 39.3, 29.0, 27.0, 26.1, 25.0 ppm; MS (CI+) m/z  224 
[M + NH4]
+.HRMS (CI+) calc’d for C13H22NO2 [M + NH4]
+ 224.1651, found: 224.1652. 
5.11 Epoxide ring-opening with Bu4N+Br- and Mg(NO3)2 
According to the procedure developed by Suh et al.,108 to a stirred solution of epoxide (±)-6 (50 
mg, 0.24 mmol, 1 eq) in CH2Cl2 (2.5 mL) was added Bu4N
+Br- (156 mg, 0.48 mmol, 2 eq) and 
Mg(NO3)2.6H2O (41 mg, 0.16 mmol, 0.66 eq) and heated at reflux for 6 h. The suspension was 
then filtered through a silica plug, concentrated under reduced pressure and chromatographed 
(15% EtOAc in pet. ether) to yield secondary alcohol bromohydrin 8a (10 mg, 15%), ketone 16 (4 
mg, 7%), secondary bromide bromohydrin 8b (16 mg, 24%) as a 3:1 mixture with allyl alcohol 14 
(4 mg, 10%). 
5.12 Epoxide ring-opening with PPh3/Br2 
The reaction was carried out according to a modified procedure of Palumbo, Ferreri and 
Caputo.109 To a solution of bromine (13 µL, 0.27 mmol, 1.1 eq) in anhydrous CH2Cl2 (7.8 mL), 
triphenylphosphine (70 mg; 0.27 mmol, 1.1 eq) was added in one portion. The brown solution 
turned immediately to a pale yellow colour and then epoxide (±)-6 (50 mg; 0.24 mmol, 1 eq) was 
added also in one portion. After stirring overnight the reaction mixture was poured onto ice in a 
sat. aq. soln NaHCO3 (25 mL), extracted with CH2Cl2 (2 × 20 mL), washed with brine (20 mL), 
concentrated under reduced pressure and chromatographed (5-25% EtOAc in pet. ether) to afford 
secondary alcohol bromohydrin 8a (20 mg, 29%) as a colourless oil, over-brominated secondary 
alcohol bromohydrin 21a (29 mg, 33%) and secondary bromide bromohydrin 8b (9 mg, 13%) as 
a 3:1 mixture and over-brominated  secondary bromide bromohydrin 21b (8 mg, 9%) as a 
colourless liquid. 
The reaction was repeated under the same conditions but with an excess of triphenylphosphine 
(114 mg, 0.44 mmol, 1.3 eq), epoxide (±)-6 (69 mg, 0.34 mmol, 1 eq), bromine (19 µL, 0.37 mmol, 
1.1 eq) to produce secondary alcohol bromohydrin 8a (29 mg, 30%) as a colourless oil and 
secondary bromide bromohydrin 8b (19 mg, 20%) and over-brominated secondary alcohol 
bromohydrin 21a (12 mg, 10%) as a 5:3 mixture as a colourless oil. 
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5.12.1  (±)-4-Bromo-1-(3-bromo-4-methoxyphenyl)-4-
methylpentan-3-ol (21a) 
 
Colourless oil. Rf = 0.50 (10% EtOAc in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 
2.2 Hz, 1H, Hc), 7.18-7.13 (m, 1H, Hb), 6.89-6.84 (m, 1H, Ha), 3.90 (s, 3H, OCH3), 3.43 (dd, J = 
10.5, 2.0 Hz, 1H, H2), 2.92 (ddd, J = 14.1, 9.5, 4.8 Hz, 1H, H4), 2.72-2.60 (m, 1H, H4), 1.90 (dddd, 
J = 13.7, 9.4, 7.5, 1.9 Hz, 1H, H3), 1.81 (s, 3H, C1(CH3)), 1.74 (s, 3H, C1(CH3)), 1.75-1.64 (m, 1H, 
H3) ppm; 13C NMR (100 MHz, CDCl3) δ 154.2, 135.4, 133.2, 128.5, 112.0, 111.5, 78.5, 56.3, 31.4, 
31.2, 28.6, 21.1 ppm; MS (CI+) m/z  224, [M-Br + NH4]
+. 
5.12.2  (±)-3-Bromo-5-(3-bromo-4-methoxyphenyl)-2-
methylpentan-2-ol (21b) 
 
Colourless oil. Rf = 0.42 (10% EtOAc in pet. ether); IR νmax 3462, 2929, 1608, 1498, 1463, 1256, 
1056, 1022, 811, 748, 579, 557 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 2.1 Hz, 1H, Hc), 
7.15 (dd, J = 8.3, 2.1 Hz, 1H, Hb), 6.86 (d, J = 8.4 Hz, 1H, Ha), 3.96 (dd, J = 11.4, 2.1 Hz, 1H, 
H2), 3.91 (s, 3H, OCH3), 2.99 (ddd, J = 13.9, 8.6, 4.5 Hz, 1H, H4), 2.66 (dt, J = 14.0, 8.3 Hz, 1H, 
H4), 2.23-2.11 (m, 1H, H3), 2.10-1.99 (m, 1H, H3) 1.35 (s, 6H, C1(CH3)) ppm; 
13C NMR (100 
MHz, CDCl3) δ 154.4, 134.4, 133.3, 128.5, 112.0, 111.6, 72.5, 70.0, 56.3, 35.7, 33.3, 26.7, 25.9 ppm; 
MS (CI+) m/z  386, 384, 382, [M + NH4]
+; HRMS (CI+) calc’d for C13H22NO2
79Br2 [M + NH4]
+ 
382.0017, found: 382.0013. 
5.13  Epoxide ring-opening with Me2SBr+Br- 
Synthesis of reagent is carried out according to the procedure of Olah et al.114 To a solution of 
dimethyl sulfide (4.36 mL, 60 mmol, 1 eq) in CH2Cl2 (12 mL) at 0 °C was added dropwise over 30 
min a solution of bromine (3.070 mL, 60 mmol, 1 eq) in CH2Cl2 (12 mL). The light-orange crystals 
were filtered and washed with dry hexane and dried under reduced pressure. The reagent (10.4 g, 
42 mmol, 1 eq) was added to a solution of epoxide (±)-6 (8.57 g, 42 mmol, 1 eq) in MeCN (25 
mL) and stirred for 30 min. The reaction was quenched with water (50 mL) and extracted with 
EtOAc (2 × 50 mL), concentrated under reduced pressure and chromatographed (5-25% EtOAc 
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in pet. ether) to afford secondary alcohol bromohydrin 8a (3.44 g, 29%) and secondary bromide 
bromohydrin 8b (2.05 g, 17%). 
5.14 2-Bromo-5-(4-methoxyphenyl)-2-methylpentan-3-yl 4-
toluenesulfonate (30) 
 
To a stirred solution of bromohydrin (±)-8a (250 mg, 0.87 mmol, 1 eq.) in pyridine (1 ml) at 
0°C was added tosic anhydride (369 mg, 1.13 mmol, 1.3 eq.) and stirred for 2 h. The reaction was 
quenched with a saturated aqueous solution of ammonium chloride and extracted with EtOAc (2  
× 25 mL), washed with water (3 × 50 mL), brine (50 mL) and concentrated under reduced pressure 
at 55°C. The crude reaction mixture was dissolved in CH2Cl2 (8 mL), stirred at -78°C and TMSOTf 
(0.17 mL, 0.96 mmol, 1.1 eq.) added dropwise and stirred for 6 h. The reaction was quenched with 
a saturated aqueous solution of NaHCO3 (25 mL), extracted with CH2Cl2 (25 mL), washed with a 
saturated aqueous solution of NaHCO3 (25 mL), brine (25 mL), dried over Na2SO4, concentrated 
under reduced pressure and chromatographed (0-20% CH2Cl2 in pet. ether) to give bromo bicycle 
(±)-29 (113 mg, 0.42 mmol, 48% yield) and ketone 16 (32 mg, 0.15 mmol, 18% yield). 
Tosylate 30 from analysis of the crude reaction mixture before reaction with TMSOTf: Rf = 
0.45 (5% EtOAc in pet. ether); 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.3 Hz, 2H, Hc), 7.38 
(d, J = 8.2 Hz, 2H, Hd), 7.05 (d, J = 8.5 Hz, 2H, Hb), 6.84 (d, J = 8.6 Hz, 2H, Ha), 4.74 (dd, J = 
8.5, 2.3 Hz, 1H, H2), 3.81 (s, 3H, OCH3), 2.89-2.83 (m, 1H, H4), 2.79-2.73 (m, 1H, H4), 2.48 (s, 
3H, PhCH3), 2.31 (dddd, J = 14.7, 10.4, 6.5, 2.2 Hz, 1H, H3), 2.07-1.96 (m, 1H, H3), 1.73 (s, 3H, 
C1CH3), 1.71 (s, 3H, C1CH3) ppm. 
5.15 (+)-(R)-2-Bromo-5-(4-methoxyphenyl)-2-methylpentan-3-yl 
2,3,4,5-tetrafluorobenzoate [(R)-31a] 
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Using the method of Steglich,116 to a stirred solution of secondary alcohol (R)-8a (250 mg, 0.87 
mmol, 1 eq) in CH2Cl2 (5 mL) was added 2,3,4,5-tetrafluorobenzoic acid (203 mg, 1.05 mmol, 1.2 
eq), DMAP (32 mg, 0.26 mmol, 30 mol%) and DCC (233 mg, 1.13 mmol, 1.3 eq) and stirred for 
4 h. The reaction mixture was then diluted with Et2O, filtered through a silica plug, concentrated 
under reduced pressure and chromatographed (0-10% Et2O in pet. ether) to afford (R)-31a (353 
mg, 88%). (±)-31a (71 mg, 88% yield) was prepared from (±)-8a (50 mg, 0.18 mmol) using the 
same procedure over 1 h. HPLC (CHIRALPAK AD; 0.25% IPA in n-hexane; 0.5 mL/min) tR = 
19.8 min, 22.4 min. 
Colourless oil; [α]D
24 +16.5 (c 1.2, CH2Cl2); Rf = 0.34 (5% EtOAc in pet. ether); IR νmax 2935, 
1725, 1628, 1613, 1526, 1513, 1485, 1371, 1282, 1225, 1178, 1097, 1034, 1000, 977, 922, 882, 829, 
775, 743, 705, 623, 581, 541 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.63 (dddd, J = 10.5, 8.4, 6.0, 2.5 
Hz, 1H, F4BzH), 7.12 (d, J = 8.6 Hz, 2H, Hb), 6.82 (d, J = 8.6 Hz, 2H, Ha), 5.33 (dd, J = 10.2, 1.8 
Hz, 1H, H2), 3.79 (s, 3H, OCH3), 2.67 (app. t, J = 7.8 Hz, 2H, H4), 2.32-2.23 (m, 1H, H3), 2.18-
2.07 (m, 1H, H3) 1.81 (s, 3H, C1(CH3)), 1.80 (s, 3H, C1(CH3)) ppm; 
13C NMR (125 MHz, CDCl3) 
δ 161.5, 158.0, 148.0 (dd, J = 262, 12 Hz), 146.4 (dd, J = 250, 10 Hz), 144.0 (ddd, J = 232, 14, 14 
Hz), 141.0 (ddd, J = 228, 14, 14 Hz), 114.6 (m), 113.8, 113.4 (dd, J = 21, 3 Hz), 81.5, 65.6, 55.1, 
32.9, 31.6, 30.3 ppm; 19F NMR (377 MHz, CDCl3) δ -153.2 (t, J = 20 Hz, 1F), -146.9 (m, 1F), -
137.7 (m, 1F), -133.5 (m, 1F) ppm; MS (CI+) m/z 482, 480, [M + NH4]
+; HRMS (CI+) calc’d for 
C20H23NO3
79BrF4 [M + NH4]
+ 480.0797, found: 480.0792. HPLC (CHIRALPAK AD; 0.25% IPA 
in n-hexane; 0.5 mL/min) tR = 19.8 min (minor), 22.0 min (major) – 92:8 e.r. (84% ee). 
5.16 Esterification using acid chloride 
To a stirred solution of 2,3,4,5-tetrafluorobenzoic acid (135 mg, 0.70 mmol, 2 eq.) in CH2Cl2 
(10 mL) was added oxalyl chloride (1 mL, 11 mmol, 33 eq.) and a drop of DMF and heated at 
refluxed for 4 h. The reaction mixture was then concentrated under reduced pressure, dissolved in 
CH2Cl2 (2 mL) and added dropwise at 0 °C to a solution of secondary alcohol bromohydrin (±)-
8a (100 mg, 0.35 mmol, 1 eq.) and DMAP (85 mg, 0.70 mmol, 2 eq.) in CH2Cl2 (15 mL), and stirred 
at room temperature for 16 h. The reaction was quenched with a saturated aqueous solution of 
NaHCO3 (30 mL) extracted with CH2Cl2 (2 × 30 mL), dried over Na2SO4, concentrated under 
reduced pressure and chromatographed (0-20% EtOAc in pet. ether) to yield epoxide 6 (23 mg, 
0.11 mmol, 33%), ketone 16 (14 mg, 0.07 mmol, 19%) and tetrafluorobenzoate ester 31a (6 mg, 
0.01 mmol, 4%). 
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5.17 (-)-(S)-3-Bromo-5-(4-methoxyphenyl)-2-methylpentan-2-yl 
2,3,4,5-tetrafluorobenzoate [(S)-31b] 
 
Tertiary alcohol (±)-8b (50 mg, 0.18 mmol) was reacted under the same conditions as used for 
the esterification of (R)-8a over 16 h to afford tertiary tetrafluorobenzoate (±)-31b (34 mg, 42%). 
Optimisation of this reaction gave improved yields with the conditions described below. 
Using the method of Steglich,116 to a stirred solution of tertiary alcohol (S)-8b containing ca. 12-
15% allyl alcohol 14 (250 mg, 0.87 mmol, 1 eq) in CH2Cl2 (1 mL) was added 2,3,4,5-
tetrafluorobenzoic acid (338 mg, 1.78 mmol, 2 eq), DMAP (32 mg, 0.262 mmol, 30 mol%) and 
DCC (538 mg, 2.61 mmol, 3 eq).  After 16 h the reaction mixture was diluted with Et2O, filtered 
through a silica plug, concentrated under reduced pressure and chromatographed (5-20% EtOAc 
in pet. ether) to afford tetrafluorobenzoate ester (S)-31b (300 mg, 62%) as a white solid containing 
ca. 15% 5-(4-methoxyphenyl)-2-methylpent-1-en-3-yl tetrafluorobenzoate (33). A sample of 
analytically pure (S)-31b was obtained by reaction of this mixture with mCPBA. 
A sample of (±)-31b (111 mg, 69%, containing ca. 10% 5-(4-methoxyphenyl)-2-methylpent-1-
en-3-yl tetrafluorobenzoate 33) was prepared from (±)-31b (100 mg, 0.35 mmol) by the same 
procedure. A sample of analytically pure (±)-31b was obtained by further careful chromatography; 
m.p. 74-77 °C. HPLC (CHIRALCEL OD-H; 0.25% IPA in n-hexane; 1.0 mL/min) tR = 16.9 min, 
19.8 min. 
White solid; m.p. 72-75 °C; [α]D
24 -37.3 (c 1.5, CH2Cl2); Rf = 0.3 (5% EtOAc in pet. ether); IR 
νmax 2994, 2937, 2841, 1729, 1717, 1631, 1612, 1583, 1526, 1512, 1485, 1392, 1363, 1325, 1285, 
1228, 1176, 1163, 1124, 1107, 1030, 984, 958, 950, 920, 875, 865, 824, 799, 778, 768, 743, 720, 704, 
679 cm-1,  1H NMR (400 MHz, CDCl3) δ 7.55 (dddd, J = 10.4, 8.4, 6.0, 2.5 Hz, 1H, F4BzH), 7.16 
(d, J = 8.6 Hz, 2H, Hb), 6.87 (d, J = 8.7 Hz, 2H, Ha), 4.51 (dd, J = 11.3, 1.9 Hz, 1H, H2), 3.83 (s, 
3H, OCH3), 3.03 (ddd, J = 13.4, 8.6, 4.5 Hz, 1H, H4), 2.70 (ddd J = 13.9, 8.3, 8.3 Hz, 1H, H4), 
2.25-2.15 (m, 1H, H3) 2.13-2.03 (m, 1H, H3) 1.74 (s, 3H, C1(CH3)), 1.72 (s, 3H, C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 160.4, 158.1, 147.8 (dddd, J = 262, 11, 4, 2 Hz), 146.4 (dddd, J = 
249, 11, 4, 2 Hz), 143.4 (dddd, J = 261, 16, 12, 3 Hz), 141.2 (dddd, J = 248, 17, 12, 4 Hz) 132.5, 
129.5, 115.8 (m), 113.9, 113.3 (dd, J = 20, 3 Hz), 86.1, 61.3, 55.2, 35.5, 33.3, 24.1, 23.1 ppm; 19F 
NMR (377 MHz, CDCl3) δ -153.5 (t, J = 20 Hz, 1F), -147.6 (m, 1F), -138.0 (m, 1F), -134.4 (m, 1F) 
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ppm; MS (CI+) m/z 482, 480, [M + NH4]
+; HRMS (CI+) calc’d for C20H23NO3
79BrF4 [M + NH4]
+ 
480.0797, found: 480.0821. HPLC (CHIRALCEL OD-H; 0.25% IPA in n-hexane; 1.0 mL/min) 
tR = 16.9 min (major), 20.2 min (minor) – 93:7 e.r. (86% ee). 
5.18 5-(4-Methoxyphenyl)-2-methylpent-1-en-3-yl 2,3,4,5-
tetrafluorobenzoate (33) 
 
Rf = 0.4 (10% EtOAc in pet. ether); 
1H NMR (400 MHz, CDCl3) δH 7.64-7.54 (m, 1H F4BzH) 
7.12 (d, J = 8.6 Hz, 2H, Hb), 6.84 (d, J = 8.6 Hz, 2H, Ha), 5.47 (dd, J = 7.2, 6.0 Hz, 1H, H2), 5.08 
(s, 1H C1=CH2),  5.03-5.01 (m, 1H, C1=CH2), 3.80 (s, 3H, OCH3), 2.99-2.84 (m, 1H, H4), 2.77-
2.59 (m, 1H, H4), 2.23-2.09 (m, 1H, H3), 2.09-1.98 (m, 1H, H3), 1.83 (s, 3H, C1CH3). 
5.19 (-)-(S)-2-Bromo-5-(4-methoxyphenyl)-2-methylpentan-3-yl 
2,3,4,5-tetrafluorobenzoate [(S)-31a] and (+)-(R)-3-bromo-5-
(4-methoxyphenyl)-2-methylpentan-2-yl 2,3,4,5-
tetrafluorobenzoate [(R)-31b] 
 
A 4:5 mixture of bromohydrins (S)-8a and (R)-8b (860 mg, 3.00 mmol) containing ca. 9% allyl 
alcohol 14 was esterified under the same conditions as used for (S)-31b to produce a 4:5 mixture 
of tetrafluorobenzoates (S)-31a and (R)-31b (644 mg, 95%) as a white oily solid containing ca. 8% 
allyl tetrafluorobenzoate 33. Tetrafluorobenzoates (R)-31b: [α]D
24 +33.1 (c 1.2, CH2Cl2);  The 
spectral data for (S)-31a and (R)-31b were identical to those of (R)-31a and (S)-31b. 
5.20 Removal of olefinic impurities 
Olefinic impurities are removed by reaction with mCPBA. An exemplary reaction is described 
below:  
135 
 
To a stirred solution of a 1:0.75 mixture of (S)-31b and 33 (175 mg, 0.38 mmol) in CH2Cl2 (6 
mL) at 0°C was added mCPBA (98 mg, 0.57 mmol) and stirred at room temperature for 16 h. To 
the reaction mixture was added mCPBA (98 mg, 0.57 mmol) and stirred at room temperature for 
a further 16 h. The reaction was quenched with a saturated aqueous solution of Na2SO3 (25 mL), 
extracted with CH2Cl2 (25 mL), washed with a saturated aqueous solution of NaHCO3 (25 mL), 
brine (25 mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed (0-
25% Et2O in pet. ether) to afford pure tetrafluorobenzoate (S)-31b (32.5 mg, 0.07 mmol, 19%) 
and 3-(4-methoxyphenyl)-1-(2-methyloxiran-2-yl)propyl 2,3,4,5-tetrafluorobenzoate (6 mg, 0.02 
mmol, 4%). 
5.21 3-(4-Methoxyphenyl)-1-(2-methyloxiran-2-yl)propyl 2,3,4,5-
tetrafluorobenzoate (57) 
 
Colourless oil; Rf = 0.43 (20% Et2O in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 7.57 (dddd, J 
= 10.4, 8.3, 6.0, 2.5 Hz, 1H, F4BzH), 7.11 (d, J = 8.6 Hz, 2H, Hb), 6.83 (d, J = 8.7 Hz, 2H, Ha), 
4.94 (dd, J = 6.1, 6.9 Hz, 1H, H2), 3.80 (s, 3H), 2.92 (d, J = 5.0 Hz, 1H, C1CH2O), 2.71 (td, J = 
7.5, 3.0 Hz, 2H, H3), 2.66 (d, J = 5.0 Hz, 1H, C1CH2O), 2.14 (t, J = 7.6 Hz, 2H, H4), 1.42 (s, 3H, 
C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 158.0, 132.8, 129.2, 113.9, 113.4, 76.7, 56.2, 55.2, 
53.0, 32.5, 31.0, 16.9 ppm; MS (CI+) m/z 416 [M + NH4]
+; HRMS (CI+) calc’d for C20H19O4F4 
399.1219 [M + H]+, found: 399.1213. 
5.22 (+)-(R)-4-Bromo-1-(4-methoxyphenyl)-4-methylpentan-3-yl 
acetate [(R)-32a] 
 
Using the method of Steglich,116 to a stirred solution of secondary alcohol (R)-8a (129 mg, 0.52 
mmol, 1 eq) in CH2Cl2 (3 mL) was added acetic acid (35 μL, 0.63 mmol, 1.2 eq), DMAP (19 mg, 
0.16 mmol, 30 mol%) and DCC (140 mg, 0.68 mmol, 1.3 eq) and stirred 48 h. The reaction mixture 
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was then diluted with Et2O, filtered through a silica plug, concentrated under reduced pressure 
and chromatographed (0-15% EtOAc in pet. ether) to afford (R)-32a (90 mg, 52%). A sample of 
(±)-32a (272 mg, 95% yield) was prepared from (±)-32a (250 mg, 0.87 mmol) by the same 
procedure over 16 h. HPLC (CHIRALCEL OD-H; 1% IPA in n-hexane; 1.0 mL/min) tR = 7.6 
min, 10.7 min. 
Colourless oil; [α]D
24 +8.7 (c 1.3, CH2Cl2); Rf = 0.38 (15% EtOAc in pet. ether); IR νmax 2995,  
2963, 2932, 2859, 2835, 1739, 1612, 1584, 1512, 1455, 1371, 1300, 1226, 1177, 1114, 1037, 987, 
964, 872, 826, 746, 702, 639, 606, 576; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 8.6 Hz, 2H, Hb), 
6.86, (d, J = 8.6 Hz, 2H. Ha), 5.05 (dd, J = 10.3, 2.1 Hz, 1H, H2), 3.82 (s, 3H, OCH3), 2.68-2.52 
(m, 2H, H4), 2.20-2.10 (m, 1H, H3), 2.16 (s, 3H, C(O)CH3) 2.03-1.92 (m, 1H, H3), 1.74 (s, 3H, 
C1(CH3)) 1.73 (s, 3H, C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 170.6, 158.0, 133.2, 129.3, 
113.9, 79.1, 66.5, 55.3, 33.3, 31.5, 30.6, 30.4, 20.9 ppm; MS (CI+, NH3) m/z 348, 346 [M + NH4]
+; 
HRMS (CI+, NH3) calc’d for C15H25NO3
79Br [M + NH4]
+ 346.1018, found: 346.1017. HPLC 
(CHIRALCEL OD-H; 1% IPA in n-hexane; 1.0 mL/min) tR = 7.6 min (major), 10.7 min (minor) 
– 92:8 e.r. (84% ee). 
5.23 (-)-(S)-3-Bromo-5-(4-methoxyphenyl)-2-methylpentan-2-yl 
acetate [(S)-32b] 
 
Using a modified procedure of Murai.75 To a stirred solution of tertiary alcohol (S)-8b (200 mg, 
0.70 mmol, 1 eq.) and acetic acid (40 μL, 0.70 mmol 1 eq.) in CH2Cl2 (2 mL) was added 
trifluoroacetic anhydride (0.57 mL, 4.11 mmol, 6 eq.) and stirred at room temperature for 3 h. The 
reaction was quenched with saturated aqueous NaHCO3 solution (20 mL) and extracted with 
CH2Cl2 (20 mL).  The organic layer was washed with brine (20 mL), dried over Na2SO4, 
concentrated under reduced pressure and chromatographed (5-20% Et2O in pet. ether) to give 
bromoacetate (S)-32b (167 mg, 73%). A sample of (±)-32b (72 mg, 63%) was prepared from (±)-
8b (100 mg, 0.35 mmol) by the same procedure over 1.5 h. HPLC (CHIRALCEL OD-H; 0.25% 
IPA in n-hexane; 1.0 mL/min) tR = 12.1 min, 13.7 min. 
Colourless oil; [α]D
24 -41.9 (c 2.1, CH2Cl2); Rf = 0.34 (10% EtOAc in pet. ether); IR νmax 2951, 
1734, 1612, 1512, 1465, 1368, 1300, 1245, 1177, 1124, 1036, 822, 607, 567 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.16 (d, J = 8.6 Hz, 2H, Hb), 6.88 (d, J = 6.8 Hz, 2H, Ha), 4.58 (dd, J = 11.2, 2.0 
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Hz, 1H, H2), 3.82 (s, 3H, OCH3), 3.01 (ddd, J = 13.9, 9.3, 4.5 Hz, 1H, H4), 2.65 (ddd, J = 13.9, 
9.4, 7.3 Hz, 1H, H4), 2.18-2.06 (m, 1H, H3), 2.05-1.95 (m, 1H, H3), 2.02 (s, 3H, C(O)CH3), 1.59 
(s, 3H, C1(CH3)), 1.57 (s, 3H, C1(CH3)) ppm;
 13C NMR (100 MHz, CDCl3) δ 170.2, 158.1, 132.9, 
129.4, 114.0, 83.2, 61.9, 55.3, 35.6, 33.6, 24.2, 23.1, 22.3 ppm; MS (CI+, NH3) m/z 348, 346 [M + 
NH4]
+; HRMS (CI+, NH3) calc’d for C15H25NO3
79Br [M + NH4]
+ 346.1018, found: 346.1019. 
HPLC (CHIRALCEL OD-H; 0.25% IPA in n-hexane; 1.0 mL/min) tR = 12.1 min (major), 13.6 
min (minor) – 92:8 e.r. (84% ee). 
5.24 Acetylation of tertiary alcohols using acetyl chloride, 
triethylamine and DMAP 
To a stirred solution of tertiary alcohol (±)-8b (350 mg, 1.22 mmol, 1 eq.), DMAP (4.5 mg, 0.37 
mmol, 0.3 eq.) and triethylamine (0.5 mL, 3.66 mmol, 3 eq.) in CH2Cl2 at 0°C was added acyl 
chloride (0.11 mL, 1.59 mmol, 1.3 eq.) and warmed to room temperature over 16 h. Acyl chloride 
(0.11 mL, 1.59 mmol, 1.3 eq.) and triethylamine (0.5 mL, 3.66 mmol, 3 eq.) were added and stirred 
at room temperature for 3 h. The reaction was quenched with water (25 mL), extracted with 
CH2Cl2 (2 × 25 mL), washed with an aqueous solution of 10% CuSO4 (50 mL), brine (50 mL), 
dried over Na2SO4, concentrated under reduced pressure and chromatographed (10-30% Et2O in 
pet. ether) to give bromo bicycle 29 (67 mg, 0.25 mmol, 17%). 
5.25 Acetylation of tertiary alcohols using catalytic NBS 
To a stirred solution of tertiary alcohol (±)-8b (90 mg, 0.31 mmol, 1 eq.) in CH2Cl2 at room 
temperature was added acetyl chloride (70 μL, 0.94 mmol, 3 eq.) and NBS (3 mg, 0.02 mmol, 5 
mol%) and heated at reflux for 8 h. Acetyl chloride (70 μL, 0.94 mmol, 3 eq.) and NBS (3 mg, 0.02 
mmol, 5 mol%) were then added and heated at reflux for 16 h. The reaction was quenched with a 
saturated aqueous solution of Na2SO3 (15 mL), extracted with CH2Cl2 (20 mL), washed with a 
saturated aqueous solution of NaHCO3 (20 mL), brine (20 mL), dried over Na2SO4, concentrated 
under reduced pressure and chromatographed (10-25% Et2O in pet. ether) to give bromo bicycle 
29 and allyl acetate 34 as a 2:1 mixture (50 mg, 32% yield of 29, 21% yield of 34). 
5.26 Acetylation of tertiary alcohols using acetic anhydride, 
triethylamine and DMAP 
To a stirred solution of tertiary alcohol (S)-8b (50 mg, 0.17 mmol, 1 eq.), triethylamine (0.45 
mL, 3.26 mmol, 18.7 eq.) in CH2Cl2 at 0°C was added DMAP (2 mg, 0.02 mmol, 11 mol%) and 
acetic anhydride (0.42 mL, 4.46 mmol, 25 eq.) and warmed to room temperature over 16 h. The 
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reaction mixture was concentrated under reduced pressure and chromatographed (10-25% Et2O 
in pet. ether) to give bromo bicycle 29 (17 mg, 0.06 mmol, 29% yield). 
5.27 1-(3-Bromo-4-methylpent-4-en-1-yl)-4-methoxybenzene 
(36) 
 
To a stirred solution of diol (±)-56 (100 mg, 0.45 mmol, 1 eq.) in CH2Cl2 (1.5 mL) at room 
temperature was added CBr4 (296 mg, 0.89 mmol, 2 eq.) and dropwise a solution of PPh3 (246 mg, 
0.94 mmol, 2.1 eq.) in CH2Cl2 (1 mL) and stirred for 24 h. To the reaction mixture was added CBr4 
(74 mg, 0.22 mmol, 0.5 eq.) and dropwise a solution of PPh3 (62 mg, 0.22 mmol, 0.5 eq.) in CH2Cl2 
(0.25 mL) and stirred for 16 h. The reaction mixture was concentrated under reduced pressure and 
chromatographed (10-25% CH2Cl2 in pet. ether) to give allyl bromide 26 (59 mg, 49% yield). 
Colourless oil: Rf = 0.62 (40:60 CH2Cl2:PE); 
1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 8.6 Hz, 
2H) 6.88 (d, J = 8.6 Hz, 2H), 5.08 (s, 1H), 5.08 (s, 1H), 4.93 (s, 1H), 4.50 (dd, J = 8.1, 6.7 Hz, 1H), 
3.82 (s, 3H), 2.80-2.58 (m, 2H), 2.40-2.22 (m, 1H) 2.20-2.10 (m, 2H), 2.22-2.00 (m, 2H), 1.89 (s, 
3H) ppm. GCMS (CI+, NH3) tR = 20.5 min, m/z 288, 286 [M + NH4]
+. 
To a stirred solution of diol (±)-56 (50 mg, 0.22 mmol, 1 eq.) in CH2Cl2 (0.75 mL) at -10°C was 
added CBr4 (89 mg, 0.27 mmol, 1.2 eq.) and dropwise a solution of PPh3 (76 mg, 0.29 mmol, 1.3 
eq.) in CH2Cl2 (0.5 mL) and allowed to warm to room temperature and stirred for 16 h. The 
reaction mixture was concentrated under reduced pressure and chromatographed (10-25% CH2Cl2 
then 5-60% EtOAc in pet. ether) to give allyl bromide 26 (2.4 mg, 4% yield), ketone 16 (6 mg, 13% 
yield), bromohydrin 8a (9 mg, 10% yield), bromohydrin 8b (6.5 mg, 14% yield) and recovered 
starting material (17 mg, 34%). 
To a stirred solution of bromohydrin (±)-8a (100 mg, 0.35 mmol, 1 eq.) in CH2Cl2 (1.5 mL) at 
-10°C was added CBr4 (139 mg, 0.42 mmol, 1.2 eq.) and dropwise a solution of PPh3 (118 mg, 0.45 
mmol, 1.3 eq.) in CH2Cl2 (1 mL) and allowed to warm to room temperature and stirred for 16 h. 
To the reaction mixture was added CBr4 (139 mg, 0.42 mmol, 1.2 eq.) and dropwise a solution of 
PPh3 (118 mg, 0.45 mmol, 1.3 eq.) in CH2Cl2 (1 mL) and stirred for 72 h. The reaction mixture 
was concentrated under reduced pressure and chromatographed (10-25% CH2Cl2 then 5-25% 
EtOAc in pet. ether) to give allyl bromide 26 (8 mg, 8% yield), ketone 16 (28 mg, 39% yield), 
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recovered starting material (13 mg, 13% yield), bromohydrin 8b (8 mg, 8% yield) and diol 56 (3 
mg, 3% yield). 
5.28 (-)-(S)-2-Bromo-7-methoxy-1,1-dimethyl-1,2,3,4-
tetrahydronaphthalene [(S)-29] 
 
General procedure. To a stirred solution of substrate in CH2Cl2 at -14 ˚C was added a solution 
of triflic acid (5-30 mol%) in CH2Cl2. The reaction was allowed to warm to room temperature and 
stirred for 16 h or heated to reflux. The reaction was quenched with a saturated aqueous solution 
of NaHCO3, extracted with CH2Cl2, washed with brine, dried over Na2SO4, concentrated under 
reduced pressure and chromatographed (10-15% CH2Cl2 in pet. ether) to afford bicycle 29. 
To secondary alcohol (±)-8a (100 mg, 0.35 mmol) in CH2Cl2 (4 mL, 0.17 M) at -14 ˚C was 
added a solution of triflic acid (9.2 μL, 30 mol%) in CH2Cl2 (2 mL, 0.05 M) and stirred for 16 h at 
room temperature, then heated at reflux for 3 h. Work-up using the same method afforded first 
the desired product (53 mg, 57%), then ketone 16 (21 mg, 30%). Reaction was repeated with 10 
mol% TfOH at reflux for 16 h to give (±)-29 (32 mg, 34%) and with 5 mol% TfOH to give (±)-
29 (29 mg, 31%) 
To tertiary alcohol (±)-8b (50 mg, 0.17 mmol) in CH2Cl2 (2 mL, 0.17 M) at -14 °C was added a 
solution of triflic acid (4.6 μL, 30 mol%) in CH2Cl2 (1 mL, 0.05 M) and stirred for 16 h at room 
temperature, then heated at reflux for 3 h. Work-up using the same method afforded (±)-29  (32 
mg, 67%). 
To secondary tetrafluorobenzoate ester (±)-31a (100 mg, 0.22 mmol) in CH2Cl2 (4 mL, 0.078 
M) at -14°C was added a solution of triflic acid (5.7 μL, 30 mol%) in CH2Cl2 (1.24 mL, 0.05 M) 
and stirred at room temperature for 16 h, then heated at reflux for 6 h. Work-up using the same 
method afforded the desired product (43 mg, 73%) and recovered starting material (6 mg, 6%). 
Reaction was repeated with 10 mol% TfOH at reflux for 16 h to give (±)-29 (38 mg, 65%) and 
with 5 mol% TfOH to give (±)-29 (9 mg, 15%). Reaction of (R)-31a with 30 mol% TfOH at reflux 
for 3 h gave (S)-29 (47 mg 0.17 mmol, 84%). [α]D
24 -5.9 (c 2.1, CH2Cl2). HPLC (CHIRALCEL OD-
H; 1% IPA in n-hexane; 1.0 mL/min) tR = 5.1 min (major), 7.2 min (minor) – 91:9 e.r. (82% ee).  
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To tertiary tetrafluorobenzoate ester (±)-31b (100 mg, 0.22 mmol) in CH2Cl2 (4 mL, 0.078 M) 
at -14°C was added a solution of triflic acid (5.7 μL, 30 mol%) in CH2Cl2 (1.24 mL, 0.05 M) and 
stirred at room temperature for 16 h. Work-up using the same method afforded the desired 
product (29 mg, 51%). Reaction of (S)-31b with 30 mol% TfOH at reflux for 4 h gave (S)-29 (38 
mg 0.14 mmol, 67%) – 92:8 e.r. (84% ee). 
To secondary acetate ester (R)-32a (90 mg, 0.27 mmol) in CH2Cl2 (3 mL) at -14 °C was added 
a solution of triflic acid (30 mol%) in CH2Cl2 (1 mL) and heated at reflux for 3 h. Work-up using 
the same method afforded (S)-29 (39 mg, 0.15 mmol 53%). HPLC (CHIRALCEL OD-H; 1% IPA 
in n-hexane; 1.0 mL/min) tR = 4.9 min (major), 6.5 min (minor) – 84:16 e.r. (68% ee). 
To tertiary acetate (S)-32b (146 mg, 0.44 mmol) in CH2Cl2 (6.16 mL) at -14 °C was added a 
solution of triflic acid (30 mol%)  in CH2Cl2 (3 mL) and stirred at room temperature for 5 h. Work-
up using the same method afforded (S)-29 and by-products as a 1:1.25 mixture (81 mg, 30% yield 
of (S)-29). 
Pale yellow oil; Rf = 0.64 (40:60 CH2Cl2:PE); [α]D
24 -5.9 (c 2.1, CH2Cl2); 
1H NMR (400 MHz, 
CDCl3) δ 7.03 (d, J = 8.5 Hz, 1H, H5), 6.93 (d, J = 2.6 Hz, 1H. H6), 6.76 (dd, J = 8.5, 2.6 Hz, 1H, 
H8), 4.47 (dd, J = 9.2, 3.1 Hz, 1H, H2), 3.84 (s, 3H, OCH3), 3.03 (ddd, J = 16.8, 6.0, 6.0 Hz, 1H, 
H4)  2.95-2.85 (m, 1H, H4), 2.52-2.33 (m, 2H, H3), 1.50 (s, 6H, C1(CH3)) ppm; 
13C NMR (100 
MHz, CDCl3) δ 158.1, 144.3, 129.8, 125.9, 112.3, 111.8, 64.8, 55.3, 39.9, 30.5, 30.1, 28.8, 28.4 ppm; 
MS (CI+, NH3) m/z 288, 286 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C13H21NO
79Br [M + NH4]
+ 
286.0807, found 286.0815. HPLC (CHIRALCEL OD-H; 1% IPA in n-hexane; 1.0 mL/min) tR = 
5.1 min (major), 7.2 min (minor) – 91:9 e.r. (82% ee).  
A reference sample of (±)-bromide 29 was prepared by direct brominative cyclisation of alkene 
1 using the method of Snyder and Treitler.48 To a stirred solution of alkene 1 (100 mg, 0.53 mmol) 
in CH3NO2 (4 mL) at -25°C was added quickly a solution of BDSB (289 mg, 0.53 mmol) in 
CH3NO2 (2 mL) and stirred for 15 min. The reaction was quenched with a 1:1 mixture of 5% 
aqueous NaHCO3 and 5% aqueous Na2SO3 (20 mL) solution and stirred for 15 min before being 
poured into water (20 mL), extracted with CH2Cl2 (2 × 20 mL), dried over MgSO4, concentrated 
under reduced pressure and chromatographed (pet. ether) to afford (±)-bromide 7 (88 mg, 63%) 
as a pale yellow oil. HPLC (CHIRALCEL OD-H; 1% IPA in n-hexane; 1.0 mL / min) tR = 5.2 
min, 7.2 min. 
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5.29 (+)-(R)-2-Bromo-7-methoxy-1,1-dimethyl-1,2,3,4-
tetrahydronaphthalene [(R)-29] 
 
To a stirred solution of (S)-31a and (R)-31b (200 mg, 0.44 mmol) in CH2Cl2 (6 mL) at -14 ˚C 
was added a solution of triflic acid (11 µL, 0.13 mmol, 30 mol%) in CH2Cl2 (2.8 mL). The reaction 
was allowed to warm to room temperature and stirred for 7 h. The reaction was quenched with a 
saturated aqueous solution of NaHCO3 (2 × 25 mL), extracted with CH2Cl2 (20 mL), washed with 
brine (25 mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed 
(10-15% CH2Cl2 in pet. ether) to afford bicycle (R)-29 (63 mg, 53%, 85% e.e.) as a pale yellow oil. 
In order to improve the e.e. of (R)-29 purification of tetrafluorobenzoates (S)-31a and (R)-31b 
is required. To remove allyl tetrafluorobenzoate 33 a stirred solution of the mixture (200 mg, 0.44 
mmol) in CH2Cl2 (4 mL) was added mCPBA (74 mg, 0.43 mmol) and stirred at room temperature 
for 16 h. The reaction was quenched with a saturated aqueous solution of Na2SO3 (25 mL), 
extracted with CH2Cl2 (20 mL), washed with an aqueous solution of NaHCO3 (25 mL), brine (25 
mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed (10:90-25:75 
Et2O:PE) to afford tetrafluorobenzoates (S)-31a and (R)-31b (143 mg, 72%) as a white solid. 
To a stirred solution of analytically pure tetrafluorobenzoates (S)-31a and (R)-31b (143 mg, 0.31 
mmol) in CH2Cl2 (4.3 mL) at -14 ˚C was added a solution of triflic acid (8.2 µL, 0.09 mmol, 30 
mol%) in CH2Cl2 (2 mL). The reaction was allowed to warm to room temperature and stirred for 
2 h then heated at reflux for 2 h. The reaction was quenched with a saturated aqueous solution of 
NaHCO3 (2 × 25 mL), extracted with CH2Cl2 (20 mL), washed with brine (25 mL), dried over 
Na2SO4, concentrated under reduced pressure and chromatographed (10:90-15:85 CH2Cl2:PE) to 
afford bicycle ent-7 (70 mg, 84%, 96:4 e.r., 92% e.e.) as a colourless oil. [α]D
24 +6.1 (c 1.1, CH2Cl2). 
5.30 Mono-cyclisation in HFIP 
Secondary tetrafluorobenzoate ester (±)-31a (29 mg, 0.063 mmol, 1 eq.) was heated in HFIP (1 
mL) at reflux over 16 h. The reaction mixture was quenched with a saturated aqueous solution 
NaHCO3 (10 mL), extracted with EtOAc (10 mL), washed with water (10 mL), dried over Na2SO4, 
concentrated under reduced pressure and chromatographed (10% Et2O in pet. ether) to afford a 
3:2 mixture of bicycle 35 (9 mg, 39%) and allyl tetrafluorobenzoate ester 33 (6 mg, 26%). 
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5.31 (±)-7-Methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-
2-yl 2,3,4,5-tetrafluorobenzoate (35) 
 
Colourless oil. Rf = 0.45 (10% EtOAc in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 7.64-7.54 
(m, 1H F4BzH) 7.05 (d, J = 8.5 1H, H5), 6.90 (d, J = 2.6, 1H, H6), 6.75 (dd, J = 8.4, 2.7, 1H, H8), 
5.37 (dd, J = 8.0, 3.3, 1H, H2), 3.83 (s, 3H, OCH3), 2.99-2.84 (m, 1H, H4), 2.77-2.59 (m, 1H, H4), 
2.23-2.09 (m, 1H, H3), 2.08-1.98 (m, 1H, H3), 1.41 (s, 3H, C1(CH3)), 1.40 (s, 3H, C1(CH3)) ppm, 
GCMS (CI+, NH3) tR = 23.9 min, m/z 400 [M + NH4]
+. 
5.32 (±)-5-(4-Methoxyphenyl)-2-methylpent-1-en-3-yl 2,3,4,5-
tetrafluorobenzoate (33) 
 
Rf = 0.45 (10% EtOAc in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 7.64-7.54 (m, 1H F4BzH) 
7.12 (d, J = 8.6, 2H, Hb), 6.84 (d, J = 8.6, 2H, Ha), 5.47 (dd, J = 7.2, 6.0, 1H, H2), 5.08 (2, 1H 
HC=C1),  5.03-5.01 (m, 1H, HC=C), 3.80 (s, 3H, OCH3), 2.99-2.84 (m, 1H, H4), 2.77-2.59 (m, 
1H, H4), 2.23-2.09 (m, 1H, H3), 2.09-1.98 (m, 1H, H3), 1.83 (s, 3H, C1(CH3)) ppm. GCMS (CI
+, 
NH3) tR = 23.3 min, m/z 400 [M + NH4]
+. 
5.33 Mono-cyclisation with ionic liquid 
A stirred solution of tertiary tetrafluorobenzoate ester (±)-31b (100 mg, 0.22 mmol, 1 eq.) in 1-
butyl-1-methylpyrrolidinium bis[(trifluoromethyl)sulfonyl]azanide (5 mL) was heated at 90°C for 
4 h. The reaction was quenched with a saturated aqueous solution of NaHCO3 (30 mL), extracted 
Et2O (3 × 30 mL), washed with brine (30 mL), dried over Na2SO4, concentrated under reduced 
pressure and chromatographed (0-15% Et2O in pet. ether) to afford the desired cyclised product 
29 (11 mg, 0.04 mmol, 19%) and allyl bromide 36 (3 mg, 0.01 mmol, 6%) as a 7:2 mixture. 
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5.34 Mono-cyclisation with BF3.OEt2 
To a stirred solution of tertiary tetrafluorobenzoate ester (±)-31b (100 mg, 0.22 mmol, 1 eq.) in 
CH2Cl2 (1 mL) at -40°C was added BF3.OEt2 (30 μL, 0.24 mmol, 1.1 eq.) and stirred for 30 mins. 
The reaction mixture was quenched with a saturated aqueous solution of NaHCO3 (20 mL), 
extracted with CH2Cl2 (20 mL), washed with brine (20 mL), dried over Na2SO4 and concentrated 
under reduced pressure to give a 4:1 mixture of starting material (±)-31b and allyl bromide (±)-36. 
5.35 Mono-cyclisation with TiCl4 
To a stirred solution of tertiary tetrafluorobenzoate ester (±)-31b (100 mg, 0.22 mmol, 1 eq.) in 
CH2Cl2 (4 mL) at -78 °C was added dropwise TiCl4 (48 μL, 0.43 mmol, 2 eq.) and stirred at -78 °C 
for 1 h. The reaction mixture was quenched with a saturated aqueous solution of NaHCO3 (10 
mL), extracted with CH2Cl2 (10 mL), dried over Na2SO4, passed through a silica plug, concentrated 
under reduced pressure and chromatographed (0-12% Et2O in pet. ether) to give the desired 
cyclised product 29 (32 mg, 0.12 mmol, 55%) as a 4:1 mixture with chlorobromide 44 (8 mg, 0.03 
mmol, 12%) 
5.36 (±)-1-(3-Bromo-4-chloro-4-methylpentyl)-4-
methoxybenzene (44) 
. 
Rf = 0.64 (40% CH2Cl2 in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 7.22-7.17 (m, 2H, Ha), 
6.90-6.86 (m, 2H, Hb), 4.03 (dd, J = 11.3, 1.6, 1H, H2), 3.83 (s, 3H, OCH3), 2.71 (dt, J = 13.6, 8.2, 
2H, H4), 2.66-2.56 (m, 1H, H3), 2.09 (dddd, J = 14.6, 11.3, 8.4, 4.3, 1H, H3), 1.79 (s, 3H, C1(CH3)), 
1.70  (s, 3H, C1(CH3)) ppm; 
13C NMR (100 MHz, CDCl3) δ 132.5, 129.6, 114.0, 71.9, 65.0, 36.12, 
33.3, 33.0, 27.3 ppm; MS (CI+) m/z 324, 322, [M + NH4]
+. 
5.37 Mono-cyclisation using Me2AlCl 
To a stirred solution of secondary tetrafluorobenzoate ester (±)-31a (100 mg, 0.22 mmol, 1 eq.) 
in CH2Cl2 (4 mL) at -78 °C was added dropwise Me2AlCl (0.24 mL, 1 M in hexane, 0.24 mmol, 1.1 
eq.) and warmed to room temperature over 16 h. The reaction mixture was quenched with HCl (1 
M, 10 mL) and extracted with CH2Cl2 (10 mL), washed with brine (20 mL), dried over Na2SO4, 
concentrated under reduced pressure and chromatographed (10-20% CH2Cl2 in pet. ether) to give 
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the bromo bicycle 29 (19 mg, 0.07 mmol, 33%) as a 5:4 mixture with chlorobromide 44 (15 mg,  
0.05 mmol, 23%) 
The reaction was repeated with tertiary tetrafluorobenzoate ester (±)-31b (100 mg, 0.22 mmol, 
1 eq.) under the same conditions for 4 h to afford bromo cycle 29 (32 mg, 0.12 mmol, 55%) as a 
10:1 mixture with chlorobromide 44 (4 mg, 0.01 mmol, 6%). 
5.38 Mono-cyclisation with TMSOTf 
To a stirred solution of tertiary tetrafluorobenzoate ester (±)-31b (100 mg, 0.22 mmol, 1 eq.) in 
CH2Cl2 (4 mL) at -78 °C was added dropwise TMSOTf (43 μL, 0.24 mmol, 1.1 eq.) and stirred for 
6 h at -78 °C and then room temperature for 16 h. The reaction mixture was quenched with a 
saturated aqueous solution of NaHCO3 (10 mL), extracted with CH2Cl2 (10 mL), washed with a 
saturated aqueous solution of NaHCO3 (20 mL), brine (20 mL), dried over Na2SO4, concentrated 
under reduced pressure and chromatographed (5-20% CH2Cl2 in pet. ether) to give bromo bicycle 
29 (26 mg, 0.10 mmol, 44%). 
The reaction was repeated using tertiary acetate ester (±)-32b (114 mg, 0.35 mmol, 1 eq.) under 
the same conditions to afford the desired bromo bicycle 29 (40 mg, 0.15 mmol, 43%).  
5.39 Mono-cyclisation with acetic acid and triflic anhydride 
 
To a stirred solution of bromohydrins (S)-8a and (R)-8b containing ca. 9% allyl alcohol 14 (100 
mg, 0.35 mmol, 1 eq.) in CH2Cl2 (1 mL) was added acetic acid (20 μL, 0.35 mmol, 1 eq.) and triflic 
anhydride (350 μL, 2.06 mmol, 6 eq.) and stirred at room temperature for 5 h. The reaction mixture 
was quenched with a saturated aqueous solution of NaHCO3 (20 mL) extracted with CH2Cl2 (20 
mL), washed with a saturated aqueous solution of NaHCO3 (20 mL), brine (20 mL), dried over 
Na2SO4, concentrated under reduced pressure and chromatographed (10-30% EtOAc in pet. 
ether) to give the title product (62 mg, 57% yield). 
White solid; Rf = 0.58 (20% EtOAc in pet. ether); IR νmax 2975, 2847, 1661, 1601, 1561, 1494, 
1455, 1404, 1334, 1260, 1242, 1232, 1185, 1103, 1039, 993, 912, 877, 865, 698, 635, 622 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.49 (s, 1H, H5), 6.91 (s, 1H, H8), 4.42 (dd, J = 8.8, 3.0 Hz, 1H, H2), 
3.93 (s, 3H, OCH3), 3.04 (dt, J = 17.0, 6.4 Hz, 1H, H4), 2.88 (dt, J = 17.0, 7.0 Hz, 1H, H4), 2.61 
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(s, 3H, COCH3), 2.46 (dtd, J = 13.1, 6.5, 3.0 Hz, 1H, H3), 2.34 (ddt, J = 13.9, 8.3, 6.9 Hz, 1H, H3), 
1.51 (s, 3H, C1CH3), 1.49 (s, 3H, C1CH3) ppm;
 13C NMR (100 MHz, CDCl3) δ 199.4, 157.4, 149.1, 
130.9, 126.4, 126.0, 109.5, 63.8, 55.6, 40.2, 31.8, 30.5, 29.6, 28.8, 27.7 ppm; MS (CI+, NH3) m/z  
313, 311 [M + H]+; HRMS (CI+, NH3) calc’d for C15H20O2Br
79 311.0647 [M + H]+, found: 
311.0638. 
5.40 (+)-(R)-2-Bromo-7-methoxy-1,1-dimethyl-6-(1-
methylcyclohexyl)-1,2,3,4-tetrahydro naphthalene [(R)-60] 
  
To a stirred solution of acetate (S)-32a (50 mg, 0.15 mmol, 1 eq., 96:4 e.r.) in CH2Cl2 (1 mL) 
was added a solution of 1-methyl-1-cyclohexene (18 μL, 0.15 mmol, 1 eq.) in CH2Cl2 (1 mL), 
cooled to -14°C, added a solution of triflic acid (4 μL, 0.05 mmol, 30 mol%) in CH2Cl2 (1 mL) and 
heated at reflux for 2 h. The reaction mixture was quenched with a saturated aqueous solution of 
NaHCO3 (10 mL) extracted with CH2Cl2 (10 mL), washed with NaHCO3 (10 mL), brine (10 mL), 
dried over Na2SO4, concentrated under reduced pressure and chromatographed (10-25% CH2Cl2 
in pet. ether) to give the title product (30 mg, 53%) and second bicycle (R)-29 (14 mg, 34%).  
Colourless oil; [α]D
24 +7.0 (c 0.4, CH2Cl2); Rf = 0.5 (10:90 CH2Cl2:pet. ether); 
1H NMR (400 
MHz, CDCl3) δ 6.92 (s, 1H), 6.81 (s, 1H), 4.44 (dd, J= 9.7, 3.7 Hz, 1H), 3.82 (s, 3H), 2.97-2.82 (m, 
2H), 2.48-2.33 (m, 2H), 2.05-1.95 (m, 2H), 1.78-1.68 (m, 2H), 1.63-1.45 (m, 6H), 1.47 (s, 3H), 1.45 
(s, 3H), 1.28 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 157.3, 141.0, 136.4, 127.7, 125.0, 110.1, 
65.4, 55.2, 39.6, 37.6, 36.9, 30.7, 30.0, 29.3, 28.5, 26.7, 24.9, 22.8 ppm; MS (CI+, NH3) m/z 384, 
382 [M + NH4]
+; HRMS (CI+) calc’d for C20H33NO
79Br [M + NH4]
+382.1746, found 382.1752; 
HPLC (CHIRALCEL OD-H; 1% IPA in n-hexane; 1.0 mL/min) tR= 5.1 min (minor), 7.2 min 
(major) – 94:6 e.r. (88% ee). 
5.41 Friedel–Crafts alkylation of bicycle [(±)-29] 
To a stirred solution of bicycle (±)-29 (100 mg, 0.37 mmol, 1 eq.) and 1-methyl-1-cyclohexene 
(44 μL, 0.37 mmol, 1 eq.) in CH2Cl2 (5 mL) at -14°C was added a solution of triflic acid (10 μL, 
0.11 mmol, 30 mol%) in CH2Cl2 (2.5 mL) and stirred at -14°C for 0.5 h, then warmed to room 
temperature and heated at reflux for 1 h. The reaction mixture was quenched with a saturated 
aqueous solution of NaHCO3 (20 mL), extracted with CH2Cl2 (20 mL), washed with brine (20 
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mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed (0-20 % 
CH2Cl2 in pet. ether) to give (R)-60 (54 mg, 40% yield). 
5.42 5-(4-Methoxyphenyl)-2-methylpentan-2-ol (45) 
 
According to a modified procedure of Sarandeses et al.,164 to a stirred solution of alkene 1 (250 
mg, 1.32 mmol, 1 eq) in THF:H2O (20 mL 1:1) was added mercury(II) trifluoroacetate (618 mg, 
1.45 mmol, 1.1 eq). The mixture was stirred at room temperature for 1.5 h and aqueous NaOH 
solution (20 mL, 3 M) was added, followed by a solution of NaBH4 (55 mg, 1.45 mmol, 1.1 eq) in 
aqueous NaOH (2 mL, 3 M). After stirring for a further 0.5 h brine (20 mL) was added and the 
mixture extracted with Et2O (3 × 30 mL), dried, concentrated under reduced pressure and 
chromatographed (20-50% EtOAc in pet. ether) to yield the title product165 (177 mg, 65%). 
Colourless oil; Rf = 0.26 (20% EtOAc in pet. ether); IR νmax 3600-3100, 2967, 2937, 1613, 1584, 
1512. 1465, 1376, 1300, 1245, 1177, 1150, 1123, 1038, 910, 830, 775, 699 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.13 (d, J = 8.6 Hz, 2H, Hb), 6.86 (d, J = 8.6 Hz, 2H, Ha), 3.82 (s, 3H, OCH3), 2.60 (t, J 
= 7.6 Hz, 2H, H4) 1.75-1.64 (m, 2H, H3) 1.60-1.50 (m, 2H, H2) 1.23 (s, 6H C1(CH3)) ppm;
 13C 
NMR (100 MHz, CDCl3) δ 157.7, 134.6, 129.3, 113.7, 70.9, 55.3, 43.5, 35.4, 29.3, 26.5 ppm; MS 
(CI+, NH3) m/z 226 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C13H24NO2 [M + NH4]
+ 226.1807, 
found: 226.1808. 
5.43 5-(4-Methoxyphenyl)-2-methylpentan-2-yl 2,3,4,5-
tetrafluorobenzoate (46) 
 
Using the method of Steglich,116 to a stirred solution of tertiary alcohol 45 (85 mg, 0.41 mmol, 
1 eq) in CH2Cl2 (2 mL) was added 2,3,4,5-tetrafluorobenzoic acid (159 mg, 0.82 mmol, 2 eq), 
DMAP (15 mg, 0.12 mmol, 30 mol%) and DCC (253 mg, 1.23 mmol, 3 eq). After 16 h the reaction 
mixture was diluted with Et2O, filtered through a silica plug, concentrated under reduced pressure 
and chromatographed (5-15% Et2O in pet. ether) to afford the title product (131 mg, 83%)  
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Colourless oil; Rf = 0.52 (10% Et2O in pet. ether); IR νmax 2937, 1716, 1627, 1613, 1584, 1525, 
1512, 1483, 1367, 1286, 1243, 1197, 1177, 1120, 1098, 1032, 920, 884, 831, 793, 713, 702, 625, 563, 
538, 527 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.54 (dddd, J = 10.5, 8.4, 6.0, 2.5 Hz, 1H, F4BzH), 
7.12 (d, J = 8.6 Hz, 2H, Hb), 6.86 (d, J = 8.6 Hz, 2H, Ha), 3.82 (s, 3H, OCH3), 2.62 (t, J = 7.6 Hz, 
2H, H4), 1.98-1.90 (m, 2H, H3), 1.78-1.62 (m, 2H H2), 1.59 (s, 6H, C1(CH3)) ppm; 
13C NMR (100 
MHz, CDCl3) δ 161.0, 157.8, 147.9 (dddd, J = 262, 11, 4, 2 Hz), 146.4 (dddd, J = 249, 11, 4, 2 Hz), 
143.1 (dddd, J = 261, 16, 12, 3 Hz), 141.2 (dddd, J = 248, 17, 12, 4 Hz), 134.1, 129.1, 116.6, 113.8, 
113.1 (d, J = 20 Hz), 85.7, 55.2, 40.6, 35.1, 26.0, 25.9 ppm; MS (CI+, NH3) m/z 402 [M + NH4]
+; 
HRMS (CI+, NH3) calc’d for C20H24NO3F4 [M + NH4]
+ 402.1692, found: 402.1707. 
5.44 7-Methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalene (47) 
 
According to the general procedure for bromo bicycle 29, tertiary alcohol 45 (80 mg, 0.39 
mmol) in CH2Cl2 (4.4 mL, 0.09 M) at -14 ˚C was added a solution of triflic acid (10.2 μL, 30 mol%) 
in CH2Cl2 (2.2 mL, 0.05 M) and heated at reflux for 3 h. Work-up using the same method afforded 
first the desired product166 (64 mg, 88%). Using the same procedure, tertiary tetrafluorobenzoate 
ester 46 (120 mg, 0.31 mmol) in CH2Cl2 (6.1 mL, 0.05 M) at -14 ˚C was added a solution of triflic 
acid (8.3 μL, 30 mol%) in CH2Cl2 (1.8 mL, 0.05 M) and stirred at room temperature for 16 h. 
Work-up using the same method afforded first the desired product (51 mg, 85%). 
Pale yellow oil; Rf = 0.43 (20% CH2Cl2 in pet. ether); IR νmax 2928, 2864, 1610, 1572, 1503, 1463, 
1287, 1236, 1188, 1163, 1076, 1047, 903, 872, 705 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.04 (d, J 
= 8.4 Hz, 1H, H5), 6.95 (d, J = 2.7 Hz, 1H, H6), 6.74 (dd, J = 8.4, 2.7 Hz, H8), 3.86 (s, 3H, OCH3), 
2.78 (t, J =  6.3 Hz, 2H, H4), 1.90-1.82 (m, 2H, H3), 1.75-1.70 (m, 2H, H2), 1.36 (s, 6H, C1(CH3)2) 
ppm; 13C NMR (100 MHz, CDCl3) δ  157.8, 147.1, 129.9, 128.4, 112.2, 111.0, 55.2, 39.3, 34.1, 31.9, 
30.0, 19.9 ppm; MS (CI+, NH3) m/z 191, [M + H]
+; HRMS (CI+, NH3) calc’d for C13H19O [M + 
H]+ 191.1436, found 191.1437. 
5.45 1,1-Dimethyl-1,2,3,4-tetrahydronaphthalen-7-ol (54) 
 
148 
 
According to the procedure by Braddock et al.,167 to a stirred solution of methyl ether 1 (100 
mg, 0.53 mmol, 1 eq.) in CH2Cl2 (3 mL) at -78°C and protected from light was added dropwise 
boron tribromide (0.8 mL, 1M solution in CH2Cl2, 0.79 mmol, 1.5 eq) and after 5 minutes was 
allowed to warm to room temperature overnight. The reaction mixture was quenched with 
methanol, concentrated under reduced pressure and chromatographed (0-20% EtOAc in pet. 
ether) to yield the title product (93 mg, 100%). 
White solid, m.p. = 98-100°C, lit.168 103.5-104.5°C; Rf = 0.29 (20% EtOAc in pet. ether);  IR 
νmax 3251, 2959, 2926, 2864, 1621, 1579, 1486, 1456, 1296, 1232, 1217, 1164, 1136, 916, 870, 813, 
740, 713, 693 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.96 (d, J = 8.2 Hz, 1H, H5), 6.87 (d, J = 2.6 
Hz, 1H, H6), 6.65 (dd, J = 8.3, 2.7 Hz, 1H, H8), 5.63 (s, 1H, OH), 2.74 (t, J = 6.4 Hz, 2H, H4), 
1.87-1.80 (m, 2H, H3), 1.71-1.67 (m, 2H, H2), 1.30 (s, 6H, C1(CH3)) ppm;
 13C NMR (100 MHz, 
CDCl3) δ 153.5, 147.4, 130.1, 128.4, 113.2, 112.9, 39.2, 34.0, 31.8, 29.9, 19.9 ppm; MS (CI
+) m/z 
176 [M]+; HRMS (CI+) calc’d for C12H16O [M]
+ 176.1201, found: 176.1199. 
5.46 4-(4-Methylpent-3-en-1-yl)phenol (53) 
 
To a stirred solution of methyl ether 1 (500 mg, 2.63 mmol, 1 eq.) in CH2Cl2 (20 mL) at -78°C 
and protected from light was added 2,6-di-tert-butylpyridine (2.0 mL, 8.92 mmol, 3.4 eq.), dropwise 
boron tribromide (2.9 mL, 1M solution in CH2Cl2, 2.89 mmol, 1.1 eq.) and after 5 minutes was 
allowed to warm to room temperature overnight. The reaction mixture was quenched with 
methanol, concentrated under reduced pressure and chromatographed (10-25% Et2O in pet. ether) 
to yield the title product (463 mg, 100%). 
Colourless oil; Rf = 0.32 (30% Et2O in pet. ether); IR νmax 3600-3050, 2967, 2925, 2857, 1614, 
1513, 1444, 1375, 1230, 1172, 1109, 1017, 988, 825 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J 
= 8.4 Hz, 2H, Hb), 6.78 (d, J = 8.5 Hz, 2H, Ha), 5.16 (t, 7.1 Hz, 1H, H2), 4.65 (br. s, 1H, OH), 
2.59 (t, J = 7.4 Hz, 2H, H4), 2.32-2.24 (m, 2H, H3), 1.72 (s, 3H, C1(CH3)), 1.59 (s, 3H, C1(CH3)) 
ppm; 13C NMR (100 MHz, CDCl3) δ 153.5, 134.7, 132.1, 129.5, 123.8, 115.1, 35.2, 30.3, 25.7, 17.7 
ppm; MS (CI+) m/z 194 [M + NH4]
+; HRMS (CI+) calc’d for C12H20NO [M + NH4]
+ 194.1545, 
found: 194.1546. 
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5.47 1-[(Trimethylsilyl)oxy]-4-(4-methylpent-3-en-1-yl)benzene 
(52) 
 
According to a modified procedure by Holmes et al.,169 to a stirred solution of phenol 53 (100 
mg, 0.57 mmol, 1 eq.) in pyridine (1.15 mL, 14.27 mmol, 25 eq.) was added dropwise 
chlorotrimethylsilane (0.23 mL, 1.81 mmol, 3 eq.) and stirred at room temperature for 16 h. The 
reaction mixture was diluted with EtOAc (10 mL), washed with water (15mL), 10% aqueous 
CuSO4 solution (15 mL), water (20 mL), brine (20 mL), dried and concentrated under reduced 
pressure to give the title product (111 mg, 78%) 
Colourless oil; Rf = 0.27 (20% Et2O in pet. ether); IR νmax 2962, 2923, 2856, 1609, 1509, 1446.5, 
1377, 1249, 1167, 1102, 1016, 911, 840, 733, 549, 540, 529 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.07 (d, J = 8.4 Hz, 2H, Hb), 6.78 (d, J = 8.4 Hz, 2H, Ha), 5.19 (t, J = 7.1 Hz, 1H, H2), 2.59 (t, J 
= 7.4 Hz, 2H, H4), 2.28 (dt, J = 7.4, 7.4 Hz, 2H, H3), 1.71 (s, 3H, C1(CH3)), 1.57 (s, 3H, C1(CH3)), 
0.28 (s, 9H, SiCH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 153.1, 135.3, 132.0, 129.3, 123.8, 119.7, 
35.3, 30.2, 25.7, 17.6, 0.2 ppm; MS (CI+) m/z 266 [M + NH4]
+; HRMS (CI+) calc’d for C15H25OSi 
[M + H]+ 249.1675, found: 249.1673. 
5.48 (±)-2-Bromo-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-7-ol 
(55) 
 
According to the method of Snyder and Treitler,48 to a stirred solution of 53 (100 mg, 0.57 
mmol) in CH3NO2 (3 mL) at -14°C was added quickly a solution of BDSB (312 mg, 0.57 mmol) 
in CH3NO2 (2 mL) and stirred for 10 min at -14°C, then 45 min at room temperature. The reaction 
was quenched with a 1:1 mixture of 5% aqueous NaHCO3 and 5% aqueous Na2SO3 (20 mL) 
solution and stirred for 15 min before being poured into water (20 mL), extracted with CH2Cl2 (2 
× 20 mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed (0 to 
25% Et2O in pet. ether) to afford cyclic bromide 55 (104 mg, 72%). Reaction was repeated with 
silyl ether 52 under the same conditions to yield (76 mg, 52 yield over 2 steps) 
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White solid; Rf = 0.29 (20% Et2O in pet. ether); IR νmax 3600-3100, 2970, 1611, 1584, 1502,,  
1444, 1289, 1232, 1198, 1161, 948, 905, 881, 864, 732, 704, 691, 568 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 6.96 (d, J = 8.1 Hz, 1H, H5), 6.86 (d, J = 2.6 Hz, 1H, H6), 6.68 (dd, J = 8.2, 2.6 Hz, 1H, 
H8), 5.44 (br. s. 1H, OH), 4.44 (dd, J = 9.2, 3.1 Hz, 1H, H2), 3.04-2.95 (m, 1H, H4), 2.92-2.83 (m, 
1H, H4), 2.45 (dddd, J = 13.3, 10.1, 6.6, 3.5 Hz, 1H, H3), 2.40-2.31 (m, 1H, H3), 1.45 (s, 6H, 
C1(CH3)2) ppm; 
13C NMR (100 MHz, CDCl3) δ 153.8, 144.5, 130.0, 125.9, 113.8, 113.3, 64.8, 39.7, 
30.4, 30.0, 28.7, 28.3 ppm; MS (CI+, NH3) m/z 272, 274 [M + NH4]
+; HRMS (CI+, NH3) calc’d for 
C12H19NO
79Br [M + NH4]
+ 272.0650, found 272.0652. 
5.49 (E)-1-(4,8-Dimethylnona-3,7-dienyl)-4-methoxybenzene (α-
61)   
 
Prepared according to a modified procedure of Snyder and Treitler.48 To a stirred solution of 
geraniol (23 mL, 133 mmol) and pyridine (32 mL, 398 mmol) in diethyl ether (80 mL) at -15°C 
was added diethyl chlorophosphate (29 mL, 199 mmol) and the mixture was allowed to warm to 
room temperature over 5 h. The reaction mixture was quenched with 1 M aqueous HCl solution 
(250 mL), extracted with ethyl acetate (2 × 250 mL), washed with saturated aqueous NaHCO3 
solution (2 × 250mL), brine (250 mL), dried over Na2SO4 and concentrated under reduced 
pressure to give geranyl diethyl phosphate as a colourless oil (46 g) which was used directly without 
purification. To magnesium turnings (7.6 g, 318 mmol) stirred in anhydrous THF (200 mL) was 
added a portion of 4-methoxybenzyl chloride (2.0 mL, 15 mmol), where the reaction could be 
started by gentle heating. Subsequently a solution of 4-methoxybenzyl chloride (19.5 mL, 144 
mmol) in anhydrous THF (200 mL) was added dropwise over 1 h at such a rate as to maintain 
reflux.  After complete addition, reflux was continued for 2 h. The reaction mixture was cooled to 
-40°C and added dropwise via cannula to a stirred solution of geranyl diethyl phosphate (23 g, 80 
mmol) in anhydrous THF (250 mL) at -40°C and allowed to warm to room temperature over 16 
h. The reaction mixture was quenched with saturated aqueous NH4Cl solution (300 mL), extracted 
with diethyl ether (2 × 300 mL), washed with saturated aqueous NaHCO3 solution (300 mL), brine 
(300 mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed (0-25% 
CH2Cl2 in pet. ether) to afford the title compound 61 as a mixture of constitutional isomers with 
branched diene α-61 in 19:1 ratio (12.7 g, 49 mmol, 61%) as a colourless oil.  A second run on the 
same scale afforded the title product α-61 as a mixture of constitutional isomers with γ-61 in ratio 
35:1 (14.0 g, 54 mmol, 68%). The purity of 61 could be increased to >98% by fractional distillation 
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of the combined diene mixtures (27 g, 26:1 α:γ-61).  Distillation (200 ˚C, 0.003 mmHg) collecting 
the fraction at 70˚C was enriched in branched isomer γ-61 and the distillation residue was linear 
diene α-61 (8.2 g, 32 mmol).  
Colourless oil, Rf = 0.35 (15% CH2Cl2 in pet. ether); IR νmax 2919, 2854, 1612, 1584 cm
-1; 1H 
NMR (400 MHz, CDCl3) δ 7.17 (d, J = 8.5 Hz, 2H, Hb), 6.88 (d, J = 8.6 Hz, 2H, Ha), 5.24 (t, J = 
7.1 Hz, 1H, H6), 5.19-5.13 (m, 1H, H2), 3.82 (s, 3H, OCH3), 2.60 (t, J = 7.8 Hz, 2H, H8), 2.34 (q, 
J = 8.5 Hz, 2H, H7), 2.17-2.02 (m, 4H, H3 and H4), 1.75 (s, 3H, C5CH3), 1.67 (s, 3H, C1CH3), 
1.62 (s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.7, 135.7, 134.6, 131.3, 129.4, 124.4, 
123.7, 113.7, 55.3, 39.8, 35.3, 30.2, 26.8, 25.7, 17.7, 16.0 ppm; MS (CI+) m/z 276 [M + NH4]
+; 
HRMS (CI+) calc’d for C18H27O [M + H]
+ 259.2062. Found: 259.2050. An analytically pure sample 
of branched diene γ-61 could be obtained after silver nitrate-doped silica gel chromatography (0:1-
3:7 Et2O:PE).  
5.50 (±)-(E)-1-(2,6-Dimethyl-2-vinylhept-5-enyl)-4-
methoxybenzene (γ-61) 
 
Colourless oil, Rf = 0.35 (15% CH2Cl2 in pet. ether); IR νmax 2920, 2854, 1612 cm
-1; 1H NMR 
(400 MHz, CDCl3) δ 7.03 (d, J = 8.6 Hz, 2H, Hb), 6.79 (d, J = 8.7 Hz, 2H, Ha), 5.76 (dd, J = 17.6, 
10.8 Hz, 1H, H7), 5.10-5.05 (m, 1H, H2), 5.00 (dd, J = 10.8, 1.4 Hz, 1H, H6), 4.82 (dd, J = 17.6, 
1.4 Hz, 1H, H6), 3.79 (s, 3H, OCH3), 2.54 (m, 2H, H6), 1.91 (q, J = 8.0 Hz, 2H, H4), 1.67 (s, 3H, 
C5CH3), 1.58 (s, 3H, C1CH3), 1.37-1.25 (m, 2H, H3), 0.94 (s, 3H, C1CH3) ppm; 
13C NMR (100 
MHz, CDCl3) δ 157.8, 146.6, 131.6, 131.0, 130.6, 125.0, 112.9, 112.1, 55.2, 47.2, 40.8, 40.4, 25.7, 
23.1, 21.9, 17.6 ppm; MS (CI+) m/z 276 [M + NH4]
+; HRMS (CI+) calc’d for C18H30NO [M + 
NH4]
+ 276.2327. Found: 276.2328. 
5.51 Li2CuCl4 catalysed Grignard alkylation of geranyl bromide 
Prepared according to a modified procedure by Steglich and Lang.170 To magnesium turnings 
(22 mg, 0.92 mmol, 1.5 eq.) stirred in anhydrous THF (4 mL) was added a portion of 4-
methoxybenzyl chloride (10 μL, 0.07 mmol, 0.12 eq.), where the reaction was started by heating at 
50°C. Subsequently a solution of 4-methoxybenzyl chloride (90 μL, 0.67 mmol, 1.08 eq.) in 
anhydrous THF (4 mL) was added dropwise over 30 min at such a rate as to maintain reflux. After 
complete addition, reflux was continued for 3 h. The reaction mixture was cooled to -20°C and 
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added dropwise via cannula to a stirred solution of Li2CuCl4 (0.25 ml, 0.1 M in THF, 40 mol%) 
and stirred for 10 minutes. A solution of geranyl bromide (0.12 mL, 0.62 mmol, 1 eq.) in THF (2 
mL) was added dropwise and stirred at -20°C for 1.5 h. The reaction was quenched with a saturated 
aqueous solution of NH4Cl (20 mL), extracted with Et2O (10 mL) and washed with NH4OH (20 
mL), brine (20 mL), dried over Na2SO4, concentrated under reduced pressure, and 
chromatographed (0-30% Et2O in pet. ether) to give polyene 61 (105 mg, 0.41 mmol, 66% yield) 
as a 2:1 mixture of constitutional isomers α:γ-61. 
5.52 (E)-3,7-Dimethylocta-2,6-dien-1-yl dimethyl phosphate (67) 
 
To a stirred solution of geraniol (1 ml, 5.77 mmol, 1 eq.) and pyridine (1.4 ml, 17.32 mmol, 3 
eq.) in Et2O (3 mL) at -15°C was added dropwise dimethyl chlorophosphate (0.95 mL, 8.66 mmol, 
1.5 eq.) and warmed to room temperature over 3 h. The reaction mixture was quenched with a 1 
M aqueous solution of HCl, extracted with EtOAc (2 × 30 mL), washed with a saturated aqueous 
solution of NaHCO3 (2 ×50 mL), brine (50 mL), concentrated under reduced pressure and 
chromatographed (40-100% EtOAc in pet. ether) to give the title product (430 mg, 1.64 mmol, 
28% yield). 
Colourless oil, Rf = 0.25 (50% EtOAc in pet. ether); IR νmax 2958, 2920, 2855, 1667, 1449, 1380, 
1267, 1187, 1037, 1007, 847, 752 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.39 (t, J = 7.1 Hz, 1H, H6), 
5.09-5.02 (m, 1H, H2), 4.56 (ap. t, J = 7.8 Hz, 2H, H7) 3.75 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 
2.12-2.00 (m, 4 H, H3 and H4), 1.69 (s, 3H, C5CH3), 1.66 (s, 3H, C1CH3), 1.58 (s, 3H, C1CH3) 
ppm; 13C NMR (100 MHz, CDCl3) δ 143.0, 131.9, 123.6, 118.7 (d, J = 6.3 Hz), 64.3 (d, J = 5.7 
Hz), 54.1 (d, J = 6.3 Hz), 39.5, 26.2, 25.6, 17.6, 16.4 ppm; 31P NMR (162 MHz, CDCl3) δ 1.9-1.4 
(m, 1P) ppm; MS (ES+) m/z 285 [M + Na]+; HRMS (ES+) calc’d for C12H23O4NaP [M + Na]
+ 
285.1232. Found: 285.1228. 
5.53 Hydroboration-oxidation of 61 
Carried out according to the procedure by Denmark and co-workers136To a stirred solution of 
a 3:1 mixture of α:γ-61 (100 mg, 0.39 mmol, 1 eq.) in THF (1 mL) was added BH3 (1.2 mL, 1 M in 
THF, 3 eq.) and heated at reflux for 3h. The reaction mixture was cooled to 0°C and H2O (0.2 
mL), NaBO3 (350 mg, 3.49 mmol, 9 eq.) and NaOH (140 mg, 3.49 mmol, 9 eq.) added and heated 
at 50°C for 4 h. The reaction mixture was diluted with H2O (20 mL), extracted with EtOAc (3 × 
153 
 
20 mL), washed with brine (50 mL), dried over Na2SO4, concentrated under reduced pressure to 
give a mixture of constitutional isomers α and γ-61 in a ratio 4.2:1. 
5.54 4-[(E)-4,8-Dimethylnona-3,7-dien-1-yl]phenol (69) 
 
Prepared according to the procedure by Ishihara and co-workers.137 To a stirred solution of 
NaH (60% in mineral oil, 140 mg, 3.50 mmol, 4.5 eq.) in DMF (2.3 mL) at 0°Cwas added dropwise 
over a period of 5 minutes a solution of ethanethiol (0.23 mL, 3.10 mmol, 4 eq.) in DMF (4.6 mL) 
and stirred at room temperature for 1 h. To this mixture was added dropwise at room temperature 
a solution of a 3:1 mixture of α:γ-61 (200 mg, 0.78 mmol, 1 eq.) in DMF (2.3 mL) and stirred at 
80°C for 16 h, and reflux for 4 h. The reaction mixture was cooled to 0°C and acidified with a 1 
M aqueous solution of HCl, extracted with Et2O (2 × 25 mL), washed with brine (50 mL), dried 
over Na2SO4, concentrated under reduced pressure and chromatographed (0-30% Et2O in pet. 
ether) to give the title product 69 (178 mg, 0.73 mmol, 94% yield) as a 3:1 mixture of α:γ-69. 
Colourless oil, Rf = 0.23 (30% Et2O in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 
8.4 Hz, 2H, Hb), 6.78 (d, J = 8.4 Hz, 2H, Ha), 5.78 (dd, J = 17.6, 10.8 Hz, 0.38H, CH=CH3 γ-69), 
5.23-5.17 (m, 1H, H6), 5.15-5.09 (m, 1H, H2), 5.03 (dd, J = 10.8, 1.3 Hz, 0.38H, CH=CH2), 4.84 
(dd, J = 17.6, 1.3 Hz, 0.38 Hz, CH=CH2), 4.55 (br. s, 1H, OH) 2.63-2.55 (m, 2H, H8), 2.29 (q, J 
= 7.4 Hz, 2H, H7) 2.13-1.90 (m, 4H, H3 and H4), 1.72 (s, 3H, C5CH3), 1.64 (s, 3H, C1CH3), 1.58 
(s, 3H, C1CH3) ppm. 
5.55 (+)-(R,E)-9-(4-Methoxyphenyl)-2,6-dimethylnon-6-ene-2,3-
diol [(R)-70] 
 
According to the method of Sharpless,127 to a stirred solution of AD-mix β (22.3 g, 1.4 gmmol-
1) and methanesulfonamide (1.5 g, 16 mmol) in water (40 mL) and tert-butanol (40 mL) at 0°C was 
added alkene 61 (4.1 g, 16 mmol). The reaction mixture was stirred vigorously for 16 h, quenched 
with saturated aqueous sodium sulfite solution (50 mL), extracted with EtOAc (2 × 100 mL), 
washed with brine (100 mL), dried over Na2SO4, concentrated under reduced pressure and 
chromatographed (50-60% EtOAc in pet. ether) to afford first unreacted diene 61 (1.64 g, 6.3 
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mmol, 40%), the title product (R)-70 (1.16 g, 4.3 mmol, 25%, 42% based on recovered starting 
material) as a colourless oil, and tetraol 70a (1.27 g, 3.9 mmol, 25%) as a white solid. 
Colourless oil, Rf = 0.42 (50% EtOAc in pet. ether); [α]D
24 = +12.3 (c 1.9, CH2Cl2); IR νmax 3600-
3100, 2931, 2858 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 8.6 Hz, 2H, Hb), 6.85 (d, J = 
8.6 Hz, 2H, Ha), 5.26 (br t, J = 7.1 Hz, 1H, H6), 3.81 (s, 3H, OCH3), 3.32 (dd, J = 10.5. 2.0 Hz, 
1H, H2), 2.63 (t, J = 7.6 Hz, 2H, H8), 2.38-2.19 (m, 3H, H7 and C1OH), 2.15-2.01 (m, 3H, H3 
and C2OH), 1.64-1.55 (m, 1H, H4) 1.60 (s, 3H, C5CH3), 1.44 (m, 1H, H4), 1.21 (s, 3H, C1CH3), 
1.18 (s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.7, 135.5, 134.4, 129.4, 124.5, 113.7, 
78.1, 73.0, 55.3, 36.7, 35.1, 30.1, 29.6, 26.4, 23.2, 15.9 ppm; MS (CI+, NH3) m/z 310 [M + NH4]
+; 
HRMS (CI+, NH3) calc’d for C18H32NO3 [M + NH4]
+ 310.2382. Found: 310.2384; HPLC 
(CHIRALCEL OJ; 10% IPA in n-hexane; 1.0 mL/min) tR = 16.2 min (major), 18.2 min (minor) - 
e.r. 99:1.  
5.56  (+)-(3R,6R,7R)-2,6-Dimethyl-9-(4-methoxyphenyl)nonane-
2,3,6,7-tetraol (70a) 
 
White solid; m.p. 130-131˚C; Rf = 0.28 (50% EtOH in pet. ether.); [α]D
24 = +20.0 (c 1.0, EtOH); 
IR νmax 3600-3100, 2972, 2952 cm
-1; 1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 8.4 Hz, 2H, Hb), 
6.86 (d, J = 8.5 Hz, 2H, Ha), 3.81 (s, 3H, OCH3), 3.41 (d, J = 9.6 Hz, 1H, H6), 3.30 (d, J = 9.6 Hz, 
1H, H2), 3.29 (br s, 2H, OH), 2.90 (ddd, J = 13.8, 8.8, 4.9 Hz, 1H, H8), 2.65 (dt, J = 13.7, 8.2 Hz, 
1H, H8), 2.53 (br s, 1H, OH), 2.20 (br s, 1H, OH), 1.81-1.56 (m, 5H, H3, H4, H7), 1.48-1.37 (m, 
1H, H7), 1.21 (s, 3H, C5CH3), 1.17 (s, 3H, C1CH3), 1.13 (s, 3H, C1CH3) ppm; 
13C NMR (100 
MHz, CDCl3) δ  157.8, 134.2, 129.4, 113.9, 78.9, 74.6, 73.2, 55.3, 50.7, 35.6, 33.6, 31.9, 26.5, 25.0, 
23.3, 20.6 ppm; MS (CI+, NH3) m/z 344 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C18H31O5 [M 
+ H]+ 327.2171. Found: 327.2164.   
5.57 (-)-(S,E)-9-(4-Methoxyphenyl)-2,6-dimethylnon-6-ene-2,3-
diol [(S)-70] 
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In a run using diene 61 (100mg, 0.39 mmol) and AD-mix α, afforded first was unreacted diene 
61 (65 mg, 0.25  mmol, 65% yield), regioisomer (S,S)-70b (18 mg, 0.06 mmol, 16% yield) and the 
title product (S)-70 (21 mg, 0.07 mmol, 19%, 54% based on recovered starting material) as a 
colourless oil: [α]D
24 = - 5.9 (c 1.0, CH2Cl2); HPLC (CHIRALCEL OJ; 10% IPA in n-hexane; 1.0 
mL/min) tR = 15.9 min (minor), 17.1 min (major) – e.r. 6:94. 
5.58 (-)-(3S,4S)-1-(4-Methoxyphenyl)-4,8-dimethylnon-7-ene-
3,4-diol [(S,S)-70b] 
 
Colourless oil, Rf = 0.46 (50% EtOAc in pet. ether); [α]D
24 = -18.0 (c 0.8, CH2Cl2); IR νmax 3600-
3100, 2927, 2857, 1612, 1511, 1455, 1376, 1300, 1244, 1177, 1074, 1036, 936, 822 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.17 (d, J = 8.5 Hz, 2H, Hb), 6.87 (d, J = 8.5 Hz, 2H, Ha), 5.13 (t, J = 7.0 
Hz, 1H, H2), 3.82 (s, 3H, OCH3), 3.47 (dd, J = 10.3, 2.2 Hz, 1H, H6), 2.90 (ddd, J = 14.2, 9.3, 5.3 
Hz, 1H, H8), 2.65 (ddd, J = 13.9, 9.1, 7.2 Hz, 1H, H8), 2.25-2.10 (br. s, 1H, C6OH), 2.10-1.99 (m, 
2H, H3), 1.80- 1.60 (m, 2H, H7,), 1.71 (s, 3H, C1CH3), 1.62 (s, 3H, C1CH3), 1.59-1.43 (m, 2H, 
H4), 1.29 (br. s, 1H, C5OH), 1.14 (s, 3H, C5CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ  134.1, 
132.2, 129.4, 124.2, 113.9, 110.1, 75.1, 55.3, 38.8, 33.5, 32.0, 25.7, 21.9, 21.0, 17.7 ppm; MS (CI+, 
NH3) m/z 310 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C18H32NO3 [M + NH4]
+ 310.2382. Found: 
310.2378. 
5.59 (±)-(E)-9-(4-Methoxyphenyl)-2,6-dimethylnon-6-ene-2,3-
diol [(±)-70] 
 
A reference sample of (±)-diol 70 was prepared following a modified procedure of Warren.129 
To a solution of potassium ferricyanide (383 mg, 1.16 mmol), potassium carbonate (161 mg, 1.16 
mmol), K2OsO4.2H2O (4 mg, 0.012 mmol), quinuclidine (1 mg, 0.012 mmol) and 
methanesulfonamide (37 mg, 0.39 mmol) in water (2.5 mL) and tert-butanol (2.5 mL) at 0°C was 
added olefin 1 (100 mg, 0.39 mmol) and stirred vigorously for 2 h. The reaction mixture was 
quenched with a saturated aqueous solution of sodium sulfite (10 mL), extracted with EtOAc (2 
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× 20 mL), washed with brine (40 mL), dried over Na2SO4, concentrated under reduced pressure 
and chromatographed (50-60% EtOAc in pet. ether) to afford (±)-diol 3 (21 mg, 19%) as a 
colourless oil. HPLC (CHIRALCEL OJ; 10% IPA in n-hexane; 1.0 mL/min) tR = 16.5 min, 17.8 
min. 
5.60 (-)-(S,E)-3-[-6-(4-Methoxyphenyl)-3-methylhex-3-enyl]-2,2-
dimethyloxirane [(S)-71] 
 
Using a modified procedure of Corey,126 to a stirred solution of (R)-diol 70 (840 mg, 2.88 mmol) 
and pyridine (0.46 mL, 5.75 mmol) in CH2Cl2 (15 mL) at 0°C was added methanesulfonyl chloride 
(0.29 mL, 3.72 mmol). After 0.5 h the mixture was allowed to warm to room temperature and 
stirred for 3 h. Additional pyridine (1.38 mL 17.7 mmol) was added and the reaction mixture stirred 
for 16 h. The reaction mixture was poured into a suspension of K2CO3 (6.63 g, 48 mmol) in 
methanol (25 mL), stirred for 6 h, concentrated under reduced pressure, diluted with water (50 
mL), extracted with EtOAc (2 × 50 mL), washed with 10% aqueous CuSO4 solution (100 mL), 
brine (100 mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed 
(5-20% EtOAc in pet. ether) to afford the title product (S)-71 (565 mg, 83%). 
Colourless oil; Rf = 0.34 (10% EtOAc in pet. ether); [α]D
24 -2.5 (c 1.6, CH2Cl2); IR νmax 2958, 
2925, 2835, 1612, 1586 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 8.6 Hz, 2H, Hb), 6.85 (d, 
J = 8.6 Hz, 2H, Ha), 5.26 (tq, J = 5.8, 1.5 Hz, 1H, H6), 3.81 (s, 3H, OCH3), 2.72 (app. t, J = 6.3 
Hz, 1H, H), 2.62 (t, J = 7.5 Hz, 2H), 2.32 (app. q, J = 7.6 Hz, 2H), 2.24-2.06 (m, 2H), 1.78-1.62 
(m, 2H), 1.61 (s, 3H, , C5CH3) 1.33 (s, 3H, C1CH3) 1.29 (s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, 
CDCl3) δ 157.7, 134.8, 134.3, 129.3, 124.3, 113.7, 64.1, 58.3, 55.2, 36.3, 35.1, 30.2, 27.5, 24.9, 18.8, 
16.0 ppm; MS (CI+, NH3) m/z 292 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C18H27O2 [M + H]
+ 
275.2011, found 275.2011.  
5.61 (-)-(S,E)-2-Bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-6-
en-3-ol [(S)-72a] and (+)-(R,E)-3-bromo-9-(4-
methoxyphenyl)-2,6-dimethylnon-6-en-2-ol [(R)-72b] 
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Following the method of Couladouros and Vidali,76 to a solution of (S)-epoxide 71 (200 mg, 
0.73 mmol) in N-methyl-2-pyrrolidone (0.22 mL) was added LiBr (99 mg, 0.95 mmol) and PPTS 
(183 mg, 0.73 mmol) and stirred at room temperature for 4 h. The reaction was quenched with 
saturated aqueous NaHCO3 solution (15 mL), extracted with EtOAc (2 × 15 mL), washed with 
brine (30 mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed 
(10-20% EtOAc in pet. ether) to yield first (E)-9-(4-methoxyphenyl)-2,6-dimethylnon-6-en-3-one 
(10 mg, 5%) as a colourless oil,  second bromohydrin (S)-72a (66 mg, 25%) as a colourless oil, and 
third, bromohydrin (R)-72b (119 mg, 46%) as a colourless oil.  
(6E)-9-(4-methoxyphenyl)-2,6-dimethylnon-6-en-3-one: Rf = 0.45 (10% EtOAc in pet. ether); 
IR νmax 2966, 2936, 1710, 1612, 1512, 1456, 1300, 1244, 1177, 1036, 821 cm
-1; 1H NMR (400 MHz, 
CDCl3) δ 7.11 (d, J = 8.5 Hz, 2H, Hb), 6.84 (d, J = 8.6 Hz, 2H, Hb), 5.20 (t, J = 7.0 Hz,1H, H6), 
3.81 (s, 3H, OCH3), 2.68-2.52 (m, 5H, H1, H3, H8), 2.32-2.22 (m, 4H, H4, H7), 1.57 (s, 3H, 
C5CH3), 1.12 (s, 3H, C1CH3), 1.10 (s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 214.5, 
157.7, 134.6, 134.3, 129.3, 124.1, 113.6, 55.3, 40.9, 39.1, 35.1, 33.5, 30.2, 18.3, 16.1, 14.2 ppm; MS 
(CI+, NH3) m/z 292 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C18H27O2 [M + H]
+ 275.2006, found 
275.2000.  
Bromohydrin (S)-72a: Rf = 0.32 (10% EtOAc in pet. ether); [α]D
24 -10.6 (c 1.3, CH2Cl2); IR νmax 
3600-3200, 2958, 2926, 2855, 2835, 1612 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 8.6 Hz, 
2H, Hb), 6.86 (d, J = 8.6 Hz, 2H, Ha), 5.27 (tq, J = 6.8, 1.4 Hz, 1H, H6), 3.82 (s, 3H, OCH3), 3.40 
(dd, J = 10.1, 3.0 Hz, 1H, H2), 2.63 (t, J = 7.5 Hz 2H, H8), 2.37-2.25 (m, 3H, OH, H7), 2.17-2.05 
(m, 2H, H3), 1.82 (s, 3H, C5CH3), 1.81-1.72 (m, 1H, H4), 1.75 (s, 3H, C1CH3), 1.59 (s, 3H, 
C1CH3), 1.49 (dddd, J = 14.0, 10.3, 8.8, 5.2 Hz, 1H, H4) ppm; 
13C NMR (100 MHz, CDCl3) δ 
157.7, 135.1, 134.4, 129.4, 124.6, 113.7, 79.0, 75.4, 55.3, 36.4, 35.1, 31.1, 30.1 (×2), 28.9, 16.0 ppm; 
MS (CI+, NH3) m/z 374, 372 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C18H31NO2
79Br [M + 
NH4]
+ 372.1538, found 372.1538.  
Bromohydrin (R)-72b: Rf = 0.24 (10% EtOAc in pet.ether); [α]D
24 +35.1 (c 1.3, CH2Cl2); IR νmax 
3600-3250, 2925, 2854, 1612 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 8.6 Hz, 2H, Hb), 
6.86 (d, J = 8.6 Hz, 2H, Ha), 5.29 (t, J = 7.3 Hz, 1H, H6), 3.95 (dd, J = 11.6, 1.9 Hz, 1H, H2), 3.82 
(s, 3H, OCH3), 2.63 (td, J = 7.4, 3.4 Hz, 2H, H8), 2.39-2.27 (m, 3H, OH, H7), 2.24 (s, 1H, H3), 
2.15 (dt, J = 14.9, 8.2 Hz, 1H, H3), 1.97 (dtd, J = 16.2, 8.0, 1.8 Hz, 1H, H4), 1.85-1.74 (m, 1H, 
H4), 1.56 (s, 3H, C5CH3), 1.354 (s, 3H, C1CH3), 1.347 (s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, 
CDCl3) δ 157.7, 134.3, 133.7, 129.4, 125.5, 113.7, 72.5, 70.8, 55.3, 38.2, 35.1, 31.8, 30.2, 26.6, 25.9 
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15.8 ppm; MS (CI+, NH3) m/z  374, 372 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C18H31NO2
79Br 
[M + NH4]
+ 372.1538, found 372.1540.  
5.62 (-)-(S,E)-2-Bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-6-
en-3-yl acetate [(S)-74a] and (+)-(R,E)-3-bromo-9-(4-
methoxyphenyl)-2,6-dimethylnon-6-en-2-yl acetate [(R)-
73b]  
 
To a stirred solution a 1:1 mixture of (S)-72a and (R)-72b (250 mg, 0.70 mmol, 1 eq.) and acetic 
acid (40 μL, 0.70 mmol, 1 eq.)) in dichloromethane (2.5 mL) was added trifluoroacetic anhydride 
(0.58 mL, 4.15 mmol, 5.9 eq.) and stirred at room temperature for 3 h. The reaction mixture was 
quenched by a saturated aqueous solution of NaHCO3 (25 mL), extracted with CH2Cl2 (2 × 25 
mL), washed with brine (50 mL), dried over Na2SO4, concentrated under reduced pressure and 
chromatographed (0-30% Et2O in pet. ether) to give the title products, (S)-73a and (R)-73b in a 
ratio of 1.0 :1.2 (126 mg, 0.32 mmol, 45% yield). 
Bromoacetate (S)-73a: Rf = 0.37 (30% Et2O in pet. ether); IR νmax 2930, 2854, 1736, 1612, 1511, 
1457, 1441, 1368, 1237, 1176, 1113, 1036, 819, 605, 560 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.15 
(dd, J = 8.5 Hz, 2H, Hb), 6.86 (d, J = 8.6 Hz, 2H, Ha), 5.23 (t, J = 7.1 Hz, 1H, H6), 4.98 (dd, J = 
10.3, 1.8 Hz, 1H, H2), 3.82 (s, 3H, OCH3), 2.67-2.58 (m, 2H, H8), 2.40-2.27 (m, 2H, H7), 2.16 (s, 
3H, (C=O)CH3), 1.76 (s, 3H, C1CH3), 1.75 (s, 3H, C1CH3) 1.60 (s, 3H, C5CH3) ppm; MS (CI
+, 
NH3) m/z  416, 414 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C20H33NO3
79Br 414.1644 [M + 
NH4]
+, found 414.1655.  
Bromoacetate (R)-73b: Rf = 0.37 (30% Et2O in pet. ether); IR νmax 2934, 1735, 1612, 1584, 1512, 
1463, 1370, 1300, 1242, 1177, 1112, 1035, 953, 827 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J 
= 8.5 Hz, 2H, Hb) 6.85 (d, J = 8.6 Hz, 2H, Ha), 5.28 (t, J = 6.8 Hz, 1H, H6), 4.53 (dd, J = 11.2, 
1.8 Hz, 1H, H2), 3.81 (s, 3H, OCH3), 2.63 (t, J = 7.7 Hz, 2H, H8), 2.39-2.25 (m, 3H, H3, H7), 
2.16-2.07 (m, 1H, H3), 2.04 (s, 3H, (C=O)CH3), 1.97-1.86 (m, 1H, H4), 1.81-1.72 (m, 1H, H4), 
1.61 (s, 3H, C5CH3), 1.58 (s, 3H, C1CH3), 1.57 (br. s, 3H, C1CH3) ppm; MS (CI
+, NH3) m/z  416, 
414 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C20H33NO3
79Br 414.1644 [M + NH4]
+, found 
414.1655.  
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5.63 (-)-(S,E)-2-Bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-6-
en-3-yl 2,3,4,5-tetrafluorobenzoate [(S)-74a] 
 
Using the method of Steglich,116 to a stirred solution of secondary alcohol (S)-72a (380 mg, 1.07 
mmol) in CH2Cl2 (7.5 mL) was added 2,3,4,5-tetrafluorobenzoic acid (228 mg, 1.18 mmol), DMAP 
(39 mg, 0.321 mmol, 30 mol%) and DCC (287 mg, 1.39 mmol). After 4 h the reaction mixture was 
filtered through a silica plug eluting with Et2O, concentrated under reduced pressure and 
chromatographed (0-15% Et2O in pet. ether) to afford bromo tetrafluorobenzoate (S)-74a (520 
mg, 92%).  
Colourless oil; Rf = 0.34 (5% EtOAc in pet. ether); [α]D
24 -22.0 (c 1.1, CH2Cl2); IR νmax  2935, 
2861, 2362, 2344, 1729 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.69 (dddd, J = 10.3, 8.3, 6.0, 2.4 Hz, 
1H, F4BzH), 7.13 (d, J = 8.5 Hz, 2H, Hb), 6.85 (d, J = 8.6 Hz, 2H, Ha), 5.27 (d, J = 9.9 Hz 1H, 
H2), 5.22 (t, J = 7.0 Hz, 1H, H6), 3.82 (s, 3H, OCH3), 2.61 (app. t, J = 7.7 Hz, 2H, H8), 2.37-2.19 
(m, 2H, H7), 2.10-2.03 (m, 3H, H3 and H4) 1.99-1.85 (m, 1H, H4), 1.83 (s, 3H, C1CH3), 1.82 (s, 
3H, C1CH3) 1.58 (s, 3H, C5CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 161.5, 157.7, 148.0 (dddd, 
J = 262, 11, 3, 1 Hz), 146.6 (dddd, J = 249, 10, 4, 2 Hz), 143.6 (dddd, J = 262, 17, 13, 3 Hz), 141.4 
(dddd, J = 255, 17, 12, 3 Hz) 134.3, 134.0, 129.4, 125.1, 114.7 (m), 113.7, 113.4 (dd, J = 21, 3 Hz), 
81.5, 65.8, 55.2, 36.0, 35.0, 30.44, 30.35, 30.15, 29.3, 15.9 ppm; 19F NMR (377 MHz, CDCl3) δ -
153.1 (t, J = 20 Hz, 1F), -147.0 (m, 1F), -137.6 (m, 1F), -133.6 (m, 1F) ppm; MS (CI+, NH3) m/z 
548, 546 [M + NH4]
+; HRMS (EI+) calc’d for C25H27O3
79BrF4 [M]
+ 530.1080, found 530.1080. 
5.64 (+)-(R,E)-3-Bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-6-
en-2-yl 2,3,4,5-tetrafluorobenzoate [(R)-74b] 
 
Using the method of Steglich,116  to a stirred solution of tertiary alcohol 5b (350 mg, 0.99 mmol) 
in CH2Cl2 (7.5 mL) was added 2,3,4,5-tetrafluorobenzoic acid (383 mg, 1.97 mmol), DMAP (36 
mg, 0.30 mmol, 30 mol%) and DCC (610 mg, 2.96 mmol). After 16 h further 2,3,4,5-
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tetrafluorobenzoic acid (191 mg, 0.98 mmol), DMAP (36 mg, 0.30 mmol, 30 mol%) and DCC 
(305 mg, 1.48 mmol) was added and stirred for 5 h, passed through a plug of silica and 
chromatographed (0-40% CH2Cl2 in pet. ether) to afford tetrafluorobenzoate ester 6b (316 mg, 
60%).  
Colourless oil; Rf = 0.30 (5% EtOAc in pet. ether); [α]D
24 +14.4 (c 1.4, CH2Cl2); IR νmax 2931, 
2858, 2362, 1719 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.66-7.56 (m, 1H, F4BzH), 7.15 (d, J = 8.6 
Hz, 2H, Hb), 6.85 (d, J = 8.6 Hz, 2H, Ha), 5.34 (t, 6.80 Hz, 1H, H6), 4.54 (dd, J = 11.5, 1.9 Hz, 
1H, H2), 3.81 (s, 3H, OCH3), 2.66 (t, J = 7.6 Hz, 2H, H8), 2.44-2.26 (m, 3H, H7 and H3) 2.21 (dt, 
J = 13.8, 8.0 Hz, 1H, H3), 2.09-2.00 (m, 1H, H4) 1.94-1.85 (m, 1H, H4) 1.79 (s, 3H, C1CH3), 1.76 
(s, 3H, C1CH3), 1.60 (s, 3H, C5CH3) ppm; 
13C NMR (125 MHz, CDCl3) δ 160.5, 157.7, 147.8 
(dddd, J = 262, 11, 4, 2 Hz), 146.4 (dddd, J = 249, 10, 4, 2 Hz), 143.4 (dddd, J = 262, 17, 13, 3 
Hz), 141.3 (dddd, J = 255, 17, 12, 3 Hz), 134.3, 133.6, 129.3, 125.7, 116.0 (m), 113.6, 113.2 (dd, J 
= 21, 2 Hz), 86.2, 61.6, 55.2, 37.8, 35.0, 31.5, 30.2, 24.1, 23.3, 15.8 ppm; 19F NMR (377 MHz, 
CDCl3) δ -153.5 (t, J = 20 Hz, 1F), -147.7 (tt, J = 19, 8 Hz, 1F), -138.0 (dt, J = 22, 12 Hz, 1F), -
134.5 (m, 1F) ppm; MS (CI+, NH3) m/z 548, 546 [M + NH4]
+; HRMS (EI+) calc’d for 
C25H27NO3
79BrF4 [M]
+ 530.1080, found 530.1082. 
5.65 (-)-(2R,4aR,10aS)- and (-)-(2R,4aS,10aR)-2-Bromo-6-
methoxy-1,1,4a-trimethyl-1,2,3,4,4a,9,10,10a-
octahydrophenanthrenes (75) from Me2Al(OTf) cyclisation of 
bromotetrafluorobenzoates (S)-74a and (R)-74b 
 
Cyclisation of tertiary bromide (S)-74a: To a stirred solution of Me3Al (2M in hexanes, 0.25 
mL, 0.5 mmol) in CH2Cl2 (2 mL) at -78°C was added a solution of trifluoromethanesulfonic acid 
(43 μL, 0.5 mmol) in CH2Cl2 (4 mL) and stirred at -78°C for 0.5 h and 0°C for 0.5 h. The white 
suspension of Me2AlOTf was re-cooled to -78 ˚C and a solution of bromo tetrafluorobenzoate 
(S)-74a (50 mg, 0.292 mmol) in CH2Cl2 (2 mL) was added dropwise at -78°C. The reaction was 
allowed to warm to room temperature over 16 h, quenched with aqueous HCl solution (1M, 10 
mL), extracted with CH2Cl2 (2 × 10 mL), washed with saturated aqueous NaHCO3 solution (10 
mL), brine (10 mL), dried over Na2SO4, concentrated under reduced pressure and 
chromatographed (0-30% CH2Cl2 in pet. ether) to afford first monocycles 77 as an inseparable 
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mixture of at least two endocyclic and two exocyclic alkenes (6 mg, 19%) as a colourless oil, R f = 
0.39 (20% CH2Cl2 in pet. ether),  and second bromides (2R,4aR,10aS)-75 and (2R,4aS,10aR)-75 as 
an inseparable mixture of diastereoisomers (d.r. 3:1, 8 mg, 25%) as a white solid: m.p. 92-93 ˚C; Rf 
= 0.64 (40% CH2Cl2 in pet. ether). The major diastereoisomer (2R,4aR,10aS)-75 was identical to 
that produced in the BDSB mediated cyclisation of polyene 61, and the minor diastereoisomer 
(2R,4aS,10aR)-75 was identified in the mixture by its characteristic 1H NMR signal at 4.42 (1H, 
CHBr) ppm as a broad singlet.   
 (2R,4aS,10aR)-75 [as 1:3 mixture with bromide (2R,4aR,10aS)-75]: 1H NMR (400 MHz; CDCl3) 
δ 7.01 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 2.8 Hz, 1H), 6.71 (dd, J = 8.3, 2.8 Hz, 1H), 4.42 (br s, 1H), 
3.81 (s, 3H), 2.94-2.75 (m, 2H), 2.42-2.38 (m, 1H), 2.21-2.06 (m, 3H), 1.89 (dd, J = 12.4, 2.5 Hz, 
1H), 1.82-1.67 (m, 2H), 1.22 (s, 3H), 1.12 (s, 6H) ppm; 13C NMR (100 MHz, CDCl3) 157.8, 150.5, 
129.8, 127.1, 111.0, 110.0, 69.1, 55.3, 43.5, 38.4, 37.8, 33.4, 32.9, 29.1, 28.7, 25.5, 22.2, 18.5 ppm; 
GCMS (EI+) m/z 337, 335 (M-H)+.   
The diastereoisomers were inseparable by standard column chromatography on silica gel, but 
could be separated by preparative HPLC (Prep Si; n-hexane; 5 mL/min) tR = 145 min 
[(2R,4aS,10aR)-75], 165 min [(2R,4aR,10aS)-75]. Bromide (2R,4aR,10aS)-75: [α]D
24 -100 (c 0.04, 
CH2Cl2). The concentration of this solution was very dilute and so the absolute magnitude of this 
measurement is liable to large error; HPLC (CHIRALPAK AD; 1% IPA in n-hexane; 1.0 mL/min) 
tR = 4.7 min (minor), 5.4 min (major), e.r. 98:2.  Bromide (2R,4aS,10aR)-2: [α]D
24 -43 (c 0.01, 
CH2Cl2). The concentration of this solution was very dilute and so the absolute magnitude of this 
measurement is liable to large error; HPLC (CHIRALPAK AD; 1% IPA in n-hexane; 1.0 mL/min) 
tR = 4.7 min (major), 6.1 min (minor), e.r. 98:2.  
Cyclisation of secondary bromide 6b (135 mg, 0.254 mmol) was conducted as above using 2.5 
equivalents of Me2AlOTf to afford first monocycles 77 as an inseparable mixture of at least two 
endocyclic and two exocyclic alkenes (21 mg, 25%) as a colourless oil, Rf = 0.39 (1:4 CH2Cl2:PE), 
and second bromides (2R,4aR,10aS)-75 and (2R,4aS,10aR)-75 as an inseparable mixture of 
diastereoisomers (d.r. 3:1, 30 mg, 35%) as a white solid. The diastereomers were separated by 
preparative HPLC (Prep Si; n-hexane; 5 mL/min) tR = 145 min and [(2R,4aS,10aR)-75] and 165 
min [(2R,4aR,10aS)-75]. Bromide (2R,4aR,10aS)-75: HPLC (CHIRALPAK AD; 1% IPA in n-
hexane; 1.0 mL/min) tR = 4.7 min (minor), 5.4 min (major), e.r. 98:2.  Bromide (2R,4aS,10aR)-75: 
HPLC (CHIRALPAK AD; 1% IPA in n-hexane; 1.0 mL/min) tR = 4.7 min (major), 6.1 min 
(minor), e.r. 98:2. 
162 
 
5.66 (±)-(2R*,4aR*,10aS*)-2-Bromo-6-methoxy-1,1,4a-trimethyl-
1,2,3,4,4a,9,10,10a-octahydrophenanthrene [(±)-(75)] by 
direct brominative cyclisation of polyene 61 with BDSB 
 
Prepared by direct brominative cyclisation of diene 61 using the method of Snyder and 
Treitler.48 To a stirred solution of alkene 61 (100 mg, 0.39 mmol) in CH3NO2 (6 mL) at -25°C was 
added quickly a solution of BDSB (213 mg, 0.39 mmol) in CH3NO2 (2 mL) and stirred for 5 min. 
The reaction mixture was quenched with a 1:1 mixture of 5% aqueous NaHCO3 and 5% aqueous 
Na2SO3 solution (20 mL) and stirred for 15 min before being poured into water (20 mL), extracted 
with CH2Cl2 (2 × 20 mL), dried over Na2SO4, concentrated under reduced pressure and 
chromatographed (pet. ether) to afford bromide (±)-75 (88 mg, 68%). 
White crystalline solid ; m.p. 86-87 ˚C. Rf = 0.64 (40% CH2Cl2 in pet. ether); IR νmax 2933, 
2851, 1611 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.00 (d, J = 8.3 Hz, 1H, H8), 6.77 (d, J = 2.8 Hz, 
1H, H5), 6.71 (dd, J = 8.3, 2.8 Hz, 1H, H7), 4.07 (dd, J = 12.5, 4.1 Hz, 1H, H2), 3.80 (s, 3H, 
OCH3), 2.98-2.76 (m, 2H, H9) 2.48-2.23 (m, 3H, H10 and H3), 1.98 (ddt, J = 13.4, 7.0, 2.2 Hz, 
1H, H3), 1.88-1.75 (m, 1H, H4), 1.69-1.56 (m, 1H, H4), 1.48 (dd, J = 12.1, 2.2 Hz, 1H, H10a), 
1.27 (s, 3H, C4aCH3), 1.18 (s, 3H, C1CH3), 1.09 (s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) 
δ 157.8, 150.0, 129.9, 127.0, 111.2, 110.2, 68.8, 55.3, 51.3, 40.1, 39.9, 38.1, 31.6, 30.6, 30.0, 24.8, 
20.8, 18.3 ppm; MS (CI+, NH3) m/z 354, 356 [M + NH4]
+; HRMS (CI+, NH3) calc’d for 
C18H29NO
79Br [M + NH4]
+ 354.1433, found 354.1433. HPLC (CHIRALPAK AD; 1% IPA in n-
hexane; 1.0 mL/min) tR = 4.9 min, 5.7 min. 
5.67 1-[(7R,E)-7-Bromo-8-chloro-4,8-dimethylnon-3-en-1-yl]-4-
methoxybenzene (76) 
  
To a stirred solution of a 1.0:1.4 mixture of bromotetrafluorobenzoates (S)-74a and (R)-74b 
(131 mg, 0.25 mmol, 1 eq) in CH2Cl2 at -78°C was added dropwise Me2AlCl (0.27 mL, 1 M in 
163 
 
hexanes, 0.27 mmol, 1.1 eq.) and slowly warmed to room temperature over 6 h. The reaction 
mixture was quenched with a 1 M aqueous solution of HCl (25 mL), extracted with CH2Cl2 (2 × 
25 mL), washed with H2O (40 mL), brine (40 mL), dried over Na2SO4, concentrated under reduced 
pressure and chromatographed (0-50% CH2Cl2 in pet. ether) to give first the title product 76 (24 
mg, 0.06 mmol, 26% yield) and then tricycle 75 (9 mg, 0.02 mmol, 11% yield) as a 3:1 mixture of 
diastereomers. 
Colourless oil; Rf = 0.32 (40% CH2Cl2 in pet. ether); IR νmax 2931, 2854, 1612, 1511, 1454, 1441, 
1387, 1371, 1300, 1244, 1177, 1103, 1038, 820 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 8.5 
Hz, 2H, Hb), 6.86 (d, J = 8.5 Hz, 2H, Ha), 5.31 (t, J = 7.2 Hz, 1H, H6), 3.98 (dd, J = 11.2, 1.2 Hz, 
1H, H2), 3.82 (s, 3H, OCH3), 2.67-2.60 (m, 2H, H8), 2.47-2.25 (m, 2H, H7), 2.23-2.12 (m, 1H, 
H3), 1.87-1.81 (m, 1H, H3), 1.80 (s, 3H, C5CH3), 1.73 (td, J = 8.1, 1.2 Hz, 2H, H4), 1.70 (s, 3H, 
C1CH3), 1.59 (s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.7, 134.3, 133.7, 129.3, 
125.6, 113.7, 72.1, 65.0, 55.3, 37.7, 35.1, 33.1 32.3, 30.1, 27.1, 15.7 ppm; MS (CI+, NH3) m/z 392, 
390 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C18H30NO
79Br [M + NH4]
+ 390.1199, found 
390.1200. 
5.68 Me2AlCl cyclisation of bromoacetates (S)-73a and (R)-73b 
To a stirred solution of a 1.0:1.2 mixture of bromoacetates (S)-73a and (R)-73b (44 mg, 0.11 
mmol, 1 eq) in CH2Cl2 at -78°C was added dropwise Me2AlCl (0.12 mL, 1 M in hexanes, 0.12 
mmol, 1.1 eq.) and slowly warmed to room temperature over 16 h. The reaction mixture cooled 
to -78°C and added dropwise was Me2AlCl (0.12 mL, 1 M in hexanes, 0.12 mmol, 1.1 eq.) and 
warmed to room temperature over 4 h. The reaction mixture was quenched with a 1 M aqueous 
solution of HCl (25 mL), extracted with CH2Cl2 (2 × 25 mL), washed with H2O (40 mL), brine (40 
mL), dried over Na2SO4, concentrated under reduced pressure and chromatographed (0-60% 
CH2Cl2 in pet. ether) to give tricycle 75 (10 mg, 0.03 mmol, 27% yield) and recovered starting 
material (S)-73a (12 mg, 0.03 mmol, 27% yield). 
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5.69 (-)-(4aR,10aR)- and (+)-(4aS,10aS)-6-Methoxy-1,1,4a-
trimethyl-1,2,3,4,4a,9,10,10a -octahydrophenanthrenes (78) 
from reduction of a 3:1 mixture of (-)-(2R,4aR,10aS)- and (-)-
(2R,4aS,10aR)-2-bromo-6-methoxy-1,1,4a-trimethyl-
1,2,3,4,4a,9,10, 10a-octahydrophenanthrenes (75) 
 
Using the method of Chatgilialoglu et al..171 To a stirred solution of (2R,4aR,10aS)-75 and 
(2R,4aS,10aR)-75 (d.r. 3:1, 15 mg, 45 μmol, 1 eq.) in toluene (2 mL) was added 
tris(trimethylsilyl)silane (16.5 μL, 53 μmol, 1.2 eq.) and azobisisobutyronitrile (0.73 mg, 40 μmol, 
0.1 eq.) and stirred at 90°C for 2 h, concentrated under reduced pressure and chromatographed 
(0-30% CH2Cl2 in pet. ether) to afford (4aR,10aR)-78 and (4aS,10aS)-78 as a single diastereomer 
(5 mg, 0.02 mmol, 43% yield). 
Colourless oil; Rf = 0.42 (20% CH2Cl2 in pet. ether); [α]D
24 -23.0 (c 0.26, CHCl3); lit.
154 (4aS, 
10aS)-78 [α]D
24 +64.0 (c 1.0, CHCl3); IR νmax 2997, 2924, 2852, 1686, 1609, 1576, 1502, 1463, 1443, 
1390, 1376, 1250, 1227, 1207, 1174, 1074, 1043, 869, 847, 834, 799, 739, 729 cm-1; 1H NMR (500 
MHz, CDCl3) δ 6.98 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 2.6 Hz, 1H), 6.68 (dd, J = 8.3, 2.7 Hz, 1H), 
3.80 (s, 3H), 2.94-2.75 (m, 2H), 2.67 (ap. dt, J = 12.7 Hz, 1H), 1.89 (ddt, J = 13.3, 7.5, 2.0 Hz, 1H), 
1.82- 1.60 (m, 3H), 1.50 (dtd, J = 13.2, 3.2, 1.6 Hz, 1H), 1.43 (td, J = 13.1, 3.7 Hz, 1H), 1.35 (dd, J 
= 12.5, 2.3 Hz, 1H), 1.26 (dd, J = 13.7, 4.0 Hz, 1H), 1.21 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.6, 151.5, 129.74, 127.5, 110.7, 110.2, 55.3, 50.3, 41.7, 38.8, 38.0, 
33.5, 33.3, 29.6, 24.8, 21.7, 19.3, 19.1 ppm; MS (CI+, NH3) m/z 259 [M + H]
+; HRMS (CI+, NH3) 
calc’d for C18H26O [M + H]
+ 259.2062, found 259.2071; HPLC (CHIRALPAK AD; 1% IPA in n-
hexane; 1.0 mL/min) tR = 4.12 min, 4.72 min. 
5.70 (3E,7E)-1-(4,8,12-Trimethyltrideca-3,7,11-trienyl)-4-
methoxybenzene (α-79) and (±)-(5E,9E)-1-(2,6,10-trimethyl-
2-vinylundec-5,9-dienyl)-4-methoxybenzene (γ-79) 
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Prepared according to the procedure used by Zhao and Loh159 and developed by Demuth.103  
To a stirred suspension of magnesium turnings (927 mg, 38 mmol, 1.25 eq.) in anhydrous THF 
(50 mL) was added p-methoxybenzyl chloride (0.46 mL, 3.36 mmol, 0.11 eq.) and heated at 50°C. 
When the colourless solution turned cloudy, a solution of p-methoxybenzyl chloride (4.09 mL, 30 
mmol, 0.99 eq.) in anhydrous THF (50 mL) was added dropwise over 30 min maintaining reflux 
for 3 h. The mixture was cooled to room temperature and added dropwise at 0°C to a stirred 
solution of farnesyl bromide (8.27 mL, 31 mmol, 1 eq.) and Pd(PPh3)4 (1.76 g, 1.52 mmol, 5 mol%) 
in THF (50 mL) and allowed to warm to room temperature and stirred for 16h. The reaction 
mixture was quenched by pouring onto ice water (100 mL) and extracted with Et2O (2 × 100 mL), 
washed with water (150 mL), brine (150 mL), dried over Na2SO4, concentrated under reduced 
pressure and chromatographed (0-5% Et2O in n-heptane) to afford the title compound (α)-79 as a 
mixture of constitutional isomers with (5E,9E)-1-(2,6,10-trimethyl-2-vinylundec-5,9-dienyl)-4-
methoxybenzene (γ-79) in ratio 17:1 (7.19 g, 22 mmol, 72% yield). 
Colourless oil; Rf = 0.37 (5% Et2O in pet. ether); IR νmax 2918, 2854, 1612, 1511, 1446, 1379, 
1300, 1244, 1177, 1107, 1039, 819 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 8.5 Hz, 2H, 
Hb), 6.87 (d, J =8.6 Hz, 2H, Ha), 5.24 (t, J = 7.2 Hz, 1H, H10), 5.20-5.13 (m, 2H, H2 and H6), 
3.84 (s, 3H, OCH3), 2.63 (dd, J = 8.9, 6.8 Hz, 2H, H12), 2.32 (ap. q, J = 7.6 Hz, 2H, H11), 2.17-
2.09 (m, 4H, H3 and H7), 2.07-2.01 (m, 4H, H4 and H8), 1.74 (s, 3H, C9CH3), 1.66 (s, 6H, C1CH3), 
1.61 (s, 3H, C5CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.7, 135.7, 135.0, 134.6, 131.3, 129.4, 
124.5, 124.3, 123.7, 113.7, 55.3, 39.8, 35.3, 30.3, 26.8, 26.7, 25.7, 17.7, 16.0 ppm; MS (CI+, NH3) 
m/z 344 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C23H35O [M + H]
+ 327.2688, found 327.2674. 
5.71 (+)-(R,6E,10E)-13-(4-Methoxyphenyl)-2,6,10-trimethyltridec-
6,10-diene-2,3-diol (α-80a), (+)-(R,E)-11-(4-
methoxyphenyl)-2,6,10-trimethyl-10-vinylundec-6-ene-2,3-
diol (γ-80a), (+)-(7R,8R,3E)-1-(4-methoxyphenyl)-4,8,12-
trimethyltridec-3,11-diene-7,8-diol (α-80b) and (+)-(6R,7R)-
11-(4-methoxyphenyl)-2,6,10-trimethyl-10-vinylundec-2-
ene-6,7-diol (γ-80b) 
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To a stirred solution of triene 79 (7.62 g, 23 mmol, 1 eq.) in tBuOH:H2O (1:1, 150 mL) at 0°C 
was added methanesulfonamide (2.22 g, 23 mmol, 1 eq.) and AD-mix β (32.66 g, 1.4 dmmol-1) and 
vigorously stirred for 3 h at 0°C before warming to room temperature and stirring over 48 h. The 
reaction mixture was quenched with a saturated aqueous solution of Na2SO3 (75 mL), extracted 
with EtOAc (2 × 150 mL), washed with brine (250 mL), dried over Na2SO4, concentrated under 
reduced pressure and chromatographed (10-60% EtOAc in n-heptane) to give first recovered 
starting material (α)-79 (2.4 g, 7.29 mmol, 31% yield) as a mixture of constitutional isomers with 
(5E,9E)-1-(2,6,10-trimethyl-2-vinylundec-5,9-dienyl)-4-methoxybenzene (γ-79) in a 23:1 ratio, 
then diol (α)-80b (1.4 g, 3.88 mmol, 17% yield) as a mixture of constitutional isomers with (+)-
(6R,7R,E)-11-(4-methoxyphenyl)-2,6,10-trimethyl-10-vinylundec-2-ene-6,7-diol (γ-80b) in a ratio 
7:1, then diol (α)-80a (1.3 g, 3.61 mmol, 15% yield) as a mixture of constitutional isomers with (+)-
(R,E)-11-(4-methoxyphenyl)-2,6,10-trimethyl-10-vinylundec-6-ene-2,3-diol (γ-80a) in a 20:1 ratio. 
Diol (α)-80b: white solid; m.p. 32-34°C; Rf = 0.46 (50% EtOAc in pet. ether); [α]D
24 +12.2 (c 
2.1, CH2Cl2); IR νmax 3600-3100, 2924, 2856, 1612, 1511, 1448, 1378, 1299, 1243, 1177, 1072, 1037, 
935, 820 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 8.5 Hz, 2H, Hb), 6.85 (d, J = 8.6 Hz, 2H, 
Ha), 5.27 (t, J = 7.2 Hz, 1H, H10), 5.16 (t, J = 6.9 Hz, 1H, H2), 3.81 (s, 3H, OCH3), 3.39 (dd, J = 
10.5, 1.3 Hz, 1H, H6), 2.70-2.40 (br. s, 1H, OH), 2.62 (t, J = 7.8 Hz, 2H, H12), 2.32 (ap. q, J = 7.3 
Hz, 2H, H11), 2.17-1.98 (m, 3H, H3 and H7), 1.73 (s, 3H, C9CH3), 1.68- 1.28 (m, 6H, H4, H7. 
H8, OH), 1.66 (s, 3H, C1CH3), 1.60 (s, 3H, C1CH3), 1.14 (s, 3H, C5CH3) ppm; 
13C NMR (100 
MHz, CDCl3) δ 157.71, 135.5, 134.4, 131.8, 129.3, 124.5, 124.4, 113.7, 76.7, 74.9, 55.2, 38.9, 36.8, 
35.1, 30.2, 29.6, 25.8, 22.1, 21.0, 17.7, 16.0 ppm; MS (CI+, NH3) m/z 378 [M + NH4]
+; HRMS (CI+, 
NH3) calc’d for C23H40NO3 [M + NH4]
+ 378.3008, found 378.3009. 
Diol (α)-80a: Colourless oil; Rf = 0.39 (50% EtOAc in pet. ether); [α]D
24 +12.3 (c 1.1, CH2Cl2); 
IR νmax 3600-3100, 2925, 2853, 1612, 1511, 1450, 1381, 1300, 1243, 1176, 1076, 1037, 909, 820, 
732 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 8.5 Hz, 2H, Hb), 6.86 (d, J = 8.7 Hz, 2H, Ha), 
5.22 (t, J = 6.8 Hz, 2H, H6 and H10), 3.81 (s, 3H, OCH3), 3.38 (d, J = 10.0 Hz, 1H, H2), 2.80 (br. 
s, 1H, C1OH), 2.69 (br. s, 1H, C2OH), 2.62 (dd, J = 8.8, 6.8 Hz, 2H, H12), 2.31 (q, J = 7.5 Hz, 
3H, H11 and H7), 2.17-2.10 (m, 5H, H7, H8 and H4), 1.66 (s, 3H, C9CH3), 1.65-1.57 (m, 1H, H, 
H4), 1.60 (s, 3H, C5CH3), 1.50-1.39 (m, 1H, H3), 1.23 (s, 3H, C1CH3), 1.19(s, 3H, C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 157.7, 135.6, 134.9, 134.5, 129.4, 124.9, 123.8, 113.7, 78.3, 73.1, 
55.3, 39.7, 36.9, 35.2, 30.2, 29.9, 26.6, 26.5, 23.3, 16.0 ppm; MS (CI+, NH3) m/z 378 [M + NH4]
+; 
HRMS (CI+, NH3) calc’d for C23H40NO3 [M + NH4]
+ 378.3008, found 378.3011. HPLC 
(CHIRALCEL OJ; 10% IPA in n-hexane; 1.0 mL/min) tR = 8.78 min (major), 10.19 min (minor) 
– 99:1 e.r. 
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5.72 (±)-(6E,10E)-13-(4-Methoxyphenyl)-2,6,10-trimethyltridec-
6,10-diene-2,3-diol [(±)-80a] 
  
A reference sample of (±)-diol 80a was prepared following a modified procedure of Warren.129 
To a solution of potassium ferricyanide (302 mg, 0.92 mmol, 3 eq.), potassium carbonate (127 mg, 
0.92 mmol, 3 eq.), K2OsO4.2H2O (3.4 mg, 9.2 μmol, 3 mol%), quinuclidine (1 mg, 9.2 μmol, 3 
mol%) and methanesulfonamide (29 mg, 0.31 mmol, 1 eq.) in water (2.5 mL) and tert-butanol (2.5 
mL) at 0°C was added olefin 79 (100 mg, 0.31 mmol) and stirred vigorously for 4 h. The reaction 
mixture was quenched with a saturated aqueous solution of sodium sulfite (10 mL), extracted with 
EtOAc (2 × 20 mL), washed with brine (40 mL), dried over Na2SO4, concentrated under reduced 
pressure and chromatographed (10-60% EtOAc in pet. ether) to afford (±)-diol 80a (15 mg, 0.04 
mmol, 13% yield). HPLC (CHIRALCEL OJ; 10% IPA in n-hexane; 1.0 mL/min) tR = 8.99 min, 
10.18 min. 
5.73 (-)-(S,3E,7E)-3-[-10-(4-Methoxyphenyl)-3,7-dimethyldec-3,7-
dienyl]-2,2-dimethyloxirane [(S)-81] 
 
Using a modified procedure of Corey,126 to a stirred solution of (R)-diol 80a (1.3 g, 3.6 mmol, 
1 eq.) and pyridine (0.58 mL, 7.21 mmol, 2 eq.) in CH2Cl2 (23 mL) at 0°C was added 
methanesulfonyl chloride (0.37 mL, 4.69 mmol, 1.3 eq.). After 0.5 h the mixture was allowed to 
warm to room temperature and stirred for 6 h. Additional pyridine (1.74 mL 21.6 mmol, 6 eq.) 
was added and the reaction mixture stirred for 16 h. The reaction mixture was poured into a 
suspension of K2CO3 (8.3 g, 60 mmol, 16.7 eq.) in methanol (40 mL), stirred for 6 h, concentrated 
under reduced pressure, diluted with water (50 mL), extracted with EtOAc (2 × 50 mL), washed 
with 10% aqueous CuSO4 solution (100 mL), brine (100 mL), dried over Na2SO4, concentrated 
under reduced pressure and chromatographed (0-20% EtOAc in pet. ether) to afford the title 
product (S)-81a (724 mg, 2.11 mmol, 54%) as a 36:1 mixture of constitutional isomers with (-)-
(S,E)-3-[-10-(4-methoxyphenyl)-3,7-dimethyl-7-vinyloct-3-enyl]-2,2-dimethyloxirane (γ)-81a. 
Colourless oil; Rf = 0.37 (20% EtOAc in pet. ether); IR νmax 2958, 2920, 2850, 1612, 1512, 1450, 
1379, 1300, 1245, 1177, 1115, 1038, 822 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 8.6 Hz, 
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2H, Hb), 6.86 (d, J = 8.7 Hz, 2H, Ha), 5.20 (ap. q, J = 7.1 Hz, 2H, H6 and H10), 3.82 (s, 3H, 
OCH3), 2.74 (t, J = 6.2 Hz, 1H, H2), 2.61 (dd, J = 8.9, 6.7 Hz, 2H, H12), 2.30 (q, J = 7.4 Hz, 2H, 
H11), 2.24-1.94 (m, 6H, H7, H4, H8), 1.75-1.60 (m, 2H, H3), 1.65 (s, 3H, C9CH3), 1.59 (s, 3H, 
C5CH3), 1.34 (s, 3H, C1CH3), 1.30 (s, 3H, C1CH3), ppm; 
13C NMR (100 MHz, CDCl3) δ 157.7, 
135.6, 134.5, 134.1, 129.4, 124.9, 123.8, 113.7, 64.2, 58.4, 55.3, 39.7, 36.3, 35.2, 30.2, 27.5, 26.6, 
24.9, 18.8, 16.0 ppm; MS (CI+, NH3) m/z 360 [M + NH4]
+; HRMS (CI+, NH3) calc’d for C23H35O2 
[M + H]+ 343.2637, found 343.2646. 
5.74 (±)-(2R*,4aS*,4bS*,10bS*,12aS*)-2-Bromo-
1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydro-1,1,4a,10b-
tetramethyl-9-methoxychrysene [(±)-83] 
 
Prepared by direct brominative cyclisation of triene 79 using the method of Snyder and 
Treitler.48 To a stirred solution of triene 79 (100 mg, 0.31 mmol, 1 eq.) in CH3NO2 (3 mL) at -14°C 
was added quickly a solution of BDSB (168 mg, 0.31 mmol, 1 eq.) in CH3NO2 (1.5 mL) and stirred 
for 5 min. At -14°C methanesulfonic acid (0.3 mL, 4.59 mmol, 15 eq.) was added dropwise and 
stirred for 1 h. The reaction mixture was quenched with a 1:1 mixture of 5% aqueous NaHCO3 
and 5% aqueous Na2SO3 solution (20 mL), extracted with CH2Cl2 (2 × 20 mL), dried over Na2SO4, 
concentrated under reduced pressure and chromatographed (0-35% CH2Cl2 in pet. ether) to afford 
bromide (±)-83 (29 mg, 0.07 mmol, 24% yield). 
Colourless oil; Rf = 0.27 (20% CH2Cl2 in pet. ether); IR νmax 2923, 2851, 1609, 1575, 1502, 1463, 
1379, 1272, 1252, 1229, 1209, 1160, 1090, 1047, 1009, 868, 849, 803, 767, 737, 701 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 6.98 (d, J = 8.4 Hz, 1H, H7), 6.81 (d, J = 2.7 Hz, 1H, H10), 6.69 (dd, J = 8.5, 
2.6 Hz, 1H, H8), 4.04 (dd, J = 12.8, 4.3 Hz, 1H, H2), 3.80 (s, 3H, OCH3), 2.91 (ddd, J = 16.8, 6.6, 
1.9 Hz, 1H, H6), 2.77 (ddd, J = 16.9, 11.4, 7.3 Hz, 1H, H6), 2.39 (dt, J = 12.7, 3.2 Hz, 1H, H5), 
2.29 (qd, J = 13.4, 3.9 Hz, 1H, H5), 2.14 (dq, J = 13.8, 3.9 Hz, 1H, H), 1.88 (dt, J = 13.0, 3.5 Hz, 
1H, H), 1.84-1.48 (m, 8H), 1.23 (s, 3H, C10bCH3), 1.11 (s, 3H, C4aCH3), 1.02 (s, 3H, C1CH3), 
1.01 (s, 3H, C1CH3), ppm; 
13C NMR (100 MHz, CDCl3) δ 157.7, 151.1, 129.6, 127.1, 110.8, 110.2, 
69.8, 56.6, 55.2, 55.0, 41.3, 40.6, 39.7, 38.0, 37.7, 30.9, 30.5, 29.8, 25.8, 20.6, 18.2, 18.1, 16.3 ppm; 
MS (CI+, NH3) m/z 407, 405 [M + H]
+; HRMS (CI+, NH3) calc’d for C23H34OBr [M + H]
+ 405.1774, 
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found 405.1776; HPLC (CHIRALPAK AD; 1% IPA in n-hexane; 1.0 mL/min) tR = 6.19 min, 6.61 
min. 
5.75 1-[(3S)-3-Bromo-4-chloro-4-methylpentyl]-4-
methoxybenzene (91a), 1-[(3R)-4-bromo-3-chloro-4-
methylpentyl]-4-methoxybenzene (91b) and 1-[(3R)-3-
chloro-4-methylpent-4-en-1-yl]-4-methoxybenzene (92) 
 
To a stirred solution of alcohol (S)-8b (100 mg, 0.35 mmol, 1 eq.) in CHCl3 (2 mL), at 0°C was 
added dropwise thionyl chloride (40 μL, 0.53 mmol, 1.5 eq.) and allowed to warm to room 
temperature over 4 h. The reaction mixture was cooled to 0°C, a further addition of thionyl 
chloride was made (40 μL, 0.53 mmol, 1.5 eq.) and the reaction stirred at room temperature for 2 
h. The reaction mixture was quenched with a saturated aqueous solution of NaHCO3 (20 mL), 
extracted with CHCl3 (20 mL), washed with brine (30 mL), dried over Na2SO4, concentrated under 
reduced pressure and chromatographed (0-30% CH2Cl2 in pet. ether) to give tertiary chloride 91a, 
secondary chloride 91b, allyl bromide 36 and allyl chloride 92 as a 2.4:0.9:1.0:0.3 mixture (23 mg). 
Colourless oil; Rf = 0.45 (30% CH2Cl2 in pet. ether); 
1H NMR (400 MHz, CDCl3) δ 7.18 (d, J = 
8.5 Hz, 6H, Hb), 7.14 (d, J = 8.5 Hz, 3H, Hb), 6.90-6.84 (m, 9H, Ha), 5.08 (s, 1H, 36 C1=CH), 
5.03 (s, 0.3H, 92 C1=CH), 4.95-4.92 (m, 1.3H, 36 C1=CH and 92 C1=CH), 4.53 (dd, J = 8.2, 6.6 
Hz, 1H, 36 H2), 4.37 (dd, J = 8.2, 6.3 Hz, 0.3H, 92, H2), 4.01 (dd, J = 11.2, 1.6 Hz, 2.4H, 91a H2), 
3.95 (dd, J = 11.5, 1.2 Hz, 0.9H, 92b, H2), 3.83 (s, 13.3H, OCH3), 3.02 (ddd, J = 13.0, 8.3, 4.3 Hz, 
2.6H, H4), 2.77-2.55 (m, 9.5H, H3), 2.37-2.25 (m, 1.6 H, H3), 2.20-2.01 (m, 4.6 H, H3), 1.91 (s, 
2H, C1CH3), 1.90 (s, 3.2H, C1CH3), 1.85 (s, 0.9 H, C1CH3), 1.79 (s, 2.3H, C1CH3), 1.78 (s, 6.3 H, 
C1CH3), 1.68 (s, 6.3 H, C1CH3) ppm; 
13C NMR (100 MHz, CDCl3) δ 
13C NMR (101 MHz, CDCl3) 
δ 158.1, 158.1, 157.9, 133.7, 133.7, 132.6, 132.4, 130.5, 130.0, 129.6, 129.5, 129.4, 114.3, 113.9, 
113.8, 77.4, 77.3, 77.1, 76.7, 65.0, 59.2, 55.3, 52.5, 41.7, 38.9, 36.4, 36.1, 34.4, 34.3, 33.3, 33.1, 33.0, 
32.4, 30.4, 30.2, 27.3, 17.8, 14.7, 14.1, 1.1 ppm; FTMS m/z 305, 303, [91 - H]- 269, 267, [36 - H]-. 
225, 223 [92 + H]-.  
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Scalemic bromonium ions generated enantiospeciﬁcally by the
action of catalytic triﬂic acid on scalemic regioisomeric
bromohydrin derivatives are trapped intramolecularly, enantio-
speciﬁcally and regioselectively to give bicyclic brominated
carbocycles in excellent yield and high enantiomeric excess.
This enantiospeciﬁc pathway is not signiﬁcantly perturbed by
the addition of a trisubstituted alkene.
Biomimetic cationic polyene cyclisations of terpenes by electro-
philic initiators to give polycyclic terpenoids are tremendously
powerful synthetic processes.1,2 The ﬁrst direct bromonium
ion-induced polyene cyclisation was described by Van Tamelen
in 1966 as initiated by NBS,3 but in this, and other early
work,4a–e the cyclisations were necessarily racemic and very
low yielding. Later, the use of 2,4,4,6-tetrabromocyclo-
hexadienone (TBCO) in acetonitrile or nitromethane resulted
in suﬃciently eﬃcient brominative cyclisations to give
monocarbocycles and/or bicarbocycles that the total synthesis
of a number of naturally occurring compounds could be
accomplished.4f–k The recent work of Snyder5 has shown
that bromodiethylsulphonium bromopentachloroantimonate
(BDSB) is an extraordinarily useful reagent for the direct
bromonium-induced cyclisation of a wide range of polyenes
giving mono-, bi, tri- and even tetracyclic carbocycles in high
yield, but as necessarily racemic products.6 A driving force for
the development of these reactions is the continual isolation of
complex polycyclic brominated natural products7—as single
enantiomers—where their biogenesis are generally considered
to be enzyme mediated asymmetric bromonium ion-induced
polyene cyclisations,8 and these isolations continue to date.9
Selected cyclisations have been eﬀected enzymatically, giving
single enantiomer products.10 However, a non-enzymatic
asymmetric polyene cyclisation as induced by an enantiopure
bromonium ion has yet to be reported.11,12 We have recently
reported the ﬁrst generation and intermolecular trapping of
enantiomerically pure bromonium ions to give enantiomerically
pure bromochloride adducts.13 In that previous work we had
generated enantiopure bromonium ions by the action of
thionyl chloride or titanium tetrachloride on enantiopure
bromohydrin or sulphonate derivatives respectively with
concomitant stereospeciﬁc NGP of the bromide. The enantiopure
bromonium ions were then captured stereospeciﬁcally, and in
high yield, by necessarily present chloride anion. In order to
extend this methodology to the initiation of polyene cyclisations
with a bromonium ion we considered that we would require
(i) synthetic access to enantiopure (or enantioenriched)
bromohydrins;z (ii) eﬃcient activation of the bromohydrin
(or derivative) to form a scalemic bromonium ion in the
absence of a nucleophilic counterion; (iii) eﬀective enantio-
speciﬁc intramolecular trapping without catastrophic erosion
of enantiomeric purity by rapid bromonium ion-alkene
exchange (Scheme 1).14 We also considered that this overall
strategy should be high yielding since the bromonium ion
Scheme 1 Preparation of enantioenriched bromohydrins.
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would be formed, and only formed, at the terminus of the
polyene. Herein, we report on the generation of bromonium
ions from scalemic bromohydrin derivatives—derived from
anionic bromide ring-opening of scalemic epoxides—as a
viable method for initiating cyclisation,15,16 and demonstrate
regioselective intramolecular trapping with a p-nucleophile to
give bicyclic brominated carbocycles with essentially complete
enantiospeciﬁcity in high yield. We also report that this
process occurs without signiﬁcant erosion of enantiomeric purity
in the presence of added trisubstituted alkene.
Trisubstituted alkene 1,17,y was dihydroxylated using
AD-mix a18 to give diol 2 in excellent yield and high enantiomer
ratio (2: e.r. 92 : 8),19,z and converted into epoxide 3 using the
method of Corey (Scheme 1).20 Ring-opening of epoxide 3
with anionic bromide was best achieved using the method of
Couladorous and Vidalif to give the separable tertiary bromide
4a and secondary bromide 4b. Their regioisomeric assignments
were secured on the basis of a bromide induced 13C isotopic
shift (see ESI)21 and their enantiomeric integrity conﬁrmed by
analysis of their derivatives (vide infra). Thus, the Sharpless
dihydroxylation method allows access to enantioenriched
bromohydrins of trisubstituted alkenes.
With scalemic bromohydrins 4a and 4b in hand, we
considered how best to activate them. We had recently observed
the spontaneous formation of a bromonium ion from a 1-bromo-
2-tetraﬂuorobenzoate on standing,22 and so we selected the
tetraﬂuorobenzoate as a suitable leaving group for this study.
Accordingly, tetraﬂuorobenzoates 5a and 5b were prepared
from alcohols 4a and 4b by Steglich esteriﬁction.23 Acetates 6a
and 6b could also be prepared by the same method.ww These
transformations to give 5a, 5b, 6a and 6b – and evidently the
preceding steps involving epoxide formation (2 into 3) and
anionic bromide ring-opening (3 into 4a+4b) cf. Scheme 1 –
proceeded without loss of any stereochemical integrity.z,** In
the event, cyclisation was eﬀectedzz by the use of catalytic
triﬂic acid in dichloromethane (Table 1). Much to our delight,
cyclisation of secondary bromobenzoate 5a with 30 mol%
Tf OH in reﬂuxing dichloromethane proceeded enantio-
speciﬁcally,z and essentially quantitatively, to bromocyclohexane
7yy (entry 1), but where lower catalyst loading were increasingly
less eﬀective (entries 2,3).
Tertiary bromobenzoate 5b was also eﬃciently cyclised
under these conditions, again with essentially complete enantio-
speciﬁcity, in excellent to good conversions either at reﬂux
(entry 4) or at r.t. (entry 5). Thus tetraﬂuorobenzoates of either
21 or 31 bromohydrins derived from trisubstituted alkenes are
excellent choices for the formation of scalemic bromonium
ions as catalysed by triﬂic acid. In addition, the reaction
proﬁles of these reactions were extremely clean. Secondary
acetate 6a was also eﬃciently cyclised under these conditions
but with a slight erosion in enantiomeric ratio of the product
(entry 6).ff However tertiary acetate 6b (entry 7) gave complex
and varied mixtures of product and rearranged compounds.www
The direct cyclisation of both bromohydrins 4a and 4b under
these conditions were also attempted, but these substrates gave
complex product mixtures, from which the desired product 7
could sometimes be isolated, but where isopropylphenethyl-
ketone17 was usually the major component.
Evidently, the transformation of 5a (and 6a) into 7 must
necessarily proceed through bromonium ion A*** by stereo-
speciﬁc NGP of the bromide—with complete inversion of
conﬁguration—on the protonated leaving group and then
enantiospeciﬁc and regioselective trapping of the bromonium
ion by the aromatic nucleus.zzz The same scalemic bromonium
ion Ayyy can be invoked from 5b.
To show the preparative utility of this method alkene 1 was
dihydroxylated with AD-mix b to give ent-2 (99%, 97 : 3 e.r.z).
Epoxide formation as before gave ent-3 (53%), and anionic
bromide ring-opening gave ent-4a and ent-4b (72%), which
were converted—without separation—into a mixture of ent-5a
and ent-5b (95%). Triﬂic acid catalysed cyclisation of the
mixture in dichloromethane (30 mol% Tf OH, 2h r.t then
2 h at reﬂux) gave ent-7 in high yield with essentially complete
enantiospeciﬁcity (84%, 96 : 4 e.r.z).zzz
In the context of developing asymmetric bromonium ion-
induced polyene cyclisations it is vital to know if these
enantiospeciﬁc intramolecular cyclisations onto bromonium
ions will be compromised by competitive intermolecular
bromonium ion transfer to alkenes14 (alkene functionality
being necessarily present in potential polyene substrates).
Accordingly, triﬂic acid catalysed cyclisation of secondary
acetate ent-6a (e.r. 96 : 4) was performed in the presence of
one equivalent of 1-methylcyclohexene. Although a Friedel–
Crafts alkylation adduct was formed in the reaction mixture,f
Table 1 Brominative cyclisation of substrates with catalytic TfOHa
Entry Substrateb x T/1C t (h) % Conversionc e.r.d
1 5a (92 : 8) 30 40 3 97 (84) 91 : 9
2 5a (92 : 8) 10 40 16 81 nd
3 5a (92 : 8) 5 40 16 20 nd
4 5b (93 : 7) 30 40 4 94 (67) 92 : 8
5 5b (93 : 7) 30 r.t. 16 79 nd
6 6a (92 : 8) 30 40 2.5 80 (68) 84 : 16
7 6b (92 : 8) 30 40 2 45 (14) nd
a See ESI for experimental conditions. b The ﬁgure in parentheses is
the e.r. for this substrate. c As determined by inspection of the 1H
NMR spectrum after aqueous work-up. Figure in parentheses is
isolated yield after column chromatography. d As determined by
HPLC analysis by reference to a racemic sample.
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the desired bromocyclohexane ent-7 was isolated in 35% yield,
and with an essentially undiminished e.r. of 94 : 6.
In conclusion, we have shown that scalemic bromohydrins
of trisubstituted alkenes can be readily prepared by application
of the Sharpless dihydroxylation method, thereby giving
access to both enantiomeric series with high enantioselectivity.
Their tetraﬂuorobenzoate derivatives are excellent substrates
for the formation of scalemic bromonium ions of a trisubstituted
alkene from either 21 or 31 bromohydrins—or as a mixture—
on treatment with catalytic quantities of triﬂic acid, and
undergo enantiospeciﬁc regioselective cyclisation with a suitably
positioned nucleophile. This enantiospeciﬁc pathway is not
signiﬁcantly perturbed by the addition of a trisubstituted
alkene. The above ﬁndings lay the groundwork for the develop-
ment of polyene cyclisations triggered by enantiomerically
pure bromonium ions. Further ﬁndings will be reported in
due course.
We thank the EPSRC, Arrow Therapeutics and AstraZeneca
for a CASE award (to J. S. M.), and the EPSRC for further
ﬁnancial support (EPSRC Grant no. EP/E058272/1).
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Since the advance of the Stork-Eschenmoser hypothesis,1–3
cation-initiated polyene cyclizations as inspired by the enzy-
matic conversions of squalene to hopene and oxidosqualene
to lanosterol have attracted much synthetic attention,4–6 with
enantioselective variants now representing the state of the
art.7–15 With the continued isolation16–29 of complex single en-
antiomer brominated (poly)cyclic terpenoid natural products
containing the signature a-bromo-b,b-dimethylcyclohexane
motif from marine sources,30–34 a consensus has arisen that
nature employs enzyme-mediated bromonium ion initiated
asymmetric polyene cyclizations to so construct them
(Fig. 1).35 While van Tamelen and Hessler36 demonstrated
the ﬁrst direct brominative cyclization of polyene methyl
farnesate with NBS nearly 50 years ago, the products were
necessarily racemic and formed in very low yields (ca. 5%).
Over the next 30 years a number of other direct brominative
polyene cyclizations have further been reported using a
variety of (achiral) reagent-solvent combinations.37–48 The
low yields generally obtained in these cyclizations must
arise in part from the requirement of the reagent to
react regioselectively with the oleﬁn at the terminus of
the polyene chain. The recent introduction of the powerful
bromodiethylsulphonium bromopentachloroantimonate re-
agent, BDSB, by Snyder and co-workers now allows for
highly efﬁcient bromonium ion initiated polyene cyclizations
to give bi- tri-, and even tetracyclic adducts, albeit still as
racemates.41–51,* Snyder and colleagues have also recently
reported a two-step mimic for direct, asymmetric
bromonium-induced polyene cyclizations using a chiral Hg(II)
salt to mediate the initial cyclization.52 However, the demon-
stration of an enantiospeciﬁc, nonenzymatic-mediated, poly-
ene cyclization initiated by an enantiopure bromonium ion
remains unreported.†
In contemplating such an asymmetric bromonium ion-
initiated polyene cyclization, challenges in each of the funda-
mental steps of initiation and propagation arise (Fig. 2), and a
suitable group must also be chosen to terminate the polyeneBDSB are also reported in Ref. 50. However, no asym-
s observed in the cyclization of a representative polyene.
idites at stoichiometric loading have delivered high
ss for direct iodonium-induced polyene cyclizations
ng NIS as the electrophilic halide source. With NBS
ce instead to effect a bromonium-ion induced cycliza-
ic induction dropped off markedly (36% ee) (Ref. 10).
dicals, Inc.
???cyclization. In any initiation step, an enantiopure bromonium
ion must be formed regioselectively at the terminus alkene
of the polyene. Currently, there is no widely applicable
method for the formation of enantiopure bromonium ions
by direct bromination of a simple trisubstituted alkene (even
before considering the required regioselectivity of
the process).53–57 In the propagation step(s) intramolecular
and/or intermolecular bromonium ion-to-alkene transfer58,59
must be avoided, where Denmark et al. have recently demon-
strated that racemization of enantiopure bromonium ions via
bromonium ion-to-oleﬁn transfer with an added alkene is
competitive with intermolecular capture by anionic nucleo-
philes.60 Since by deﬁnition a polyene cyclization substrate
will always contain alkene functional groups, it is not unrea-
sonable to ask if such asymmetric cyclizations are therefore
inherently compromised when not under enzymatic control.
Thus, methods for the initiation of polyene cyclizations with
enantiopure bromonium ions are required to be developed,
so that the extent of the racemization via either intramolecu-
lar or intermolecular bromonium ion-to-alkene transfer can
be assessed. An enantiomerically pure bromonium ion was
generated in the formation of a vicinal bromochloride in the
total synthesis of (+)-intricatetraol.61 Lewis acid-mediated
carbocyclizations of (racemic) 1,2-bromohydrins (3˚ alcohol
and/or esteriﬁed derivatives, 2˚ bromide) have been demon-
strated previously,62–66 and a cyclization of an enantiopure
1,2-bromohydrin (3˚ alcohol, 2˚ bromide) to an enantiopure
1-bromo-2,2,4-trimethylcyclohexane has been reported,67 but
bromonium ions were not invoked. Herein, as an extension of
our previous work, we report the formation of an enantiopure
bromonium ion at the terminus of a polyene by suitable activa-
tion of an enantiopure bromohydrin,68,69 thereby initiating
polyene cyclization to produce tricyclic carbocycles with the
characteristic a-bromo-b,b-dimethylcyclohexane motif of
(poly)cyclic naturally occurring terpenoids. Under theseAstraZeneca for a CASE award (to J. S. M.), and the EPSRC for further ﬁnan-
cial support; Contract grant number: EPSRC Grant no. EP/E058272/1.
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Fig. 2. Challenges for enantiospeciﬁc polyene cyclization initiated by an
enantiopure bromonium ion.
Fig. 1. Selected single enantiomer terpenoid natural products containing the
a-bromo-b,b-dimethylcyclohexane motif (highlighted in blue) considered to arise
via bromonium ion-initiated polyene cyclization.
ENANTIOSPECIFIC BROMONIUM ION POLYENE CYCL. 693conditions—even with a necessarily present trisubstituted al-
kene in the cyclization substrates—the brominated tricyclic
carbocycles are isolated in high enantiomeric excess. Race-
mization via either intramolecular or intermolecular
bromonium ion-to-alkene transfer is evidently not in opera-
tion, and the cyclizations proceed enantiospeciﬁcally.MATERIALS AND METHODS
General Experimental
Reagents. 4-Methoxybenzyl chloride was prepared from 4-
methoxybenzyl alcohol according to a procedure by Yadav and col-
leagues.70 Bromodiethylsulphide pentachloroantimonybromide (BDSB)
was prepared according to the procedure by Snyder and Treitler.51
Pyridine was distilled from CaH2. Methanesulphonamide was puriﬁed
by recrystallization from EtOH. All other regents were obtained from
commercial sources and used as received.
Solvents. All reactions were carried out in anhydrous solvents unless
used in combination with H2O. CH2Cl2, Et2O, and THF were dried by
passing through a column of alumina beads. N-Methyl-2-pyrrolidone
was puriﬁed by distillation and stored over 4Å molecular sieves. All other
reaction solvents, extraction solvents, and chromatography eluents were
used as received. MeOH and CH2Cl2 were HiPerSolv grade, EtOH was
AnalaR grade, and Et2O, EtOAc, and petroleum ether 40-60 (referred
to as PE) were GPR grade. n-Hexane and i-PrOH for analytical???high-performance liquid chromatography (HPLC) were HPLC grade
and used as received.
Experimental techniques. Reactions were carried out in oven-dried
glassware under an inert atmosphere of nitrogen, unless otherwise
stated. Air and moisture-sensitive reagents were transferred by syringe.
Reaction temperatures other than room temperature were recorded as
aluminum alloy heating block, or bath temperatures. Concentrated under
reduced pressure refers to rotary evaporation. Brine refers to a saturated
aqueous solution of NaCl. Column chromatography was performed on sil-
ica gel, particle size 40-63 mm unless otherwise stated. Chiral HPLC was
performed on CHIRALCEL OJ or CHIRALPAK AD columns detecting
at 284 nm. Retention times (tR) are reported inminutes. Analytical thin-layer
chromatography (TLC) was performed on Kieselgel 60 F254 precoated alu-
minum-backed plates visualized by ultraviolet light (350 nm) and/or chem-
ical staining using potassium permanganate solution. Silver nitrate-doped
silica gel was obtained after slurrying silica in aqueous AgNO3 solution
(0.1 M, 4 mLg-1 silica) and concentrating under reduced pressure
azeotroping with toluene until dryness.
Characterization. Fourier transform IR spectra were recorded neat
using an ATR-IR spectrometer. 1H, 13C and 19F NMR spectra were
recorded on Brüker AV400 and AV500 spectrometers at 400 MHz and
500 MHz, and 100 MHz and 125 MHz, and 377 (AV500 only) MHz, re-
spectively. Chemical shifts (d) are quoted in parts per million (ppm)
and are referenced to the residual solvent resonance. Coupling constants
(J) are quoted in Hertz (Hz). Low-resolution mass spectroscopy (MS) (EI,
CI), gas chromatography MS (GCMS), and high-resolution MS (HRMS)
were recorded by the Imperial College Department of Chemistry Mass
Spectrometry Service.
(E)-1-(4,8-Dimethylnona-3,7-dienyl)-4-methoxybenzene (1). Pre-
pared according to a modiﬁed procedure of Snyder and Treitler.49 To a
stirred solution of geraniol (23 mL, 133 mmol) and pyridine (32 mL, 398
mmol) in diethyl ether (80 mL) at –15 C was added diethyl
chlorophosphate (29 mL, 199 mmol) and the mixture was allowed to
warm to room temperature over 5 h. The reaction mixture was quenched
with 1M aqueous HCl solution (250 mL), extracted with ethyl acetate
(2 250 mL), washed with saturated aqueous NaHCO3 solution
(2 250mL), brine (250 mL), dried over Na2SO4 and concentrated under
reduced pressure to give geranyl diethyl phosphate as a colorless oil
(46 g) which was used directly without puriﬁcation. To magnesium turn-
ings (7.6 g, 318 mmol) stirred in anhydrous THF (200 mL) was added a
portion of 4-methoxybenzyl chloride (2.0 mL, 15 mmol), where the
reaction could be started by gentle heating. Subsequently, a solution of
4-methoxybenzyl chloride (19.5 mL, 144 mmol) in anhydrous THF
(200 mL) was added dropwise over 1 h at such a rate as to maintain reﬂux.
After complete addition, reﬂux was continued for 2 h. The reaction mix-
ture was cooled to -40 C and added dropwise via cannula to a stirred so-
lution of geranyl diethyl phosphate (23 g, 80 mmol) in anhydrous THF
(250 mL) at -40 C and allowed to warm to room temperature over 16 h.
The reaction mixture was quenched with saturated aqueous NH4Cl solu-
tion (300 mL), extracted with diethyl ether (2 300 mL), washed with sat-
urated aqueous NaHCO3 solution (300 mL), brine (300 mL), dried over
Na2SO4, concentrated under reduced pressure, and chromatographed
(0:1-1:3 CH2Cl2:PE) to afford the title compound 1 as a mixture of consti-
tutional isomers with branched diene 1a in 19:1 ratio (12.7 g, 49 mmol,
61%) as a colorless oil. A second run on the same scale afforded the title
product 1 as a mixture of constitutional isomers with 1a in ratio 35:1
(14.0 g, 54 mmol, 68%). The purity of 1 could be increased to >98% by
fractional distillation of the combined diene mixtures (27 g, 26:1 1:1a).
Distillation (200 ˚C, 0.003 mmHg) collecting the fraction at 70 ˚C was
enriched in branched isomer 1a and the distillation residue was linear
diene 1 (8.2 g, 32 mmol). Diene 1: Rf = 0.35 (15% CH2Cl2 in PE); IR nmax
2919, 2854, 1612, 1584 cm-1; 1H NMR (400 MHz, CDCl3) d 7.17 (d, J = 8.5
Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 5.24 (t, J = 7.1 Hz, 1H), 5.19-5.13 (m, 1H),
3.82 (s, 3H), 2.60 (t, J= 7.8 Hz, 2H), 2.34 (q, J = 8.5 Hz, 2H), 2.17-2.02 (m, 4H),
1.75 (s, 3H), 1.67 (s, 3H), 1.62 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3)
d 157.7, 135.7, 134.6, 131.3, 129.4, 124.4, 123.7, 113.7, 55.3, 39.8, 35.3, 30.2,Chirality DOI 10.1002/chir
BRADDOCK ET AL.69426.8, 25.7, 17.7, 16.0 ppm;MS (CI+)m/z 276 [M+NH4]
+; HRMS (CI+) calcd.
for C18H27O [M+H]
+ 259.2062. Found: 259.2050. An analytically pure sam-
ple of branched diene 1a could be obtained after silver nitrate-doped silica
gel chromatography (0:1-3:7 Et2O:PE).
(E)-1-(2,6-Dimethyl-2-vinylhept-5-enyl)-4-methoxybenzene (1a).
Rf = 0.35 (15% CH2Cl2 in PE); IR nmax 2920, 2854, 1612 cm
-1; 1H NMR
(400 MHz, CDCl3) d 7.03 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.7 Hz, 2H),
5.76 (dd, J = 17.6, 10.8 Hz, 1H), 5.10-5.05 (m, 1H), 5.00 (dd, J = 10.8, 1.4
Hz, 1H), 4.82 (dd, J = 17.6, 1.4 Hz, 1H), 3.79 (s, 3H), 2.54 (m, 2H), 1.91
(q, J = 8.0 Hz, 2H), 1.67 (s, 3H), 1.58 (s, 3H), 1.37-1.25 (m, 2H), 0.94
(s, 3H) ppm; 13C NMR (100 MHz, CDCl3) d 157.8, 146.6, 131.6, 131.0,
130.6, 125.0, 112.9, 112.1, 55.2, 47.2, 40.8, 40.4, 25.7, 23.1, 21.9, 17.6
ppm; MS (CI+) m/z 276 [M+NH4]
+; HRMS (CI+) calcd. for C18H30NO
[M+NH4]
+ 276.2327. Found: 276.2328.
(2R*,4aR*,10aS*)-2-Bromo-6-methoxy-1,1,4a-trimethyl-
1,2,3,4,4a,9,10,10a-octahydrophenanthrene (2R*,4aR*,10aS*)-
(2) by direct brominative cyclization of polyene 1 with BDSB. Bro-
mide (2R*,4aR*,10aS*)-2 was prepared by direct brominative cyclization
of diene 1 using the method of Snyder and Treitler.49 To a stirred solution
of alkene 1 (100 mg, 0.39 mmol) in CH3NO2 (6 mL) at -25 C was added
quickly a solution of BDSB (213 mg, 0.39 mmol) in CH3NO2 (2 mL) and
stirred for 5 min. The reaction mixture was quenched with a 1:1 mixture
of 5% aqueous NaHCO3 and 5% aqueous Na2SO3 solution (20 mL) and
stirred for 15 min before being poured into water (20 mL), extracted with
CH2Cl2 (2 20 mL), dried over Na2SO4, concentrated under reduced pres-
sure, and chromatographed (PE) to afford bromide (2R*,4aR*,10aS*)-2
(88 mg, 68%) as a white solid: m.p. 86-87 ˚C. Rf = 0.64 (40:60 CH2Cl2:PE);
IR nmax 2933, 2851, 1611 cm
-1; 1H NMR (400 MHz, CDCl3) d 7.00
(d, J = 8.3 Hz, 1H,), 6.77 (d, J = 2.8 Hz, 1H), 6.71 (dd, J = 8.3, 2.8 Hz, 1H),
4.07 (dd, J = 12.5, 4.1 Hz, 1H), 3.80 (s, 3H), 2.98-2.76 (m, 2H) 2.48-2.23
(m, 3H), 1.98 (ddt, J= 13.4, 7.0, 2.2 Hz, 1H), 1.88-1.75 (m, 1H), 1.69-1.56
(m, 1H), 1.48 (dd, J = 12.1, 2.2 Hz, 1H), 1.27 (s, 3H), 1.18 (s, 3H), 1.09
(s, 3H) ppm; 13C NMR (100 MHz, CDCl3) d 157.8, 150.0, 129.9, 127.0,
111.2, 110.2, 68.8, 55.3, 51.3, 40.1, 39.9, 38.1, 31.6, 30.6, 30.0, 24.8, 20.8,
18.3 ppm; MS (CI+, NH3) m/z 354, 356 [M+NH4]
+; HRMS (CI+, NH3)
calcd. for C18H29NO
79Br [M+NH4]
+ 354.1433, found 354.1433. HPLC
(CHIRALPAK AD; 1% IPA in n-hexane; 1.0 mL/min) tR = 4.9 min, 5.7 min.
(+)-(R,E)-9-(4-Methoxyphenyl)-2,6-dimethylnon-6-ene-2,3-diol
(3). According to the method of Sharpless,71 to a stirred solution of
AD-mix b (22.3 g, 1.4 gmmol-1) and methanesulphonamide (1.5 g,
16 mmol) in water (40 mL) and tert-butanol (40 mL) at 0 C was added
alkene 1 (4.1 g, 16 mmol). The reaction mixture was stirred vigorously
for 16 h, quenched with saturated aqueous sodium sulﬁte solution
(50 mL), extracted with EtOAc (2 100 mL), washed with brine
(100 mL), dried over Na2SO4, concentrated under reduced pressure,
and chromatographed (1:1-3:2 EtOAc:PE) to afford ﬁrst unreacted diene
1 (1.64 g, 6.3 mmol, 40%), the title product 3 (1.16 g, 4.3 mmol, 27%, 67%
based on recovered starting material) as a colorless oil, and tetraol 3a
(1.27 g, 3.9 mmol, 24%) as a white solid. Diol 3: Rf = 0.42 (1:1 EtOAc:
PE); [a]D
24 = +12.3 (c 1.9, CH2Cl2); IR nmax 3600-3100, 2931, 2858, cm
-1;
1H NMR (400 MHz, CDCl3) d 7.13 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6
Hz, 2H), 5.26 (br t, J = 7.1 Hz, 1H), 3.81 (s, 3H), 3.32 (dd, J = 10.5. 2.0
Hz, 1H), 2.63 (t, J = 7.6 Hz, 2H), 2.38-2.19 (m, 3H), 2.15-2.01 (m, 3H),
1.64-1.55 (m, 1H) 1.60 (s, 3H), 1.44 (m, 1H), 1.21 (s, 3H), 1.18 (s, 3H)
ppm; 13C NMR (100 MHz, CDCl3) d 157.7, 135.5, 134.4, 129.4, 124.5,
113.7, 78.1, 73.0, 55.3, 36.7, 35.1, 30.1, 29.6, 26.4, 23.2, 15.9 ppm; MS
(CI+, NH3) m/z 310 [M+NH4]
+; HRMS (CI+, NH3) calcd. for
C18H32NO3 [M+NH4]
+ 310.2382. Found: 310.2384; HPLC (CHIRALCEL
OJ; 10% IPA in n-hexane; 1.0 mL/min) tR = 16.2 min (major), 18.2 min
(minor) – e.r. 99:1. In a run using AD - mix a, (S)-diol ent-3 was obtained:
[a]D
24 = - 5.9 (c 1.0, CH2Cl2); HPLC (CHIRALCEL OJ; 10% IPA in n-hexane;
1.0 mL/min) tR = 15.9 min (minor), 17.1 min (major) – e.r. 6:94.
(+)-(3R,6R,7R)-2,6-Dimethyl-9-(4-methoxyphenyl)nonane-2,3,6,7-
tetraol (3a). m.p. 130-131˚C. [a]D
24 = +20.0 (c 1.0, EtOH); Rf = 0.28 (1:1
EtOH:PE); IR nmax 3600-3100, 2972, 2952 cm
-1; 1H NMR (400MHz, CDCl3)
d 7.16 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 3.81 (s, 3H), 3.41 (d, J = 9.6
Chirality DOI 10.1002/chir
???Hz, 1H), 3.30 (d, J = 9.6 Hz, 1H), 3.29 (br s, 2H), 2.90 (ddd, J = 13.8, 8.8, 4.9
Hz, 1H), 2.65 (dt, J = 13.7, 8.2 Hz, 1H), 2.53 (br s, 1H), 2.20 (br s, 1H), 1.81-
1.56 (m, 5H), 1.48-1.37 (m, 1H), 1.21 (s, 3H), 1.17 (s, 3H), 1.13 (s, 3H) ppm;
13C NMR (100 MHz, CDCl3) d 157.8, 134.2, 129.4, 113.9, 78.9, 74.6,
73.2, 55.3, 50.7, 35.6, 33.6, 31.9, 26.5, 25.0, 23.3, 20.6 ppm; MS (CI+, NH3)
m/z 344 [M+NH4]
+; HRMS (CI+, NH3) calcd. for C18H31O5 [M+H]
+
327.2171. Found: 327.2164. A reference sample of ()-diol 3 was prepared
following a modiﬁed procedure of Warren and colleagues.72 To a solution
of potassium ferricyanide (383 mg, 1.16 mmol), potassium carbonate
(161 mg, 1.16 mmol), K2OsO4.2H2O (4 mg, 0.012 mmol), quinuclidine
(1 mg, 0.012 mmol), and methanesulphonamide (37 mg, 0.39 mmol) in
water (2.5 mL) and tert-butanol (2.5 mL) at 0 C was added oleﬁn 1
(100 mg, 0.39 mmol) and stirred vigorously for 2 h. The reaction mixture
was quenched with a saturated aqueous solution of sodium sulﬁte
(10 mL), extracted with EtOAc (2 20 mL), washed with brine (40 mL),
dried over Na2SO4, concentrated under reduced pressure, and
chromatographed (1:1-3:2 EtOAc:PE) to afford ()-diol 3 (21 mg, 19%) as
a colorless oil. HPLC (CHIRALCEL OJ; 10% IPA in n-hexane; 1.0 mL/min)
tR = 16.5 min, 17.8 min.
(-)-(S,E)-3-[-6-(4-Methoxyphenyl)-3-methylhex-3-enyl]-2,2-
dimethyloxirane (4). Using a modiﬁed procedure of Corey et al.,73 to a
stirred solution of (R)-diol 3 (840 mg, 2.88 mmol) and pyridine (0.46 mL,
5.75 mmol) in CH2Cl2 (15 mL) at 0 C was added methanesulphonyl chlo-
ride (0.29 mL, 3.72 mmol). After 0.5 h the mixture was allowed to warm to
room temperature and stirred for 3 h. Additional pyridine (1.38 mL
17.7 mmol) was added and the reaction mixture stirred for 16 h. The reac-
tion mixture was poured into a suspension of K2CO3 (6.63 g, 48 mmol) in
methanol (25 mL), stirred for 6 h, concentrated under reduced pressure,
diluted with water (50 mL), extracted with EtOAc (2 50mL), washed with
10% aqueous CuSO4 solution (100 mL), brine (100 mL), dried over Na2SO4,
concentrated under reduced pressure, and chromatographed (1:19-1:4
EtOAc:PE) to afford the title product (S)-4 (565 mg, 83%) as a colorless
oil: Rf = 0.34 (1:9 EtOAc:PE); [a]D
24 -2.5 (c 1.6, CH2Cl2); IR nmax 2958, 2925,
2835, 1612, 1586 cm-1; 1H NMR (400 MHz, CDCl3) d 7.13 (d, J = 8.6 Hz,
2H), 6.85 (d, J = 8.6 Hz, 2H), 5.26 (tq, J = 5.8, 1.5 Hz, 1H), 3.81 (s, 3H), 2.72
(app. t, J = 6.3 Hz, 1H), 2.62 (t, J = 7.5 Hz, 2H), 2.32 (app. q, J = 7.6 Hz, 2H),
2.24-2.06 (m, 2H), 1.78-1.62 (m, 2H), 1.61 (s, 3H) 1.33 (s, 3H) 1.29 (s, 3H)
ppm; 13C NMR (100 MHz, CDCl3) d 157.7, 134.8, 134.3, 129.3, 124.3,
113.7, 64.1, 58.3, 55.2, 36.3, 35.1, 30.2, 27.5, 24.9, 18.8, 16.0 ppm; MS (CI+,
NH3) m/z 292 [M+NH4]
+; HRMS (CI+, NH3) calcd. for C18H27O2 [M+H]
+
275.2011, found 275.2011.
(-)-(S,E)-2-Bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-6-en-3-ol
(5a) and (+)-(R,E)-3-bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-
6-en-2-ol (5b). Following the method of Couladouros and Vidali,67 to a
solution of (S)-epoxide 4 (200 mg, 0.73 mmol) in N-methyl-2-pyrrolidone
(0.22 mL) was added LiBr (99 mg, 0.95 mmol) and PPTS (183 mg,
0.73 mmol) and stirred at room temperature for 4 h. The reaction was
quenchedwith saturated aqueousNaHCO3 solution (15mL), extractedwith
EtOAc (2 15mL), washed with brine (30 mL), dried over Na2SO4, concen-
trated under reduced pressure, and chromatographed (1:9-1:4 EtOAc:PE)
to yield ﬁrst (E)-9-(4-methoxyphenyl)-2,6-dimethylnon-6-en-3-one (10 mg,
5%) as a colorless oil, second bromohydrin 5a (66 mg, 25%) as a colorless
oil, and third, bromohydrin 5b (119 mg, 46%) as a colorless oil.
Bromohydrin 5a: Rf = 0.32 (1:9 EtOAc:PE); [a]D
24 -10.6 (c 1.3, CH2Cl2); IR
nmax 3600-3200, 2958, 2926, 2855, 2835, 1612 cm
-1; 1H NMR (400 MHz,
CDCl3) d 7.14 (d, J = 8.6 Hz, 2H), 6.86 (d, J= 8.6 Hz, 2H), 5.27 (tq, J = 6.8,
1.4 Hz, 1H), 3.82 (s, 3H), 3.40 (dd, J= 10.1, 3.0 Hz, 1H), 2.63 (t, J = 7.5 Hz
2H), 2.37-2.25 (m, 3H), 2.17-2.05 (m, 2H), 1.82 (s, 3H), 1.81-1.72 (m, 1H),
1.75 (s, 3H), 1.59 (s, 3H), 1.49 (dddd, J = 14.0, 10.3, 8.8, 5.2 Hz, 1H) ppm;
13C NMR (100 MHz, CDCl3) d 157.7, 135.1, 134.4, 129.4, 124.6, 113.7,
79.0, 75.4, 55.3, 36.4, 35.1, 31.1, 30.1 (2), 28.9, 16.0 ppm; MS (CI+, NH3)
m/z 374, 372 [M+NH4]
+; HRMS (CI+, NH3) calcd. for C18H31NO2
79Br
[M+NH4]
+ 372.1538, found 372.1538. Bromohydrin 5b: Rf = 0.24 (1:9
EtOAc:PE); [a]D
24 +35.1 (c 1.3, CH2Cl2); IR nmax 3600-3250, 2925, 2854,
1612 cm-1; 1H NMR (400 MHz, CDCl3) d 7.13 (d, J= 8.6 Hz, 2H), 6.86
(d, J= 8.6 Hz, 2H), 5.29 (t, J= 7.3 Hz, 1H), 3.95 (dd, J= 11.6, 1.9 Hz, 1H),
3.82 (s, 3H), 2.63 (td, J= 7.4, 3.4 Hz, 2H), 2.39-2.27 (m, 3H), 2.24 (s, 1H),
{The concentration of this solution is very dilute and the absolute magni-
tude of this measurement is liable to a large error.
ENANTIOSPECIFIC BROMONIUM ION POLYENE CYCL. 6952.15 (dt, J = 14.9, 8.2 Hz, 1H), 1.97 (dtd, J = 16.2, 8.0, 1.8 Hz, 1H), 1.85-1.74
(m, 1H), 1.56 (s, 3H), 1.354 (s, 3H), 1.347 (s, 3H) ppm; 13C NMR
(100 MHz, CDCl3) d 157.7, 134.3, 133.7, 129.4, 125.5, 113.7, 72.5, 70.8,
55.3, 38.2, 35.1, 31.8, 30.2, 26.6, 25.9 15.8 ppm; MS (CI+, NH3) m/z 374,
372 [M+NH4]
+; HRMS (CI+, NH3) calcd. for C18H31NO2
79Br [M+NH4]
+
372.1538, found 372.1540.
(-)-(S,E)-2-Bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-6-en-3-yl
2,3,4,5-tetraﬂuorobenzoate (6a). Using the method of Neises and
Steglich,74 to a stirred solution of secondary alcohol 5a (380 mg,
1.07 mmol) in CH2Cl2 (7.5 mL) was added 2,3,4,5-tetraﬂuorobenzoic acid
(228 mg, 1.18 mmol), DMAP (39 mg, 0.321 mmol, 30 mol%) and DCC
(287 mg, 1.39 mmol). After 4 h the reaction mixture was ﬁltered through
a silica plug eluting with Et2O, concentrated under reduced pressure, and
chromatographed (0:1-3:17 Et2O:PE) to afford bromo tetraﬂuorobenzoate
6a (520 mg, 92%) as a colorless oil. Rf = 0.34 (5:95 EtOAc:PE);
[a]D
24 -22.0 (c 1.1, CH2Cl2); IR nmax 2935, 2861, 2362, 2344, 1729 cm
-1;
1H NMR (400 MHz, CDCl3) d 7.69 (dddd, J=10.3, 8.3, 6.0, 2.4 Hz, 1H), 7.13
(d, J=8.5 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 5.27 (d, J=9.9 Hz 1H),
5.22 (t, J=7.0 Hz, 1H), 3.82 (s, 3H), 2.61 (app. t, J=7.7 Hz, 2H), 2.37-2.19
(m, 2H), 2.10-2.03 (m, 3H) 1.99-1.85 (m, 1H), 1.83 (s, 3H), 1.82 (s, 3H)
1.58 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) d 161.5, 157.7, 148.0 (dddd,
J= 262, 11, 3, 1 Hz), 146.6 (dddd, J = 249, 10, 4, 2 Hz), 143.6 (dddd, J = 262, 17,
13, 3 Hz), 141.4 (dddd, J = 255, 17, 12, 3 Hz) 134.3, 134.0, 129.4, 125.1, 114.7
(m), 113.7, 113.4 (dd, J = 21, 3 Hz), 81.5, 65.8, 55.2, 36.0, 35.0, 30.44, 30.35,
30.15, 29.3, 15.9 ppm; 19F NMR (377 MHz, CDCl3) d -153.1 (t, J = 20 Hz,
1F), -147.0 (m, 1F), -137.6 (m, 1F), -133.6 (m, 1F) ppm; MS (CI+, NH3)
m/z 548, 546 [M+NH4]
+; HRMS (EI+) calcd. for C25H27O3
79BrF4 [M]
+
530.1080, found 530.1080.
(+)-(R,E)-3-Bromo-9-(4-methoxyphenyl)-2,6-dimethylnon-6-en-2-yl
2,3,4,5-tetraﬂuorobenzoate (6b). Using the method of Neises and
Steglich,74 to a stirred solution of tertiary alcohol 5b (350 mg, 0.99 mmol)
in CH2Cl2 (7.5 mL) was added 2,3,4,5-tetraﬂuorobenzoic acid
(383 mg, 1.97 mmol), DMAP (36 mg, 0.30 mmol, 30 mol%), and DCC
(610 mg, 2.96 mmol). After 16 h further 2,3,4,5-tetraﬂuorobenzoic acid
(191 mg, 0.98 mmol), DMAP (36 mg, 0.30 mmol, 30 mol%), and DCC (305
mg, 1.48 mmol) was added and stirred for 5 h, passed through a plug of sil-
ica, and chromatographed (0:1-2:3 CH2Cl2:PE) to afford tetraﬂuorobenzoate
ester 6b (316 mg, 60%) as a colorless oil. Rf = 0.3 (5:95 EtOAc:PE); [a]D
24
+14.4 (c 1.4, CH2Cl2); IR nmax 2931, 2858, 2362, 1719 cm
-1; 1H NMR
(400 MHz, CDCl3) d 7.66-7.56 (m, 1H), 7.15 (d, J = 8.6 Hz, 2H), 6.85
(d, J = 8.6 Hz, 2H), 5.34 (t, 6.80 Hz, 1H), 4.54 (dd, J = 11.5, 1.9 Hz, 1H), 3.81
(s, 3H), 2.66 (t, J = 7.6 Hz, 2H), 2.44-2.26 (m, 3H) 2.21 (dt, J= 13.8, 8.0 Hz,
1H), 2.09-2.00 (m, 1H) 1.94-1.85 (m, 1H) 1.79 (s, 3H), 1.76 (s, 3H), 1.60
(s, 3H) ppm; 13C NMR (125 MHz, CDCl3) d 160.5, 157.7, 147.8 (dddd,
J= 262, 11, 4, 2 Hz), 146.4 (dddd, J= 249, 10, 4, 2 Hz), 143.4 (dddd, J = 262,
17, 13, 3 Hz), 141.3 (dddd, J = 255, 17, 12, 3 Hz), 134.3, 133.6, 129.3, 125.7,
116.0 (m), 113.6, 113.2 (dd, J= 21, 2 Hz), 86.2, 61.6, 55.2, 37.8, 35.0, 31.5,
30.2, 24.1, 23.3, 15.8 ppm; 19F NMR (377 MHz, CDCl3) d -153.5 (t, J= 20
Hz, 1F), -147.7 (tt, J= 19, 8 Hz, 1F), -138.0 (dt, J= 22, 12 Hz, 1F), -134.5
(m, 1F) ppm; MS (CI+, NH3) m/z 548, 546 [M+NH4]
+; HRMS (EI+) calcd.
for C25H27NO3
79BrF4 [M]
+ 530.1080, found 530.1082.
(-)-(2R,4aR,10aS)- and (-)-(2R,4aS,10aR)-2-Bromo-6-methoxy-
1,1,4a-trimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrenes (2)
from cyclization of bromotetraﬂuorobenzoates 6a and 6b. Cyclization
of tertiary bromide 6a: To a stirred solution of Me3Al (2M in hexanes,
0.25 mL, 0.5 mmol) in CH2Cl2 (2 mL) at –78 C was added a solution
of triﬂuoromethanesulphonic acid (43 mL, 0.5 mmol) in CH2Cl2 (4 mL)
and stirred at –78 C for 0.5 h and 0 C for 0.5 h. The white suspension
of Me2AlOTf was recooled to –78 ˚C and a solution of bromo
tetraﬂuorobenzoate 6a (50 mg, 0.292 mmol) in CH2Cl2 (2 mL) was added
dropwise at –78 C. The reaction was allowed to warm to room temperature
over 16 h, quenchedwith aqueousHCl solution (1M, 10mL), extracted with
CH2Cl2 (2 10 mL), washed with saturated aqueous NaHCO3 solution
(10mL) and brine (10mL), dried overNa2SO4, concentrated under reduced
pressure, and chromatographed (0:1-3:7 CH2Cl2:PE) to afford ﬁrst
monocycles 7 as an inseparable mixture of at least two endocyclic and???two exocyclic alkenes (6 mg, 19%) as a colorless oil, Rf = 0.39 (1:4 CH2Cl2:
PE), and second bromides (2R,4aR,10aS)-2 and (2R,4aS,10aR)-2 as an in-
separable mixture of diastereoisomers (d.r. 3:1, 8 mg, 25%) as a white solid:
m.p. 92-93 ˚C; Rf = 0.64 (40:60 CH2Cl2:PE). The major diastereoisomer
(2R,4aR,10aS)-2 was identical to that produced in the BDSB mediated
cyclization of polyene 1, and the minor diastereoisomer (2R,4aS,10aR)-2
was identiﬁed in the mixture by its characteristic 1H NMR signal at 4.42
(1H, CHBr) ppm as a broad singlet (see SI 11 for 1H and 13C NMR spectra).
Data for (2R,4aS,10aR)-2 [as 1:3 mixture with bromide (2R,4aR,10aS)-2]: 1H
NMR (400 MHz; CDCl3) d 7.01 (d, J=8.3 Hz, 1H,), 6.84 (d, J=2.8 Hz, 1H),
6.71 (dd, J=8.3, 2.8 Hz, 1H), 4.42 (br s, 1H), 3.81 (s, 3H), 2.94-2.75 (m, 2H),
2.42-2.38 (m, 1H), 2.21-2.06 (m, 3H), 1.89 (dd, J=12.4, 2.5 Hz, 1H), 1.82-1.67
(m, 2H), 1.22 (s, 3H), 1.12 (s, 6H) ppm; 13C NMR (100 MHz, CDCl3)
d 157.8, 150.5, 129.8, 127.1, 111.0, 110.0, 69.1, 55.3, 43.5, 38.4, 37.8, 33.4,
32.9, 29.1, 28.7, 25.5, 22.2, 18.5 ppm; GCMS (EI+) m/z 337, 335 [M -H]+.
The diastereoisomers were inseparable by standard column chromatog-
raphy on silica gel, but could be separated by preparative HPLC (Prep Si;
n-hexane; 5 mL/min) tR = 145 min [(2R,4aS,10aR)-2], 165 min
[(2R,4aR,10aS)-2]. Bromide (2R,4aR,10aS)-2: [a]D
24 -100 (c 0.04, CH2Cl2)
{;
HPLC (CHIRALPAK AD; 1% IPA in n-hexane; 1.0 mL/min) tR = 4.7
min (minor), 5.4 min (major), e.r. 98:2. Bromide (2R,4aS,10aR)-2: [a]D
24 -43
(c 0.01, CH2Cl2)
{; HPLC (CHIRALPAK AD; 1% IPA in n-hexane;
1.0 mL/min) tR = 4.7 min (major), 6.1 min (minor), e.r. 98:2. Cyclization
of secondary bromide 6b (135 mg, 0.254 mmol) was conducted as above
using 2.5 equivalents of Me2AlOTf to afford ﬁrst monocycles 7 as an
inseparable mixture of at least two endocyclic and two exocyclic alkenes
(21 mg, 25%) as a colorless oil, Rf = 0.39 (1:4 CH2Cl2:PE), and second
bromides (2R,4aR,10aS)-2 and (2R,4aS,10aR)-2 as an inseparable
mixture of diastereoisomers (d.r. 3:1, 30 mg, 35%) as a white solid. The
diastereomers were separated by preparative HPLC (Prep Si; n-hexane;
5 mL/min) tR = 145 min and [(2R,4aS,10aR)-2] and 165 min
[(2R,4aR,10aS)-2]. Bromide (2R,4aR,10aS)-2: HPLC (CHIRALPAK AD; 1%
IPA in n-hexane; 1.0 mL/min) tR = 4.7 min (minor), 5.4 min (major), e.r.
98:2. Bromide (2R,4aS,10aR)-2: HPLC (CHIRALPAKAD; 1% IPA in n-hexane;
1.0 mL/min) tR=4.7 min (major), 6.1 min (minor), e.r. 98:2.
(-)-(4aS,10aS)- and (+)-(4aS,10aS)-6-methoxy-1,1,4a-trimethyl-
1,2,3,4,4a,9,10,10a -octahydrophenanthrenes (8) from reduction
of a 3:1 mixture of (-)-(2R,4aR,10aS)- and (-)-(2R,4aS,10aR)-
2-Bromo-6-methoxy-1,1,4a-tr imethyl -1,2,3,4,4a,9,10,
10a-octahydrophenanthrenes (2). Using the method of Chatgilialoglu
and colleagues,75 to a stirred solution of (2R,4aR,10aS)-2 and
(2R,4aS,10aR)-2 (d.r. 3:1, 15 mg, 45 mmol) in toluene (2 mL) was added
tris(trimethylsilyl)silane (16.5 mL, 53 mmol) and azobisisobutyronitrile
(0.73 mg, 40 mmol) and heated to 90 C for 2 h. The mixture was allowed
to cool, concentrated under reduced pressure, and chromatographed
(0:1-3:7 CH2Cl2:PE) to give trans-decalin 8 (5 mg, 43%) as a single diastereo-
isomer as a colorless oil. Rf = 0.42 (20:80 CH2Cl2:PE); [a]D
24 -23.0 (c 0.26,
CH2Cl2); lit.
76 (4aS,10aS)-8 [a]D +64.0 (c 1.0, CHCl3); IR nmax 2997, 2924,
2852, 1686, 1609 cm-1; 1H NMR (500 MHz, CDCl3) d 6.96 (d, J = 8.3 Hz,
1H), 6.81 (d, J = 2.7 Hz, 1H), 6.66 (dd, J= 8.3, 2.7 Hz, 1H), 3.78 (s, 3H), 2.88
(ddd, J = 16.8, 6.9, 1.3 Hz, 1H), 2.78 (ddd, J= 16.8, 11.2, 7.4 Hz, 1H), 2.24
(br d, J = 12.6 Hz, 1H), 1.86 (dddd, J = 13.3, 7.5, 2.0, 2.0 Hz, 1H), 1.80-1.57
(m, 3H), 1.48 (br d, J = 13.2 Hz, 1H), 1.41 (td, J = 13.1, 3.7 Hz, 1H), 1.32
(dd, J = 12.5, 2.3 Hz, 1H), 1.23 (dd, J= 13.7, 4.0 Hz, 1H), 1.21 (s, 3H), 0.97
(s, 3H), 0.95 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) d 157.6, 151.5,
129.7, 127.5, 110.7, 110.2, 55.3, 50.3, 41.7, 38.8, 38.0, 33.5, 33.3, 29.6, 24.8,
21.7, 19.3, 19.1 ppm; MS (CI+, NH3) m/z 259 [M+H]
+; HRMS (CI+, NH3)
calcd. for C18H27O [M+H]
+ 259.2062, found 259.2071. HPLC (CHIRALPAK
AD; 1% IPA in n-hexane; 1.0 mL/min) tR = 4.12 min [(4aS,10aS)-8],
4.72 min [(4aR,10aR)-8], e.r. 25:75.
RESULTS AND DISCUSSION
Polyene 149 (Fig. 3) was selected as the basic carbon
framework for our investigations, with the enantiopureChirality DOI 10.1002/chir
Fig. 3. Polyene 1 and isomer 1a.
Fig. 4. The crystal structure of (2R*,4aR*,10aS*)-2. Crystallographic data
for the structure reported in this paper have been deposited with the Cam-
bridge Crystallographic Data Centre (CCDC 928846.). Copies of the data
can be obtained, free of charge, on application to the Director, CCDC, 12
Union Road, Cambridge CB2 1EZ, United Kingdom (Fax: 44-1223-336033 or
e-mail: deposit@ccdc.cam.ac.uk).
Scheme 2. Asymmetric dihydroxylation of diene 1.
Scheme 1. BDSB mediated cyclization of polyene 1 into racemic tricyclic
bromide (2R*,4aR*,10aS*)-2.
BRADDOCK ET AL.696bromonium ion to be formed on the terminus alkene, the sec-
ond, internal alkene acting as the propagating oleﬁn, and the
polyene cyclization to be terminated by the aromatic nucleus.
Diene 1 could be prepared by the palladium(0) catalyzed cou-
pling of p-methoxybenzyl magnesium chloride with geranyl
bromide,77 but in our hands variable and signiﬁcant quanti-
ties of the inseparable branched regioisomer 1a were also
observed.} The noncatalyzed coupling of the same Grignard
reagent with geranyl diethyl phosphate as described by
Synder49 gave signiﬁcantly improved regioselectivity.} The
direct action of BDSB on diene 1 as described by Synder49
gave racemic tricyclic bromide (2R*,4aR*,10aS*)-2
(Scheme 1) in good yield as a single diastereoisomer, which
in our hands proved to be crystalline. Single crystal x-ray de-
termination (Fig. 4) of tricyclic bromide (2R*,4aR*,10aS*)-2
conﬁrms the formation of the two six-membered carbocyclic
rings as a trans-fused decalin ring system, and also the equa-
torial positioning of the bromine atom.
To the end of generating enantiopure bromohydrins,69–78
high purity diene 1** was ﬁrst dihydroxylated using AD-
mix b71 in good regioselectivity to give diol (R)-3, in excellent}In multiple runs the ratio of 1:1a was found to vary unpredictably from
35:1 to 10:1. The two isomers could not be separated by simple column
chromatography.
}In two 80 mmol batch reactions, the ratio of 1:1a was determined to be
19:1 and 35:1. Analytically pure 1a could be obtained from silver nitrate-
doped silica gel column chromatography. The purity of 1 could be im-
proved to >98% by a fractional distillation process (see Experimental).
**High purity diene 1 free from branched 1a was found to be essential for
subsequent HPLC enantiomeric excess determination of products. The
branched isomers were inseparable at all stages of the subsequent syn-
thesis and overlapped and/or obscured the minor and/or major enantio-
mer signal in the HPLC analyses. This was especially problematic since
the asymmetric dihydroxylation of diene 1 is so highly enantioselective
(99:1 e.r.), and therefore high purity was required for accurate ee assess-
ment. Moreover, in dihydroxylation runs using lower purity diene 1, the
branched isomer actually accumulated (e.g., in multiple runs using dienes
1:1a in a 13:1 ratio, the ratio of linear diol 3 to its inseparable branched
diol counterpart was 5:1). Evidently, while 3 could be further
dihydroxylated to tetraol 3a thus depleting the amount of 3, the terminal
alkene of the branched isomer diol was more resistant to further
dihydroxylation.
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???enantioselectivity (R)-3; e.r. 99:1)†† along with unavoidable
formation of tetraol (3R,6R,7R)-3a (Scheme 2). The absolute
conﬁguration of diol (R)-3 was assigned on the basis of the
Sharpless mnemonic.71,79 Diol (R)-3 was converted stereo-
speciﬁcally into epoxide (S)-4 by the Corey et al. method,73
followed by stereospeciﬁc (but non-regioselective) epoxide
ring-opening by bromide anion55 providing the separable
regioisomeric bromohydrins (S)-5a and (R)-5b (Scheme 3).
The regioisomeric bromohydrins (S)-5a and (R)-5b were
assigned on the basis of their distinctive chemical shifts at
3.40 and 3.95 ppm in their 1H NMR spectra, respectively,
where two regioisomeric bromohydrins of a trisubstituted
alkene were previously distinguished unambiguously by bro-
mide induced 13C isotopic shifts.69
In our previous work with non-alkene-containing sub-
strates,69 and on the basis of an earlier observation where
we had observed the spontaneous formation of a bromonium
ion from a 1-bromo-2-tetraﬂuorobenzoate on standing,80
enantiopure bromonium ions had been generated by
ﬁrst converting enantiopure bromohydrins into 2,3,4,5-
tetraﬂuorobenzoates, followed by activation with catalytic
amounts of triﬂic acid. While we were conﬁdent that the cor-
responding tetraﬂuorobenzoates of bromohydrins (S)-5a and
(R)-5b could be synthesized, the presence of the acid-sensi-
tive trisubstituted alkenes in these substrates would render
the use of triﬂic acid to subsequently generate bromonium
ions undoubtedly problematic. Nevertheless, knowing that a
suitable Lewis acid should offer an alternative activation
mode, tetraﬂuorobenzoates (S)-6a (92%) and (R)-6b (60%)
(Fig. 5) were prepared from alcohols (S)-5a and (R)-5b,
respectively, by Steglich esteriﬁcation74 with 2,3,4,5-
tetraﬂuorobenzoic acid. On activation—and stereospeciﬁc††The enantiomeric purity was assayed by chiral HPLC methods (see
Supporting Information).
†††The two diastereoisomers were not separable by column chromatogra-
phy, but could be separated by preparative HPLC. This enabled the enan-
tiomeric purity of each to be established without interference from the
other (see Supporting Information).
{{{A mixture of inseparable monocyclisation adducts 7 could be isolated
by column chromatography after cyclization. Inspection of the alkene re-
gion of the 1H NMR spectrum reveals two monocycles with exocyclic
methylene groups [dH 5.03 (s, 1H), 4.79 (s, 1H), and 4.90 (s, 1H), 4.17
(s, 1H) in a 3:1 ratio respectively] and two monocycles with endocyclic tri-
substituted alkenes [dH 5.27 (br s, 1H), and 5.20 (br s, 1H) in a 3:1 ratio,
respectively]. The endocyclic:exocyclic alkenes ratio is 1.5:1.
}}}Attempts to convert the isolated monocyclic alkene mixture 7 into tricy-
clic adducts 2 with chlorosulphonic acid in nitromethane as previously
Scheme 3. Synthesis of enantiopure bromohydrins (S)-5a and (R)-5b.
ENANTIOSPECIFIC BROMONIUM ION POLYENE CYCL. 697displacement of the activated leaving group by neighboring
group participation of the bromide—each of (S)-6a and (R)-6b
should re-converge on the same R-conﬁgured enantiomerically
pure bromonium ion A (Fig. 5).
Attempted bromonium ion initiated cyclization of (S)-6a or
(R)-6b with catalytic quantities of triﬂic acid,69 led, as pre-
dicted (vide supra), to extensive decomposition, and previous
attempts to generate bromonium ions from vicinal bromo
tetraﬂuorobenzoates of trisubstituted alkenes by solvolysis
were unsuccessful69 and not pursued in this study. Lewis acid
activation was then explored, where the use of alkyl alumi-
num reagents as Lewis acids that lead to rigorously proton-
free solutions81 was expected to be beneﬁcial (oxophilic
Lewis acid metal halides were rejected as potential mediators
of the cyclization on the basis that hydrohalic acids would be
generated during the course of the reaction), and preliminary
studies with stoichiometric quantities of Yb(OTf)3 and/or Eu
(fod)3 in CH2Cl2 or chlorobenzene were ineffective in initiat-
ing the cyclization even at elevated temperatures and/or
under microwave irradiation. The use of stoichiometric quan-
tities of trimethylaluminum to mediate the cyclization was
found to be ineffective, leading to decomposition of both of
the substrates (S)-6a or (R)-6b. Some cyclization adduct
was observed using dimethylaluminum chloride as the Lewis
acid activator, but a bromochloride was also observed as
the major product, where intermolecular attack of any
incipient bromonium ion by anionic chloride from the
Lewis acid is evidently competing.{{ The use of the Lewis
acid dimethylaluminum triﬂate, incorporating the non-
nucleophilic triﬂate anion—ﬁrst reported in the 1980s82 and
only infrequently employed83—on either bromide (S)-6a
(5 eq. Me2AlOTf)}} or (R)-6b (2.5 eq. Me2AlOTf)}} led to
clean and complete conversion of substrates into cyclization
adducts (Scheme 4).}} *** In both cases, enantiopure bromide{{From a run using 131 mg of a mixture of 6a and 6b (1:2) 9 mg of cycli-
zation adducts 2 (d.r. 3:1) were isolated after extensive column chroma-
tography. A noncyclized bromochloride (24 mg) was obtained with a
characteristic mass spectrometry isotope pattern of 390 (82%), 392
(100%), 394 (49%) (M+NH4)
+ .
}}The use of less equivalents of Me2AlOTf led to incomplete consumption
of starting tetraﬂuorobenzoates. Evidently the 2˚ benzoate 6a is less read-
ily activated than the 3˚ benzoate 6b.
}}The use of MeAl(OTf)2 as prepared from Me3Al and 2TfOH in CH2Cl2
led to decomposition of the substrates.
***Inspection of the 1H NMR spectrum of the crude reaction mixtures
show that all starting material has cleanly been converted to product.
The relatively low isolated yields (scheme 4) reﬂect the difﬁcult chro-
matographic puriﬁcation/separation of these non-polar compounds.
???(2R,4aR,10aS)-2 (e.r. 98:2)†† was provided as a 3:1 mixture
with diastereomeric enantiopure bromide (2R,4aS,10aR)-2
(e.r. 98:2),††,††† along with monocyclization adducts 7.,{{{ }}}
The relative conﬁguration of (2R,4aR,10aS)-2 had already
been established by x-ray crystallography (Fig. 4) from
direct BDSB mediated cyclization of polyene 1 (Scheme 1),
and the assignment of absolute conﬁguration follows from
an R-conﬁgured bromonium ion. The relative conﬁguration
of (2R,4aS,10aR)-2 was established by (Me3Si)3SiH mediated
dehalogenation of a 3:1 mixture of (2R,4aR,10aS)-2 and
(2R,4aS,10aR)-2 diastereomers with essentially quantitative
conversion (43% isolated yield) to give a single diastereomeric
trans-decalin 8 (Scheme 5). The observed 3:1 e.r. for trans-
decalin 8 allows assignment of the absolute conﬁgurations
as (4aR,10aR)-8 and (4aS,10aS)-8 from (2R,4aR,10aS)-2 and
(2R,4aS,10aR)-2, respectively. The absolute conﬁgurations
were conﬁrmed by comparison of the negative sign of optical
rotation for the 3:1 enantiomeric mixture of (4aR,10aR)-
8 and (4aS,10aS)-8 with the rotation already reported for
(+)-(4aS,10aS)-8.76
Evidently, the bromonium ion initiated cyclizations de-
scribed herein (Scheme 4) are proceeding enantiospeciﬁcally
via enantiomerically pure bromonium ions68,}}}**** without
problematic intramolecular or intermolecular bromonium
ion-to-alkene transfer.53 We invoke a chair-like conformation
C in the cyclization leading to (2R,4aR,10aS)-2, and a boat-like
conformation B in the cyclization leading to (2R,4aS,10aR)-2
(Fig. 6), each with the same absolute conﬁguration of the
bromonium ion (R-conﬁgured).}}}****CONCLUSION
In conclusion, we have demonstrated the ﬁrst
enantiospeciﬁc polyene cyclizations initiated by enantiopure
bromonium ions. We have identiﬁed the stoichiometric use
of dimethylaluminum triﬂate to activate tetraﬂuorobenzoates
of enantiopure bromohydrins to initiate such processes,
where other Lewis and Brönsted acids fail. Notably, underdemonstrated by Sakakura et al. (Ref. 10) in a similar system, led instead
to extensive decomposition.
}}}The exact structure of a “bromonium ion” of an alkene will depend
strongly on the substitution pattern of the alkene, the solvent, and its
counterion. It is understood that a cyclic bromonium ion and an open b-
bromocarbocation represent the two extremes of a spectrum of ionic in-
termediates that are possible.
****The enantiospeciﬁc cyclization of tertiary bromide (S)-6a requires the
intermediacy of an R-conﬁgured enantiomerically pure bromonium ion by
stereospeciﬁc NGP displacement of the tetraﬂuorobenzoate group,
whereas cyclization of secondary bromide (R)-6bmay proceed instead di-
rectly via a tertiary carbocation. The near identical product distributions
for each substrate as observed by inspection of the crude reaction mix-
tures by 1H NMR implicate a single common intermediate viz. a
bromonium ion.
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Scheme 4. Enantiospeciﬁc cyclization of tetraﬂuorobenzoates (S)-6a and
(R)-6b with stoichiometric dimethylaluminum triﬂate.
Scheme 5. Correlation of absolute and relative conﬁgurations by reduction
of a 3:1 diastereomeric bromide mixture 2 to trans-decalin 8.
Fig. 5. Tetraﬂuorobenzoates (S)-6a and (R)-6b as precursors to the same
enantiomerically pure bromonium ion A.
Fig. 6. Chair-like C and boat-like B geometries in the cyclizations leading
to (2R,4aR,10aS)-2 and (2R,4aS,10aR)-2, respectively.
BRADDOCK ET AL.698
Chirality DOI 10.1002/chir
???the reported cyclization conditions, any intramolecular or
intermolecular bromonium ion-to-alkene transfer is evidently
not in operation. Further work will require the identiﬁcation
of other Lewis acid-leaving group combinations to improve
overall yields of polycyclic products and to expand the sub-
strate scope.
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